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1. General introduction 
1.1. Anatomy and function of the human eye  
The eye is the light perceiving system responsible for vision. Due to environmental 
adaptations the anatomy and the function of this sensory organ varies enormous among 
species. The human eyes are constructed to discriminate shapes and colors. Since the 
human eyes are highly important for spatial orientation, they can be moved by six extraocular 
muscles and are protected against harmful influences by the eyebrows, the eyelids, the 
eyelashes and the conjunctiva. In addition, the human eyes are embedded in the fatty tissue 
lining the eye sockets. The interior of the eyeball is filled with vitreous humor surrounded by 
three different layers: the outer fibrous, the vascular and the inner nervous layer. The 
avascular fibrous layer or sclera is responsible for the stabilization of the eyeball and consists 
of the conjunctiva and collagen, which pass into the converged cornea at its anterior site 
(Figure 1A). The middle layer or uvea is vascular rich consisting of the oxygen supplying 
choroidea, the ciliary body fixing the crystalline lens and the colored iris with the pupil (Lamb 
and Pugh, Jr., 2004). Muscles in the iris regulate the size of the pupil depending on the light 
intensity by the so called light reflex. In contrast, the ciliary muscles change the bend of the 
lens for accommodation. The anterior chamber, located between cornea and iris, and the 
posterior chamber, between iris and lens, are both filled with transparent aqueous humor 
supplying the lens with nutrition. The nervous layer includes the light sensitive retina and the 
retinal pigment epithelium (RPE), which supports the metabolism of the retina and represents 
a part of the blood-brain barrier (Lamb and Pugh, Jr., 2004). For maximum light absorption 
the retina is generally smooth, but contains two dips in its central part called macula, the 
optic disc and the fovea visible by funduscopy and fluorescence angiography (Figures 1B 
and C). In the optic disc, the optic nerve enters the eye and retinal blood vessels radiate into 
the retina and supply the tissue with oxygen and nutrition in three layers of capillaries (Yu 
and Cringle, 2005). Directly opposite of the lens marked by a reddish spot lays the fovea 
allowing sharp vision in humans. Furthermore, the fovea is blood vessel and capillary free as 
seen by fluorescence angiography. 
The retina is composed of six classes of neurons organized in highly differentiated layers: the 
outer nuclear (ONL), the outer plexiform (OPL), the inner nuclear (INL), the inner plexiform 
(IPL) and the ganglion cell layer (GCL) (Farrar et al., 2002). At the outside, a barrier of 
collagen and elastic fibers forming the Bruch’s membrane is located between the choroidea 
and the RPE (Lamb and Pugh, Jr., 2004). Pseudopodia of the RPE separate the outer (OS) 
and inner segments (IS) of each photoreceptor (PR) (Figure 1D). Adjacent, the outer limiting 
membrane (OLM) forms the boundary to the ONL including the cell bodies of the PRs. In 
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contrast, in the OPL connections between PR axons and dendrites of horizontal and bipolar 
cells occur. The following INL consists of nuclei of the bipolar, horizontal, amacrine and 
Muller cells. Muller cells send processes to all retinal layers. Crosslinking of bipolar cells by 
horizontal and amacrine cells integrate and modify synaptic signals before transmitting to the 
ganglion cells. The IPL forms again connections between axons of bipolar and amacrine 
cells and the dendrites of ganglion cells. The GCL consists of the ganglion cells and their 
axons which leave the retina through the optic nerve. The inner limiting membrane (ILM) is 
forming a barrier between the retina and the vitreous humor. 
 
 
 
Figure 1. Anatomy of the human eye and retina 
The cornea and the sclera form the outer fibrous layer of the eyeball (A). The vascular layer 
consists of the choroid and the ciliary muscles positioning the lens behind the iris and the pupil. 
The anterior and posterior chambers are filled with aqueous liquid. The nervous layer includes 
the retina with the fovea and the optic disc, where the optic nerve and retinal vessels enter the 
eye. The interior of the eye is filled with vitreous humor. Funduscopy (B) and fluorescence 
angiography (C) of the human retina shows the vessel-free fovea and the optic disc where the 
vessels emerge. The retina consists of several distinct layers with different neuronal cells (D). 
The innermost layer is the retinal pigment epithelium (RPE) which builds pseudopodia around 
the outer segments (OS) of the photoreceptors (PRs). The inner segments (IS) of the PRs are 
separated from the cellular body in the outer nuclear layer (ONL) by the outer limiting 
membrane (OLM). In the outer plexiform layer (OPL), the axons of the PRs and the dendrites 
of the bipolar and horizontal cells are connected. The cell body of these two cell types as well 
as the amacrine and Muller cells lay in the inner nuclear layer (INL). Axons of the horizontal 
and amacrine cells are connected to the dendrites of the ganglion cells in the inner plexiform 
layer (IPL). The ganglion cell bodies are located in the ganglion cell layer (GCL). Finally, the 
inner limiting membrane (ILM) is located outside of the ganglion cell axons and separates the 
retina from the vitreous humor. Figures adapted from Neuroscience, 4th edition, Purves, D., 
Augustine, GA., Fitzpatrick, D., Hall W., LaMantia, A-S., McNamara, JO., Williams, SM., 
Sinauer Associates: Sunderland, MA., 2007, www.webvision.com and (Hartong et al., 2006). 
 
Photoreceptors have four morphological structures: axon, cell body, inner segments (IS) and 
outer segments (OS) (Figure 2). The axons reach into the OPL, where they are connected to 
the dendrites of bipolar cells for signal transduction. The cell bodies contain the nucleus and 
is separated from the IS by the OLM. The IS contain the cell organelles including the 
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mitochondria which provide energy as adenosine-tri-phosphate (ATP) to maintain PR 
function (Hamel, 2006). The photosensitive OS is connected to the IS by a modified, immotile 
cilium. This so called connecting cilium (CC) compromises the cytoskeletal axoneme. In 
order to increase light capturing, the surface of the OS is enlarged by stacked disc 
membranes containing proteins for light perception (Lacalli, 2004; Arendt et al., 2004). This 
arrangement increases the probability of light capturing. The stacks are continuously formed 
by invagination of the plasma membrane at the base of the OS (van Soest et al., 1999). The 
discs mature as they migrate to the RPE, where they are shed and phagocytosed (Lamb and 
Pugh, Jr., 2004). 
 
 
 
Figure 2. Morphology of rod photoreceptor 
The choroid is separated from the retinal pigment epithelium (RPE) by the Bruch’s 
membrane. The RPE builds pseudopodia around the outer segments (OS) of the 
photoreceptors (PRs) which shed the mature stacked disc membranes containing proteins 
important for phototransduction. The mitochondria rich inner segments (IS) are separated 
from the OS by the connecting cilium (CC) and the axoneme. The outer limiting membrane 
(OLM) separates the PR segments from the inner nuclear layer where the cell body with the 
nucleus is located. The axon of the PR reaches into the inner plexiform layer where it is 
connected to the dendrites of a bipolar cell. Picture is adapted from (Kennan et al., 2005).  
 
Two types of PRs with different function exist in the retina (Ebrey and Koutalos, 2001). The 
highly light-sensitive rods which account for about 97% of all PRs allow contrast vision under 
dim light conditions (van Soest et al., 1999). In contrast, the cones need more intense light 
conditions, but allow high visual acuity and can discriminate colors. Cones reach their 
highest concentration in the macula, whereas the rods accumulate in the peripheral retina 
with decreasing occurrence in the macula. Since the fovea contains exclusively cones this 
explains why sharp vision is only perceived in the fovea. The differences of visual acuity 
between rods and cones result from the fact that several rods are connected to a single 
bipolar cell. Thus, hyperpolarization of one rod may not be enough to hyperpolarize the 
bipolar cell. Conversely, each cone is connected to a single bipolar cell which leads to the 
higher visual acuity.  
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1.1.1. Phototransduction cascade and visual cycle 
For visual perception, the light is refracted at the cornea and enters the eye through the 
pupil. By passing the lens, the light is focused inside the vitreous humor and may be 
reflected at the RPE before projecting the images upside-down on the retina. The PRs 
convert the electromagnetic light stimulus by photon absorption first into a chemical and later 
in an electrical signal. This process is called the phototransduction cascade. The electrical 
signals are finally transmitted through the optic nerve along the visual pathway into the 
posterior brain region. For signal transfer along the visual pathway, the retina is divided into 
the temporal and nasal parts. The axons from the nasal region cross the brain at the optic 
chiasm, while the ones from the temporal region pass directly into the lateral geniculate 
body. In the visual cortex, the nerve impulses from both eyes are translated into a picture. 
The wavelengths of the light stimulating the PRs lay in a range of 400 to 700 nanometers 
(nm). Due to different chromophore binding proteins, rods and cones respond to different 
light frequencies. Rods contain the transmembrane G-protein coupled receptor opsin, 
whereas cones contain three different proteins either sensitive to short (blue, 420–440 nm), 
medium (green, 534–545 nm) or to long (yellow-red, 564-580 nm) wavelengths (Ebrey and 
Koutalos, 2001). All these proteins form with the small molecular weight chromophore 11-cis 
retinal the rhodopsin (RHO) in rods and iodopsins in cones (Rando, 2001; Lamb and Pugh, 
Jr., 2004). The covalent binding of the chromophore to a conserved lysine residue (K296) 
protonates the Schiff base and shifts its absorption spectrum from ultraviolet (UV) to the 
visible light thereby activating rhodopsin. Photoisomerization of the 11-cis to all-trans retinal 
by light absorption initiates the phototransduction cascade (Figure 3) (Ebrey and Koutalos, 
2001; Lamb and Pugh, Jr., 2004). The elongation of the chromophore induces 
conformational changes of RHO forming an intermediate state (RHO+). This enzymatically 
active RHO+ binds the heterotrimeric G-protein transducin (T) at the membrane surface 
causing guanosine-tri-phosphate (GTP) to guanosine-di-phosphate (GDP) exchange and 
separation of the T α-subunit (T+) (Ebrey and Koutalos, 2001). Each RHO+ can activate 
about hundred of T and thus greatly amplify the light signal. T+ removes the inhibitory γ-
subunit of the PR-specific cyclic guanosine-mono-phosphate (cGMP) phosphodiesterase 
(PDE) (van Soest et al., 1999). In a second signal amplification step the activated α- and β-
units (PDE+) hydrolyze thousands of cGMP to guanosine-mono-phosphate (GMP). In the 
dark state, cGMP binds to cGMP-gated ion channels in the plasmamembrane of the OS. 
This allows sodium (Na+) import and depolarization of the PRs, which in turn opens the 
voltage-gated calcium (Ca2+) channels (Ebrey and Koutalos, 2001). The high intracellular 
Ca2+ levels induce glutamate release at the presynaptic terminal in the dark (Ebrey and 
Koutalos, 2001). A reduced cGMP concentration due to phototransduction in the light leads 
to the closure of the cGMP-gated channels and causes hyperpolarization of the PRs due to 
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continuous potassium (K+) export. Hyperpolarization reduces the Ca2+ influx and decreases 
the release of glutamate (Ebrey and Koutalos, 2001). In addition, low intracellular Ca2+ levels 
inactivates the phototransduction cascade indirectly by restoring the cGMP levels and by 
phosphorylation of RHO through the RHO kinase PCK (Ebrey and Koutalos, 2001). The 
phosphorylated RHO binds to arrestin which sterically inhibits the binding and activation of T 
(Fain, 2006). When all T-bound GTP is hydrolyzed to GDP and no further activation of GTP 
is generated by RHO the phototransduction is stopped (Ebrey and Koutalos, 2001). 
 
 
 
Figure 3. Phototransduction cascade 
The visual pigment 11-cis retinal of rhodopsin (RHO) which is located in the disc membrane of 
the photoreceptor (PR) outer segments is photoisomerized to all-trans retinal (RHO+). This 
leads to conformational changes in the protein inducing guanosine-tri-phosphate (GTP) for 
guanosine-di-phosphate (GDP) exchange in the G-protein transducin (T). Activated transducin 
(T+) removes the inhibitory subunits of the phosphodiesterase (PDE) and activates the 
phosphodiesterase (PDE+), which then hydrolyzes cyclic guanosine-mono-phosphate (cGMP) 
to guanosine-mono-phosphate (GMP). In the dark state, cGMP binds to the cGMP-gated 
channel in the plasma membrane and opens the channel for sodium (Na+) and calcium (Ca2+) 
import which depolarize the PR. Reduced cGMP levels due to phototransduction removes 
cGMP from the channels, closes them and stops cation import leading to PR hyperpolarization. 
This electrical signal is transmitted over the bipolar and ganglion cells to the brain. Picture 
adapted from (Kennan et al., 2005). 
 
Photoisomerization not only starts the phototransduction, but also deprotonates the Schiff 
base and consequently disrupts the covalent binding between the opsin and the 
chromophore all-trans retinal (Figure 4) (Rando, 2001; Lamb and Pugh, Jr., 2004; Ebrey and 
Koutalos, 2001). Since this aldehyde is highly reactive, it must be rapidly reduced to all-trans 
retinol (vitamin A) by a membrane associated all-trans retinal dehydrogenase (all-trans RDH) 
(Lamb and Pugh, Jr., 2004; Rando, 2001). For continuous vision, regeneration of the visual 
pigment by the visual cycle is needed. Assisted by the interphotoreceptor retinoid binding 
protein (IRBP), the vitamin A is transported across the interphotoreceptor matrix to the RPE 
cells (Lamb and Pugh, Jr., 2004). In the RPE cytoplasm, all-trans retinol is chaperoned by 
the cellular retinol binding protein (CRBP). The reconversion into 11-cis retinal starts by 
esterification to all-trans retinyl ester catalyzed by the lecithin retinal acyl transferase (LRAT) 
(Lamb and Pugh, Jr., 2004). Chaperoned again by the RPE-specific 65kDa protein (RPE65), 
the retinyl ester is delivered to a retinyl ester isomerhydrolase which converts the ester into 
11-cis retinol. The oxidation of the alcohol to 11-cis retinal is catalyzed by an 11-cis retinol 
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dehydrogenase (11-cis RDH) and the product is chaperoned by the cellular retinaldehyde 
binding protein (CRALBP) (Lamb and Pugh, Jr., 2004). Assisted again by IRBP, the 11-cis 
retinal is transported back to the PR OS where it crosses the cytoplasmic space to reach the 
disc membranes. There it binds to opsin to form again the Schiff base and reconstitute RHO 
(Lamb and Pugh, Jr., 2004). The whole regeneration cycle after bleaching takes 6 minutes in 
cones, while in rods 30 minutes are required. Thus, adaptation to bright light conditions is 
shorter than adaptation to dim light. 
 
 
 
Figure 4. Regeneration of 11-cis-retinal by the visual cycle 
Light isomerizes 11-cis retinal to all-trans retinal, which is highly reactive. Rapid reduction to 
all-trans retinol (vitamin A) is taking place in the photoreceptor outer segments (OS) 
catalyzed by a all-trans retinol dehydrogenase. The aldehyde is then transported into the 
retinal pigment epithelium (RPE) by two chaperones, the interphotoreceptor retinoid binding 
protein (IRBP) and the cellular retinol binding protein (CRBP). By lecithin retinal acyl 
transferase (LRAT) it is converted to all-trans retinyl ester, before RPE65 transports the 
ester to an isomerhydrolase which produces 11-cis retinol. Oxidation by 11-cis retinol 
dehydrogenase (11-cis-RHD) regenerates 11-cis retinal which is transported by the cellular 
retinaldehyde binding protein (CRALPB) and the IRBP back to the OS. There the 
chromophore binds to opsin to reconstitute again reactive RHO. AL stands for retinal, OL for 
retinol and E for retinyl ester. Figure is adapted from (Lamb and Pugh, Jr., 2004). 
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1.2. Retinal dystrophies 
Retinal dystrophies (RDs) refers to a heterogeneous group of hereditary degenerative 
disorders, while retinopathies designates noninflammatory retinal diseases with various 
causes besides genetic ones (Kellner et al., 2004b; Rivolta et al., 2002). Typically, RDs are 
monogenic disorders characterized by loss of visual acuity or visual field, which are currently 
incurable. So far, over 150 loci are linked to RDs and many different mutations affecting the 
RPE and the retina can lead to the same disease. However, different mutations in the same 
gene may also lead to different diseases (Kellner et al., 2004b; Yu and Cringle, 2005). RDs 
can be subdivided into progressive generalized types affecting the whole retina either 
starting in the peripheral or central part, sector-restricted or stationary types (Kellner et al., 
2004a). Peripheral onset of generalized RDs is caused by initial loss of rod function and 
viability that manifest in form of night blindness. The most prevalent disorder in this group is 
retinitis pigmentosa (RP), which can be either syndromic or nonsyndromic. About 20-30% of 
the RP patients have additional non-ocular phenotypes (Hartong et al., 2006). Leber 
congenital amaurosis (LCA), which constitutes the second group of disorders with peripheral 
onset, is more severe than RP with obvious visual impairments in the first year of life caused 
by both rod and cone cell death. A third main group of peripheral RDs constitutes the late 
onset rod dystrophy (Kellner et al., 2004a). In contrast to peripheral manifestations, initial 
central symptoms may be triggered by increased cone cell death resulting in reduced visual 
acuity. Cone and cone-rod dystrophies are the most frequent retinal disorders with central 
onset (Kellner et al., 2004a). Macular dystrophies like Morbus Stargardt or Morbus Best 
affect limited regions of the retina and cause loss of visual acuity, central vision loss and loss 
of color vision (Kellner et al., 2004a). Some patients suffer from stationary inherited diseases 
like Oguchi disease and congenital stationary night blindness (CSNB) (Kellner et al., 2004a). 
Syndromic RDs are often associated with hearing impairment, renal abnormalities, 
dysmorphic features, metabolic and/or neurological malfunctions (Hamel, 2006). Usher 
syndrome, which is associated with hearing impairment, is the most frequent form of 
syndromic RDs and can be divided into three different types depending on the age of onset 
(Kellner et al., 2004a). Patients suffering from Bardet-Biedl syndrome (BBS) show a variable 
combination of RP, obesity, cognitive impairment, polydactyly, hypogentitalism and renal 
defects (Kellner et al., 2004a). In contrast, Senior Loken syndrome is only associated with 
nephronophtisis and cerebellar ataxia as well as Joubert syndrome with neurological 
symptoms (Hamel, 2006). In metabolic RDs, like Refsum and Bassen-Kornzweig syndrome, 
patients can be treated by special diabetic nutrition plans (Hamel, 2006). 
Photoreceptor cell death is a common feature of all RDs (Wenzel et al., 2005), since their 
last phase include retinal damaging and degeneration by apoptosis (Kellner et al., 2004b; Yu 
Gaby-Gerda Tanner  General Introduction 
 17
and Cringle, 2005). Apoptosis is a tightly regulated process eliminating individual cells in 
healthy tissues. However, mis-regulated apoptosis can destroy and degenerate nerve cells 
and on this way lead to neurodegenerative disorders like RDs. Caspase-dependent and -
independent signal transduction pathways inducing apoptosis can be discriminated. 
Caspase-independent pathways activate oxidoreductases which induce chromatin 
condensation upon activation of endonucleases (Wenzel et al., 2005). Two caspase-
dependent processes can be distinguished, namely the intrinsic and extrinsic one. Both 
finally activate caspase 3 (Figure 5) (Kermer and Bahr, 2005). The extrinsic pathway is 
triggered by activation of the tumor necrosis factors (TNF) receptors at the cell surface. 
Whereas the intrinsic pathway is activated by disintegration and functional impairment of the 
mitochondria followed by release of cytochrom C (Kermer and Bahr, 2005). Additionally, 
various anti- and proapoptotic factors can influence the cytochrom C release from the 
mitochondria. 
 
 
 
Figure 5. Intrinsic and extrinsic caspase-dependent apoptotic pathways 
The intrinsic caspase-dependent signal transduction pathway is triggered by destruction of 
the mitochondrial integrity and functionality or by pro-apoptotic factors, while anti-apoptotic 
factors can inhibit the intrinsic pathway. Pro-apoptotic stimuli induce cytochrom C release 
which induces maturation of pro-caspase 9. Caspase 9 can activate caspase 3 and induce 
apoptosis. The extrinsic pathway is initiated by extracellular signals stimulating receptors of 
the tumour necrosis factor (TNF) family at the cell membrane. These receptors cleave the 
pro-caspase 8 which in turn can again activate caspase 3. Figure adapted from (Kermer and 
Bahr, 2005). 
 
The mechanisms that trigger apoptosis were unknown for quite a long time (van Soest et al., 
1999). Recent research discusses three ways how apoptosis may be induced in RDs. First: 
By constant and excessive stimulation of the phototransduction cascade (Fain, 2006). This 
continuously lowers the intracellular Ca2+ concentration of the PRs and triggers apoptosis. To 
keep Ca2+ at non toxic levels, rods have evolved protective mechanisms as modulation of 
channels and ion transport (Fain, 2006). Second: Another way includes the unfolded protein 
response (UPR) (Ryoo et al., 2007). In a drosophila model for autosomal dominant RP 
(adRP) mutated RHO activates UPR due to stress in the endoplasmatic reticulum (ER). In 
first instance, the UPR mechanism tries to restore normal physiology and delays apoptosis. 
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Nevertheless, a certain level of stimulation of UPR may activate apoptosis and initiate retinal 
degeneration (Ryoo et al., 2007). Third: An additional possibility includes disturbances in the 
oxygen supply and consumption needed for the tightly balanced retinal homeostasis. 
Decreased essential oxygen supply due to mutations first leads to OS destabilization and 
shortening. Finally, the oxygen stress causes toxic conditions for PR cell bodies (Hamel, 
2006). 
1.2.1. Retinitis pigmentosa 
The rod-cone dystrophy RP is a leading cause of visual handicap affecting over 1.5 million 
individuals worldwide (Farrar et al., 2002). RP patients typically have a sparse retina due to 
compromised rod viability and function (Hamel, 2006). The manifestations of RP can develop 
over several decades with patients suffering in early stages from mild sometimes even 
ignored night blindness reflecting the reduced rod function. In this stage, peripheral visual 
loss in dim light can be observed by reduced visual field measurement and slightly 
diminished wave amplitudes in scotopic electroretinogram (ERG) (Hartong et al., 2006). 
Periodical ERG evaluations in families with RP are recommended, since ERG signals are 
reduced before night blindness becomes obvious. In mid stages of the disease, night 
blindness becomes obvious and remarkable constriction of peripheral vision in day light 
occurs. Reduced color vision, photophobia and decreased visual acuity are further 
complaints of the patients due to secondary effects on cone viability and function. 
Additionally, patients frequently develop posterior subcapsular cataracts and have particles 
in the vitreous humor. In this stage, funduscopy reveals peripheral integration of pigment 
deposits, narrowed vasculature, waxy pallor of the optic disc and retinal atrophy. ERGs are 
inrecordable under scotopic conditions and clearly reduced in photopic ones (Hamel, 2006). 
In the late stages of RP, severe constriction of the visual field develops, photophobia 
becomes intense and complete blindness may occur in the presence of macular atrophy or 
edema (Figure 6). The fundus of patients with late stage RP reveal clear mottled 
pigmentation with bone spicules and thin retinal vessels. Fluorescence angiography detects 
retinal atrophy and often macular edema. Finally, ERGs are inrecordable in both conditions 
(Hamel, 2006). Although the different stages of RP can be distinguished, the disease 
progression, severity and age of onset are highly variable between patients. Typically, early 
onset is considered if mid stage phenotype develop at an age of two year, whereas late 
onset patients complain about early symptoms after or at mid life (Hamel, 2006). However, 
most patients develop night blindness and loss of peripheral vision in young adulthood. The 
majority is legally blind by an age of 40 years (Hartong et al., 2006). The earlier the age of 
onset, the more severe the disease course develops usually. 
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RP is not only clinically heterogeneous, but can also be caused by a variety of mutations with 
the majority of them identified in genes either expressed in PRs or which are essential for 
retinal development (Lord-Grignon et al., 2004). So far, mutations in 41 genes and 10 loci are 
associated with the disease and the inheritance includes adRP or autosomal recessive RP 
(arRP) as well as X-linked forms (XlRP) (Table 1). Simultaneous occurrence of a mutation 
(Leu185Pro) in the retinal degeneration slow/ peripherin 2 (RDS/ PRPH2) gene and 
mutations in the rod outer segment protein 1 (ROM1) gene can cause digenic RP (van Soest 
et al., 1999). However, most patients suffer from arRP (20-40%), followed by adRP (15-25%) 
and XlRP (5-10%) whereas the remaining cases (40-50%) cannot be classified and are thus 
referred as simplex ones (Hartong et al., 2006). Some correlation between the mode of 
inheritance and clinical course were observed, indicating that patients with adRP tend to 
have milder phenotypes compared to recessive forms. In contrast, males with XlRP often 
have worst prognosis and show an early onset of the disease, whereas simplex RP and 
arRP cases are of intermediate severity (Fishman, 1978; Hamel, 2006). However, huge 
variation and incomplete penetrance occur in all groups (Fishman, 1978). 
 
 
 
Figure 6. Clinical manifestations of late stage retinitis pigmentosa 
The fundus of healthy individual shows the retinal vessels emerging from the optic disc and 
the fovea. In contrast, vasculature is narrowed and peripheral intraretinal pigment deposits 
are visible by funduscopy of retinitis pigmentosa (RP) patients. Compared to the visual field 
(white) of a healthy person, only residual field remains in the tunnel vision of RP patients. 
Scotopic and photopic electroretinogram (ERG) of the RP patient is extinguished, compared 
to the clear a- and b-wave of a healthy person. Figures taken from www.webvision.com and 
www.arlainst.fi/nv-peda/naonkavtto/ongelmat.html 
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functional group Gene symbols Location inheritance protein function expression
RPE65, LCA2, RP20 1p31.2 arRP retinal pigment epithelium-specific 65 kD protein vitamin A trans-cis isomerase RPE
ABCA4, ABCR, ARMD2, 
CORD3, RP19, STGD1 1p22.1 arRP
ATP-binding cassette 
transporter A4
photoreceptor disc membrane flippase for all-trans 
retinal PR
LRAT 4q32.1 arRP lecithin retinol acyltransferase synthesis of vitamin A esters widely (RPE)
RBP3, IRBP 10q11.22 arRP retinol binding protein 3 transports retinoids in the interphotoreceptor matrix between the RPE and photoreceptors PR
RGR 10q23.1 arRP retinal G protein-coupled receptor member of the opsin subfamily RPE, PR, INL
RDH12 14q24.1 adRP retinol dehydrogenase 12 NADPH-dependent retinal reductase with specificity for all-trans-retinols and cis-retinols  RPE
RLBP1, CRALBP 15q26.1 arRP retinaldehyde-binding protein 1 11-cis retinaldehyde carrier RPE, PR, INL, GCL
SAG 2q37.1 arRP arrestin (s-antigen) rhodopsin deactivator PR
RHO, OPN2, RP4 3q22.1 adRP, arRP rhodopsin G-protein coupled receptor PR
PDE6B, CSNB3 4p16.3 arRP cGMP phosphodiesterase beta subunit G-protein effector enzyme PR
CNGA1, CNCG, CNCG1 4p12 arRP rod cGMP-gated channel alpha subunit catalytically active subunit PR
PDE6A 5q33.1 arRP cGMP phosphodiesterase alpha subunit G-protein effector enzyme PR
GUCA1B, GCAP2 6p21.1 adRP guanylate cyclase activating protein 1B PR
CNGB1, CNCG2, 
CNCG3L, GAR1, GARP 16q13 arRP
rod cGMP-gated channel 
beta subunit catalytically active subunit PR, INL, GCL
USH2A 1q41 arRP usherin basement membrane protein (extracellular matrix) widely (PR, INL, GCL)
PROM1, PROML1 4p15.32 arRP prominin-like 1 transmembrane glycoprotein associated with plasma membrane evaginations in ROS widely
EYS, RP25, SPAM 6p12 arRP eyes shut homologue 1 essential for phororeceptor morphology PR
PRPH2, RDS, RP7 6p21.2 adRP peripherin 2 outer disc segment membrane protein PR
TULP1, RP14 6p21.31 arRP tubby-like protein 1 possibly involved in transport of rhodopsin from inner to outer segment PR, INL, GCL
IMPDH1, LCA11, RP10 7q32.1 adRP inosine monophosphate dehydrogenase 1
catalyzes the rate-limiting step in de novo guanine 
synthesis; regulate cell growth widely (PR, INL, GCL)
RP1, ORP1 8q12.1 adRP, arRP RP1 protein microtubule-associated protein PR
ROM1 11q12.3 adRP retinal outer segment membrane protein 1 rod outer segment protein PR
FSCN2, RP30 17q25.3 retinal fascin homolog 2 actin bundling protein PR, INL, GCL
IDH3B 20p13 adRP NAD(+)-specific isocitrate dehydrogenase 3 beta 
catalyzes conversion of isocitrate to α-ketogluterate 
in the citric acid cycle (cellular respiration) widely
RPGR, CORDX1, RP3 Xp11.4 XlRP retinitis pigmentosa GTPase regulator trafficking protein in cilia widely (PR, INL)
SEMA4A, CORD10, 
SEMAB, RP35 1q22 adRP  semaphorin B
transmembrane protein involved in neuronal 
development and/or immune response
widely (RPE, INL, 
GCL)
CRB1, LCA8, RP12 1q31.3 arRP crumbs homologue 1 transmembrane protein possibly involved in cell-cell interactions (adherent junction) and cell polarity PR, INL
MERTK 2q13 arRP c-mer protooncogene receptor tyrosine kinase
RPE receptor incolved in outer segment 
phagocytosis widely
CERKL, RP26 2q31.3 arRP ceramide kinase-like protein invloved in neuronal cell survival and apopotosis PR, INL, GCL
KLHL7, RP42 7p15.3 adRP kelch-like 7 protein (Drosophila) 
member of the BTB-Kelch superfamily and plays a 
role in the ubiquitin-proteasome pathway widely
CA4, RP17 17q23.2 adRP carbonic anhydrase IV bicarbonate balance; pH regulation choriocapillaries, PR, INL, GCL
RP2 Xp11.23 XlRP novel XRP2 protein similar to human cofactor C plasma membrane associated protein PR, INL, GCL
NRL, RP27 14q11.2 adRP, arRP neural retina leucine zipper transcription factor, is required for rod photoreceptor development PR, INL, GCL
NR2E3, ESCS, PNR 15q23 adRP, arRP nuclear receptor subfamily 2 group E3 transcription factor PR
CRX, CORD2, LCA7 19q13.32 adRP
otx-like photoreceptor 
homeobox transcription 
factor
transcription factor PR, INL
PRPF3, HPRP3, PRP3, 
RP18 1q21.2 ad RP
human homolog of yeast 
pre-mRNA splicing factor 3 member of the U4/U6-U5 tri-snRNP particle complex widely (PR, INL, GCL)
RP9, PAP1, PIM1K 7p14.3 ad RP PIM1-kinase associated protein 1 binding with PRPF3 widely (PR, INL, GCL)
PRPF8, PRPC8, RP13 17p13.3 adRP
human homolog of yeast 
pre-mRNA splicing factor 
C8
member of the U4/U6-U5 tri-snRNP particle complex widely (PR, INL, GCL)
PRPF31, PRP31, RP11 19q13.42 adRP
human homolog of yeast 
pre-mRNA splicing factor 
31
member of the U4/U6-U5 tri-snRNP particle complex widely (PR, INL, GCL)
TOPORS, LUN, P53BP3, 
RP31 9p21.1 adRP
topoisomerase I binding 
arginine/serine rich protein
may be involved in transcription, splicing and/or cell-
cycle regulation widely
unknown PRCD, RP36 17q25.1 arRP progressive rod-cone degneration protein unkown RPE, PR, GCL
visual cycle
cellular structural maintenance
tissue development and maintenance
splicing
phototransduction
transcription factor
 
 
Table 1. Function of the genes associated with retinitis pigmentosa. 
Retinitis pigmentosa (RP)-associated genes can be grouped according to their function into 
genes involved in the visual cycle, phototransduction, cellular and structural maintenance, 
tissue development and maintenance, transcription factors, splicing factors and genes of 
unknown function. Only two of the genes lead to XlRP. The remaining 34 genes are equally 
divided into genes with either causing arRP or adRP. Some of the genes have more than 
one mode of inheritance. For each gene symbols are shown with the official one in bold 
letters (www.genenames.org). Chromosome location, mode of inheritance, protein name, 
and functional information as well as the expression pattern are shown in the columns. 
Retinal pigment epithelium is abbreviated with RPE, PR stands for photoreceptor, INL for 
inner nuclear layer and GCL for ganglion cell layer. Table is adapted according to Farrar et 
al., 2002; Kennan et al., 2005; (Wang et al., 2005; Kennan et al., 2005; Hartong et al., 2006; 
Farrar et al., 2002). 
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The first step for gene identification was made in 1984 with linkage analysis of a gene to Xp 
(Bhattacharya et al., 1984). In 1989, the first adRP gene was localized to 3q (McWilliam et 
al., 1989) and a mutation (Pro23His) in rhodopsin (RHO) was subsequently identified (Dryja 
et al., 1990). With the increasing identification of RP-associated genes, they were grouped 
according to their clinical phenotype (Kaplan et al., 1990; Fishman et al., 1985). Newer 
studies discriminated genes due to their involvement in phototransduction, visual cycle, 
splicing, transcription, cellular structural maintenance, tissue development and maintenance 
as well as genes of yet unknown function (Table 1) (Wang et al., 2005; Kennan et al., 2005; 
Hartong et al., 2006; Farrar et al., 2002). 
Most genes cause only a small proportion of the RP cases. Exceptions for adRP are RHO 
(25-30%), the retinitis pigmentosa 1 gene (RP1, 4-10%) and RDS (5-10%) (van Soest et al., 
1999; Sohocki et al., 2001; Wang et al., 2005; Daiger et al., 2007; Hartong et al., 2006). 
Interestingly, the RHO amino acid substitution p.Pro23His cases 12% of the adRP cases in 
the American population (van Soest et al., 1999). In addition, pre-mRNA processing factor 31 
(PRPF31) cause substantial fractions of adRP (Rivolta et al., 2002). Most arRP cases are 
rare, but RPE65, phosphodiesterase 6A and B (PDE6A and PDE6B) cause 2-5% of the 
cases and mutations in usherin (USH2A) may even account for 5-20% (Daiger et al., 2007; 
Hartong et al., 2006). Mutations in the retinitis pigmentosa GTPase regulator (RPGR) and 
retinitis pigmentosa 2 (RP2) genes are the most common cause of XlRP accounting 70-90% 
and 10-20% of the cases, respectively (Wang et al., 2005; Daiger et al., 2007; Hartong et al., 
2006). 
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1.3. Pre-mRNA splicing 
Precursor messenger ribonucleic acids (pre-mRNA) produced by transcription must undergo 
post-transcriptional modifications to generate messenger ribonucleic acid (mRNA). Only 
thereafter, the mRNA can be translocated into the cytoplasm and translated into the 
corresponding protein. The three essential ribonucleic acid (RNA) processing mechanisms 
include capping of the 5’ end, pre-mRNA splicing as well as polyadenylation (Figure 7). 
Capping with seven-methyl guanosine nucleotides (mG7) protects the transcripts from 
degradation and supports the nuclear export, whereas polyadenylation controls transcript 
stability and facilitates translation. Noncoding intervening sequences (introns) in pre-mRNAs 
interrupting the protein coding regions (exons) are eliminated by pre-mRNA splicing (Mordes 
et al., 2006). The number of introns is highly variable similar as the intron length which may 
exceed 200’000 base pairs (bp). Compared to introns, exons are relatively small and typically 
contain between 10 and 400 bp (Kramer, 1996). 
 
5‘ UTR 3‘ UTRintron exonDNA
transcription
pre-
mRNA
5‘ 3‘
5‘ capping
splicing
polyadenylation
mRNA
poly(A)
mG7
5‘ 3‘
3‘5‘
5‘ 3‘  
 
Figure 7. RNA processing mechanisms 
Transcription of deoxyribonucleic acid (DNA) produces precursor mRNAs (pre-mRNAs) in 
which introns (blue) interrupt the protein coding sequences of the exons (red). Capping of 
the 5’ untranslated regions (UTRs, green) with seven-methyl guanosine nucleotides (mG7, 
black), intron removal by splicing and cleavage of the 3’ UTR followed by polyadenosine 
substitution (poly(A), black) are essential RNA processing mechanisms to generate 
messenger RNA (mRNA) transcripts. 
 
The key steps of the splicing process include recognition of intron-exon junctions, accurate 
excision and religation of the exons. All are catalyzed by the spliceosome, a large dynamic 
RNA-protein complex built of small nuclear ribonucleoproteins (snRNPs) (Will and Luhrmann, 
2005; Mordes et al., 2006). Two types of spliceosomes have been identified in eukaryotic 
cells: a major (U2-dependent) and a minor (U12-dependent) one (Will and Luhrmann, 2005). 
The major spliceosome is composed of five snRNPs (U1, U2, U4, U5 and U6) each of them 
consisting of a specific small nuclear RNA (snRNA), core proteins (Sm proteins) and snRNP-
specific proteins which are despite their uniqueness essential for splicing (Kramer, 1996). U1 
to U5 snRNAs are transcribed by RNA polymerase II, capped and polyadenylated (Kramer et 
al., 1984), while U6 is transcribed by RNA polymerase III (Konarska and Sharp, 1987). Sm 
proteins are common to all snRNPs except to U6 which has seven Sm-like (Lsm) proteins 
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(Vidal et al., 1999). Assembly of the snRNA and Sm-proteins in the cytosol is assisted by the 
survival of motor neurons (SMN) complex (Yong et al., 2004) prior to re-import of mature 
snRNPs into the nucleus (Vidal et al., 1999). The minor spliceosome contains the same U5 
snRNP, but has functionally analogous snRNPs called U11, U12, U4atac and U6atac. 
Three conserved sequences located in the intron and at the splices site (SS) are important 
for accurate intron removal: the acceptor splice site (AS), the donor splice site (DS) and the 
branch site (BS) (Figure 8). A typical BS is located between 18 and 40 bp upstream of the 
AS which often is preceded by a polypyrimidine stretch (Kramer, 1996). The majority of 
introns is highly similar to the consensus sequence and uses the nearly invariant GU at the 
DS and the AG dinucleotide at the AS. Splicing of these introns as well as of the suboptimal 
introns with a GC dinucleotide at the DS is carried out by the so called lariat or canonical 
pathway catalyzed by the major spliceosome. Noncanonical splicing meditated by the minor 
spliceosome occurs if the introns do not follow the GU-AG, respectively GC-AG rule, but 
contain AU dinucleotides at the DS and AC at the AS (Konarska and Query, 2005). Although 
rare introns account for less than 1% of all introns in humans, they are found in genes with 
essential cellular functions, e.g. deoxyribonucleic acid (DNA) replication, transcription, RNA 
processing and translation (Will and Luhrmann, 2005). Only residual numbers of introns do 
not have an adenosine (A) at the BS and use completely different AS and DS sequences. 
 
GURAGU YNYURAC (Y)n CAGAG GU5‘ 3‘ 99.24%
GCAAGU YNYURAC (Y)n CAGAG GU5‘ 3‘ 0.69%
AUAUCCT UCCUUAAC YYCCAC5‘ 3‘ 0.05%
NN ? NN5‘ 3‘ 0.02%
DS branch site AS
 
 
Figure 8. Frequencies of splice consensus sequences 
The majority of the introns (blue) in eukaryotes are similar to the conserved sequences of 
the donor splice site (DS), the branch site and the acceptor splice site (AS). Nearly invariant 
nucleotides of these consensus sequences are shown in bold letters. However, some rare 
introns use a GC dinucleotide at the DS (yellow) or an AU at the DS and an AC at the AS 
(green). Additionally, some introns do not have any of the conserved nucleotides (pink). 
Figure adapted from www.exonhit.com. 
 
The process of splicing can be divided into three main steps: spliceosome assembly, 
creation of a catalytically active site and subsequent transesterification. Spliceosome 
assembly is a dynamic precisely regulated process, which is conserved between the two 
spliceosomes (Staley and Guthrie, 1998). Each round of splicing requires novel stepwise 
formation of RNA-RNA, RNA-protein and protein-protein interactions (Mordes et al., 2006). It 
starts with DS recognition mediated by base pairing between the U1 snRNA and the 
consensus sequence (Figure 9A). After DS selection, the U2 specific proteins splice factor 1 
(SF1) and U2 auxiliary factor (U2AF) recognize the BS to form an intermediate complex E 
(Kramer, 1996). Assembly of the pre-spliceosomal complex A includes binding of U2 to the 
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BS preparing the conserved A for the following transestification reactions (Kramer, 1996). 
Simultaneously, a particle consisting of the U4 and U6 snRNA interacts with U5 to form a tri-
small nuclear ribonucleoprotein (tri-snRNP) subcomplex (Kramer, 1996). The recruitment of 
the tri-snRNP is rate-limiting and converts complex A into complex B (Staley and Guthrie, 
1998). Conformational rearrangements of the snRNAs create the catalytically active centre of 
complex C (Kramer, 1996). These reorganizations include replacement of U1 by U6, shifting 
of U5 binding to the intron, and release of U1 and U4 from the spliceosome (Konarska and 
Sharp, 1987). This brings the BS in close vicinity to the DS such that a nucleophilic attack of 
the hydroxyl group (OH) of A at the BS towards the phosphate (P) of the guanosine (G) at 
the DS is initiated (Figure 9B). Thereby, covalent binding of the 5’ end of the intron and the 
BS forms a circular lariat intermediate (Konarska and Sharp, 1987). Further rearrangements 
allow a non-Watson Crick base pairing between the two Gs at the DS and the AS. This 
permits a second attack of the OH of G at the DS on the P of the G at the AS (Staley and 
Guthrie, 1998). This second transesterification joins the exons and the spliced mRNA is 
immediately released from the spliceosome. The lariat remains bound during spliceosome 
disassembly and is finally disbranched and degraded (Kramer, 1996). The snRNPs must be 
recycled and restored to their original conformation before a new round of splicing can start 
(Staley and Guthrie, 1998). 
 
 
 
Figure 9. Spliceosome assembly and biochemical splicing reaction 
During spliceosome assembly three subcomplexes and one active complex can be 
distinguished (A). Complex E (yellow) is built by base pairing of U1 to the donor splice site 
(DS) and binding of splice factor 1 (SF1) at the branch site (BS) and U2 auxiliary factor 
(U2AF) at the acceptor splice site (AS). During complex A (green) formation SF1 is replaced 
by U2. Tri-snRNP (U4, U5 and U6) binding produces complex B (blue). Rearrangements of 
the spliceosome and release of U1 and U4 are needed to form the catalytically active 
complex C (magenta) which allows the actual splicing reactions by transesterification (B). 
Exposure of the hydroxyl group (OH) of the adenosine (A) at the BS initiates its nucleophilic 
attack on the guanosine (G) at the DS. The phosphate (P) is thereby covalently bound to the 
BS and the intron forms a lariat intermediate. During the second transesterifiaction, the free 
G at the DS attacks the G at the AS and binds the P to form spliced mRNA and lariat intron. 
Figures are adapted from (Turner et al., 2004) and (Blaustein et al., 2007). 
Gaby-Gerda Tanner  General Introduction 
 25
1.3.1. Alternative splicing 
Sequencing of the human genome corrected the number of human genes from estimated 
150’000 down to 30’000 (Modrek and Lee, 2002). This has caused a discrepancy between 
the number of genes and a much larger amount of proteins reaching about 90’000 (Graveley, 
2001; Stoilov et al., 2002). Mechanisms that explain this huge protein diversity include 
multiple transcription start or polyadenylation sites, alternative splicing, and post-translational 
protein modifications (Maniatis and Tasic, 2002). However, alternative splicing, which 
designates the differential selection of SS, is considered to be the most important source of 
proteomic diversity in higher eukaryotes (Mordes et al., 2006). Splicing of pre-mRNAs allows 
expression of many different proteins from one single gene by variable composition of the 
coding sequences. At least 70% of the human genes are estimated to undergo alternative 
splicing (Hastings and Krainer, 2001; Modrek and Lee, 2002; Hui and Bindereif, 2005). Over 
80% of them are predicted to change the amino acid sequence by insertion of alternative 
cassette or mutually exclusive exons, exon skipping, intron retention or usage of alternative 
DS or AS (Figure 10). These splice variants can either be functionally relevant or may 
truncate the protein by frameshift and introduction of premature termination codon (PTC) 
(Modrek and Lee, 2002; Neverov et al., 2005; Faustino and Cooper, 2003). In contrast, the 
remaining 20% of the cases seem to change noncoding sequences by alternative promoter 
or polyadenylation sites, thereby altering gene expression by changing regulatory elements 
controlling translation and/or mRNA stability (Modrek and Lee, 2002). 
 
Alternative promoters
Alternative DS
Alternative cassette exon
Retained intron
Mutually exclusive exons
Alternative AS
Alternative polyA sites
polyA
polyA
Exon skipping
 
 
Figure 10. Alternatively spliced transcripts 
Alternative promoter (magenta) and polyadenylation sites (polyA, purple) can change splice 
isoform expression. Truncation and elongation of constitutive exons (light blue) lead to 
selection of alternative donor (DS) or acceptor splice sites (AS) (dark blue). Novel coding 
regions can be introduced by cassette exons, mutually exclusive exons (green) or by intron 
retention (orange). Skipping of constitutive exons excludes part of the coding region. Figure 
adapted from (Li et al., 2007). 
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Accurate SS recognition is a critical step in pre-mRNA splicing because cryptic splice sites 
(CS) compete with authentic ones (Maniatis and Tasic, 2002). In fact, it is expected that less 
than 50% of the information for SS selection is provided by the SS or BS itself (Hui and 
Bindereif, 2005). The observation that weakly or nonconserved sequences can serve as SS 
lead to the discovery of auxiliary cis-acting sequences that influence SS usage (Kramer, 
1996). These sequences can act positively on exon recognition as exonic splicing enhancers 
(ESE) or negatively as exonic splicing silencers (ESS). Analogous intronic elements exist 
(ISE and ISS). Their organization within pre-mRNAs determine the SS used in the splicing 
reaction and thereby the exons included in the mRNA (Maniatis and Tasic, 2002). Regulatory 
sequences are usually short repetitive elements of 8 to 10bp length consisting of several 
dinucleotide repeats, G-triplets, CUG clusters or purine- or A/C-rich regions (Hui and 
Bindereif, 2005). Competitive binding of functionally antagonistic proteins results in 
combinatorial effects on splicing efficiency and/or SS definition (Hastings and Krainer, 2001). 
ESSs are bound by heterogeneous nuclear ribonucleoproteins (hnRNPs) which contain 
several RNA binding domains and a glycine-rich auxiliary domain (Black, 2003), while ISEs 
are recognized by CUG binding and elav-type RNA binding (ETR) -like factors (CELFs) or 
hnRNP K homology (KH) -type regulatory proteins (KSRP) (Black, 2003). In contrast, ESEs 
and ISSs are recognized by serine/arginine rich (SR) proteins through weak interactions with 
their N-terminal RNA recognition motif (RRM), while the C-terminal domain enriched in SR 
residues is important for protein-protein interactions (Kramer, 1996). Besides their role in 
alternative splicing, SR proteins facilitate the incorporation of the tri-snRNP complex and 
spliceosomal rearrangements in constitutive splicing (Kramer, 1996; Velazquez-Dones et al., 
2005; Ibrahim et al., 2005; Shi et al., 2006). The abundance SR proteins and their activity 
can be modulated by phosphorylation/dephosphorylation cycles (Blaustein et al., 2007; 
Velazquez-Dones et al., 2005). The phosphorylation status affects their intranuclear 
distribution as well as RNA binding and protein–protein interactions efficiency, and 
consequently regulates their activity in constitutive and alternative splicing (Sanford et al., 
2005). One protein kinase, the SR protein kinase 1 (SRPK1), which specifically 
phosphorylates the serine residues of SR proteins was identified to be essential for splicing 
(Velazquez-Dones et al., 2005; Kramer, 1996). Together, this implies that the reversible 
phosphorylation status of SR proteins is involved in the regulation of developmental stage-, 
gender-, or tissue-specific differences in gene expression and/or changes in response to 
other external stimuli via alternative splicing (Blaustein et al., 2007; Faustino and Cooper, 
2003). 
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1.3.2. mRNA surveillance 
Proof-reading mechanisms are known to control the accuracy of DNA replication and RNA 
transcription. Similarly, proof-reading of RNA splicing is a conserved essential process 
among eukaryotes to detect splicing errors by assessing the position of stop codons in RNA 
transcripts (Figure 11) (Nilsen, 2003; Lejeune and Maquat, 2005). Typically, termination 
codons are located in the last exon of the pre-mRNA. If the mRNA surveillance mechanism 
detects a PTC, it rapidly eliminates the aberrant mRNAs and downregulates its amount to 
prevent synthesis of truncated proteins (Conti and Izaurralde, 2005). Thus, the quality control 
protects against severe dominant negative or gain-of-function effects of deleterious proteins 
(Bateman et al., 2003). In order to verify the PTC position during splicing, exon boundaries 
are marked by a so called exon junction complex (EJC) and up-frameshift (Upf) binding 
proteins deposited about twenty nucleotides upstream of the AS (Reed and Hurt, 2002; 
Singh and Lykke-Andersen, 2003; Lejeune and Maquat, 2005; Graham, 2003). This explains 
why only PTC over 50 nucleotides upstream of an exon junction are recognized by the 
mRNA surveillance (Reed and Hurt, 2002; Singh and Lykke-Andersen, 2003; Lejeune and 
Maquat, 2005; Ni et al., 2007). However, an EJC-independent mechanism in β-globin mRNA 
has been proposed to recognize a sequence that functionally substitutes for an EJC and 
recruits nonsense-mediated decay (NMD) associated factors (Lejeune and Maquat, 2005). If 
the stop codon is in the last exon, all EJC are removed by the ribosome during translation 
(Reed and Hurt, 2002; Singh and Lykke-Andersen, 2003). If a PTC exists, the ribosome is 
stalled at the PTC and dissociates from the transcript without having removed the EJCs. 
Detection of the EJC after translation initiates degradation by NMD (Conti and Izaurralde, 
2005; Singh and Lykke-Andersen, 2003). Besides its role in proteome diversity and tissue-
specific expression, alternative splicing produces splice isoforms that have regulatory roles in 
gene expression as they are degraded by NMD (Magen and Ast, 2005). About 10-20% of the 
human transcriptome is expected to be regulated by NMD (Conti and Izaurralde, 2005). 
Additionally, about 20-30% of naturally occurring alternatively spliced mRNAs introduce 
PTCs (Lejeune and Maquat, 2005; McGlincy and Smith, 2008; Saltzman et al., 2008). 
Hence, NMD together with alternative splicing is a common mechanism to regulate gene 
expression post-transcriptionally (Stoilov et al., 2002; Lejeune and Maquat, 2005; Ni et al., 
2007; Saltzman et al., 2008). 
While NMD is a well known process responsible for phenotypic differences between 
individuals, alternative splicing by nonsense-associated altered splicing (NAS) is more 
controversial (Baralle and Baralle, 2005). NAS induces changes in the selection or efficiency 
of SS to maintain reading frames by elimination of PTCs only and generate near full length 
proteins (Baralle and Baralle, 2005; Lejeune and Maquat, 2005). Thus, PCT containing 
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exons may be skipped under certain, not well described circumstances. A third mRNA 
surveillance mechanism is non-stop decay. If no stop codon occurs in the transcript, 
destruction by non-stop decay is initiated as the ribosome is stalled at the 3’ polyadenylation 
site and had encountered no stop codon. 
 
Full length protein
STOP STOP STOP
STOP
STOPSTOP
Near full length protein
mRNA degradation
NMD
NAS
STOP STOP STOPSTOP
mRNA degradation
Non-stop
decay
STOP STOP
 
 
Figure 11. mRNA surveillance mechanisms 
Three different processes were identified to proof-read mRNA co-translationally. All of them 
control accurate positioning of termination codons (indicated by the stop signal) typically 
residing in the last exon. Introduction of premature stop codons can initiate either nonsense-
mediated decay (NMD) leading to transcript degradation or to nonsense-altered splicing 
(NAS) generating nearly full length proteins. No termination codon in an mRNA is 
introducing non-stop decay. Figure adapted from www.exonhits.com. 
 
The presence of intronic nonsense codons has also been correlated with SS choice in 
another controversial process called suppression of splicing (SOS). Over 90% of human 
genes have at least one inframe nonsense codon between the normal DS and an intronic CS 
(Kamhi et al., 2006). Removal of the nonsense codon can activate the CS indicating that 
recognition of the mRNA reading frame and of nonsense codons should occur by a nuclear 
scanning mechanism before splicing (Lejeune and Maquat, 2005; Kamhi et al., 2006). 
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1.4. Splicing and human hereditary diseases 
Since splicing is an essential and tightly regulated process, it is not surprising that defects 
and disturbances in the splicing reaction can cause or modify human genetic diseases 
(Faustino and Cooper, 2003). In recent years, splicing has been identified to play a role in 
pathogenic mechanisms of many human diseases. In general, three main possibilities how 
splicing can cause human diseases have been discriminated (Mordes et al., 2006). 
First of all, mutations can be located in tissue-specific splice isoforms affecting the function of 
a particular gene only in a certain tissue. In recent years, it became obvious that most genes 
have various isoforms often expressed in a tissue-specific manner. For example Stickler 
syndrome type I which is characterized by ocular and extraocular symptoms is caused by 
mutations in procollagen II (COL2A1). Alternative splicing of COL2A1 results in two isoforms 
either including (long) or skipping (short) exon 2 (McAlinden et al., 2008). While the short 
variant is expressed in cartilage, the long isoform is expressed during early eye development 
and in the vitreous of the adult eye. In patients with only ocular manifestations, expression of 
the long isoforms was found to be highly decreased due to nonsense and missense 
mutations in exon 2. The shift in the splicing pattern indicates that the long transcripts 
undergo NAS and skip exon 2 producing short isoforms rather than leading to 
haploinsufficiency. These observations imply an important role for COL2A1 exon 2 in eye 
development (McAlinden et al., 2008). 
Not only tissue-specific splicing can be associated with disease pathogenesis, but also 
mutations their selves can directly lead to disturbances of splicing. Hence, the second and 
most obviously role of splicing in disease is mutation induced mis-splicing. These so called 
cis-acting mutations can lead to usage of CS or create new SS that are recognized instead of 
the authentic ones (Maniatis and Tasic, 2002). Moreover, missense mutations within exons 
or introns can interfere with regulatory elements and disturb binding of SR proteins (Maniatis 
and Tasic, 2002). In fact, point mutations are the most common cause of human hereditary 
diseases (Lopez-Bigas et al., 2005). Recently, a considerable number of mutations (15-
30%), formerly classified as silent alterations or categorized as missense and nonsense 
mutations, were found to interfere with splicing since they are either embedded in consensus 
or regulatory elements or activate NAS (Nissim-Rafinia and Kerem, 2005; Modrek and Lee, 
2002; Faustino and Cooper, 2003). In neurofibromatosis type 1 (NF1) and ataxia 
telangiectasia (ATM) mis-splicing was found to be the most common disease cause since 
over 50% of the mutations have been identified to change the splicing pattern (Hastings and 
Krainer, 2001). Interestingly, the majority of the splicing mutations in the NF1 and ATM did 
not locate to SS, but to enhancers or silencers (Baralle and Baralle, 2005). Usually cis-acting 
mutations lead to a mixture of aberrant and constitutive transcripts since they often do not 
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completely destroy the splicing pattern but rather shift the ratio of alternative splice isoforms 
to pathogenic levels (Faustino and Cooper, 2003). Mutations in the tubulin-associated unit 
(tau) protein for example are changing the ratio of exon 10 inclusion (Grabowski and Black, 
2001). Even a twofold increase in expression of exon 10 including transcripts that code for 
proteins with four instead of three microtubule binding domains leads to the disease. This 
suggests that a sensitive balance of different splice isoforms is necessary for accurate 
protein function preventing from different progressive dementia like Alzheimer’s disease, 
frontotemporal dementia and Parkinsonism (Faustino and Cooper, 2003). 
The third possibility how splicing can be involved in the pathogenesis of diseases is through 
so called trans-acting mutations affecting the basal function of the spliceosome. Either 
mutations in essential splice factors or transcript expansions can interfere with correct 
function of the splicing machinery. However, null mutations in essential spliceosome 
components are generally lethal (Faustino and Cooper, 2003). In contrast to tissue-specific 
splicing and cis-acting mutation affecting only the expression of a single gene, trans-acting 
mutations can affect expression of many genes (Wang and Cooper, 2007a). The motor 
neuron degenerative spinal muscular atrophy (SMA) is one of the rare diseases caused by 
mutations in the essential splice factor SMN1 which is involved in snRNP assembly. 
Although drop in SMN protein levels due to SMN1 mutations was observed to be ubiquitous, 
patients develop the tissue-restricted manifestations of SMA (Mordes et al., 2006; Zhang et 
al., 2008). Interestingly, the altered snRNA stochiometry through mis-regulated snRNP 
assembly was found to cause splicing defects in several transcripts responsible for the 
disease manifestations (Zhang et al., 2008). This spliceopathy provides explanations how 
mutations in the ubiquitously expressed SMN1 lead to tissue-restricted manifestations 
through a subset of aberrantly spliced genes (Licatalosi and Darnell, 2006; Zhang et al., 
2008). In contrast to the rare disorders caused by mutations in essential splice factors, there 
are several genetic diseases found to be triggered by transcript expansions absorbing RNA 
binding proteins and hence disrupt spliceosome regulation. Myotonic dystrophy (DM) for 
example is either caused by CTG expansions in the 3’ untranslated region (UTR) of the DM 
protein kinase (DMPK) or CCTG expansions in intron 1 of the zinc finger protein 9 (ZNF9) 
(Faustino and Cooper, 2003). The secondary structures of these expansions facilitate 
interactions of two RNA-binding proteins, the CUG-binding protein 1 (CUG-BP1) and 
muscleblind-like protein 1 (MBNL1), which are involved in the regulation of alternative 
splicing of selected pre-mRNAs (Osborne and Thornton, 2006). Since the expansions absorb 
the majority of these proteins, their activity in splicing is highly restricted. Due to the resulting 
stochiometric imbalance of transcripts and RNA-binding proteins, the splicing pattern of 
some transcripts seems to be reversed to characteristics of embryonic tissues (Wang and 
Cooper, 2007a; Osborne and Thornton, 2006; Licatalosi and Darnell, 2006).  
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Interestingly, MBNL1 was found in nuclear inclusion of fragile X mental retardation 1 (FMR1) 
transcripts. This indicates that the CGG repeat expansions in the 5’ UTR resulting in the 
fragile-X-associated tremor/ataxia syndrome (FXTAS) may also absorb regulatory proteins 
(Wang and Cooper, 2007a). This suggests that a similar mechanism might underlie the 
pathogenesis of DM and FXTAS (Licatalosi and Darnell, 2006). Furthermore, repeat 
expansions in protein-coding regions of several other genes, e.g. leading to spinocerebellar 
ataxia (SCA) or Huntington’s disease, are also discussed to share this type of pathogenic 
mechanism (Osborne and Thornton, 2006; Licatalosi and Darnell, 2006).  
Depending on the disease, the severity of the manifestations may correlate with the level of 
aberrant splicing or with the ratio of differentially spliced isoforms. Disruptions of ESEs in the 
dystrophin gene induce alternative splicing causing Duchenne muscular dystrophy (DMD) in 
patients. Interestingly, mutations that preserve the open reading frame (ORF) of the 
dystrophin gene lead to the clinically milder expression of Becker’s muscular dystrophy 
(BMD) (Licatalosi and Darnell, 2006). However, splicing is also discussed as genetic modifier 
(Nissim-Rafinia and Kerem, 2005). A well characterized case is the effect of the sodium 
channel modifier 1 (Scnm1) on the neurological phenotype of a mutation in the sodium 
channel gene Scn8a. This DS mutation in exon 3 of Scn8a reduces the amount of normal 
mRNA to 10% in C3H, respectively to 5% in C57BL/6J mice. Interestingly, mice of the C3H 
strain suffer from progressive tremor and ataxia, whereas the phenotype of the C57BL/6J 
mice is characterized by severe paralysis and juvenile lethality (Buchner et al., 2003). A 
missense mutation in Scnm1 in C57BL/6J mice was found to disrupt an ESE and induce 
exon skipping in this gene. In turn, the mis-spliced Scnm1 leads to a more pronounced 
reduction of correctly spliced Scn8a transcripts (Wang and Cooper, 2007a; Buchner et al., 
2003). Although, the reduction of normal Scn8a transcripts due to the mis-splicing of the 
putative splicing regulator Scnm1 is small, the impact on the phenotype is fatal. 
1.4.1. Retinitis pigmentosa and splicing 
The interconnections between RP and splicing are exceptionally interesting because three 
aspects of splicing have been identified to be involved in the pathogenesis: tissue-specific 
alternative splicing of some RP-associated genes, numerous cis-acting mutations in various 
genes and rare trans-acting mutations in basal splice factors were found to be responsible 
for the pathogenesis of RP.  
So far, alternative splicing has been identified or predicted for ten RP-associated genes 
(Table 2). Genes like the ceramide kinase like protein (CERKL), inositol monophosphate 
dehydrogenase 1 (IMPDH1) and retinal G-protein coupled receptor (RGR) express several 
splicing variants, whereas for LRAT, eyes shut homologue (EYS), crumbs homologue 1 
(CRB1) and rod cGMP gated channel subunit B (CNGB1) only the expression of one isoform 
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has been verified (Bornancin et al., 2005; Colville and Molday, 1996; den Hollander et al., 
2001; Bowne et al., 2006; Zolfaghari and Ross, 2004; Lin et al., 2007b).  
 
Gene symbols Isoforms Publication
ABCA4, ABCR, ARMD2, 
CORD3, RP19, STGD1 -
CA4, RP17 -
skipping exon 3 (predicted)
exon 4 truncation
skipping exon 4
exon 8 elongation
skipping exon 9 (predicted)
skipping exon 10 (predicted)
exon 11 elongation (predicted)
CNGA1, CNCG, CNCG1 -
CNGB1, CNCG2, CNCG3L, 
GAR1, GARP exon 12 elongation (Colville and Molday, 1996)
exon 11 elongation 
exon 12 elongation (predicted)
skipping exon 12 (predicted)
exon 12a (predicted)
exon 1 elongation 1
exon 1 elongation 2
exon 1a
exon 1b
exon 2a
skipping exon 2
EYS, RP25, SPAM skipping exon 42 (Collin et al., 2008)
FSCN2, RP30 -
GUCA1B, GCAP2 -
IDH3B -
skipping exon 2
skipping 2-3
exon 17a
KLHL7, RP42 -
LRAT intron 1 retention (Zolfaghari and Ross, 2004)
MERTK -
NRL, RP27 Exon 2a (predicted) (Wistow et al., 2002)
NR2E3, ESCS, PNR -
PDE6A -
PDE6B, CSNB3 -
PRCD, RP36 -
PROM1, PROML1 -
PRPF3, HPRP3, PRP3, RP18 -
PRPF8, PRPC8, RP13 -
PRPF31, PRP31, RP11 -
PRPH2, RDS, RP7 -
RBP3, IRBP -
RDH12 -
exon 3 truncation (isoform 2)
skipping exon 6 (isoform 3)
RHO, OPN2, RP4 -
RLBP1, CRALBP -
ROM1 -
RPE65, LCA2, RP20 -
exon 9a (Neidhardt et al., 2007)
skipping exon 14-15 (Kirschner et al., 1999)
intron 14 retention
exon ORF15
exon 15b1
exon 15b2
exon 15a (Kirschner et al., 1999)
RP1, ORP1 -
RP2 -
RP9, PAP1, PIM1K -
SAG -
SEMA4A, CORD10, SEMAB, 
RP35 -
TOPORS, LUN, P53BP3, RP31 -
TULP1, RP14 -
USH2A
(Lin et al., 2007)RGR
(Vervoort et al., 2000)RPGR, CORDX1, RP3
CERKL, RP26 (Bornancin et al., 2005)
CRB1, LCA8, RP12 (den Hollander et al., 2001)
(Hodges et al., 2002)
IMPDH1, LCA11, RP10
CRX, CORD2, LCA7
(Bowne et al., 2006)
 
 
Table 2. Splice isoforms of human genes associated with retinitis pigmentosa 
In ten of 41 human genes associated with retinitis pigmentosa (RP), alternative splice 
isoforms were identified or predicted. For all of them expect for nuclear leucine zipper (NRL) 
expression of at least one alternative splice isoforms could be verified. LRAT, eyes shut 
homologue (EYS), crumbs homologue 1 (CRB1) and rod cGMP gated channel subunit B 
(CNGB1) show only one confirmed isoform. In contrast, ceramide kinase like protein 
(CERKL), inositol monophosphate dehydrogenase 1 (IMPDH1) and retinal G-protein 
coupled receptor (RGR) express several isoforms. Nevertheless, they show less extensive 
splicing as retinitis pigmentosa GTPase regulator (RPGR) and cone-rod homeobox gene 
(CRX) with seven and six splice variants, respectively.  
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For the nuclear leucine zipper gene (NRL) the inclusion of a novel exon was only predicted, 
but not verified (Wistow et al., 2002). However, RPGR and the cone-rod homeobox 
transcription factor (CRX) show extensive alternative splicing (Table 2) (Hodges et al., 2002; 
Kirschner et al., 1999; Kirschner et al., 1999; Kirschner et al., 1999); (Vervoort et al., 2000; 
Kirschner et al., 1999); Hodges et al., 2002; Neidhardt et al., 2007). Recently, additional 
novel exons in RPGR have been identified and shown to be expressed in tissue- and cell 
type-specific manner. Furthermore, overexpression or deletion of these exons have been 
associated with XlRP phenotypes (Neidhardt et al., 2007)  
Cis-acting mutations were identified in many neurodegenerative disorders including RP 
(Mordes et al., 2006). So far, 18 of 41 genes associated with RP revealed splicing mutations 
(Table 3). But some thereof showed unusual high numbers of splicing mutations, e.g. ATP-
binding cassette transporter A4 (ABCA4) with 52 mutations. Not all of these mutations cause 
RP, but may also lead to other hereditary eye disease like Stargardt disease or macular 
degeneration. However, these 52 mutations account for only 12% of all known ABCA4 
mutations.  In contrast, over 20% of the known mutations in CNGB1, PRPF31 and RGR are 
expected to influence splicing (Table 3). Furthermore, detailed examination of a DS mutation 
(c. 213G>A) in RPGR at the last nucleotide of exon 2 of RPGR revealed that this substitution 
is not a missense mutation, but changes the splicing pattern by skipping of exon 2. The 
inframe deletion of exon 2 affects the critical regulator of chromosome condensation 1 
(RCC1) domain of the protein and on this way probably inhibit accurate protein function 
(Demirci et al., 2004). Two other mutations were detected to skip exon 4 and 7 both also 
truncating the RCC1 domain (Buraczynska et al., 1997), while another mutation was shown 
to induce the usage of CS (Fujita et al., 1997). Altogether, 19 substitutions are assigned to 
affect splicing (http://www.hgmd.cf.ac.uk), which accounts for 19% of the known RPGR 
mutations (Table 3). Interestingly, one of them lays not in a highly conserved SS, but locates 
in intron 9 and affects the level of exon 9a expression (Neidhardt et al., 2007). Numerous SS 
mutations have also been documented in RHO more than a decade ago (Bell et al., 1994; 
Macke et al., 1993; Reig et al., 1996), but the proof for their influence on splicing followed 
only recently (Gamundi et al., 2008) 
Recently, mutations in four essential splice factors have been associated with adRP (Mordes 
et al., 2006). The three highly conserved pre-mRNA processing factors 3, 8 and 31 (PRPF3, 
PRPF8 and PRPF31) and the proto-oncogene serine/threonine kinase 1 (PIM-1) associated 
protein (PAP1) encode proteins which are members of the tri-snRNP important for 
spliceosome assembly (Mordes et al., 2006). Besides the neurological disorder SMA, RP is 
the second disease caused by trans-acting mutations affecting the basal splicing machinery 
and not spliceosome regulation (Faustino and Cooper, 2003; Licatalosi and Darnell, 2006; 
Wang and Cooper, 2007a). 
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total mutations
Gene symbols absolut number relative amount [%] absolut number
ABCA4, ABCR, ARMD2, CORD3, RP19, STGD1 52 12 450
CA4, RP17 n.d. n.d. n.d.
CERKL, RP26 0 0 1
CNGA1, CNCG, CNCG1 0 0 6
CNGB1, CNCG2, CNCG3L, GAR1, GARP 1 50 2
CRB1, LCA8, RP12 3 4 85
CRX, CORD2, LCA7 0 0 28
EYS, RP25, SPAM n.d. n.d. n.d.
FSCN2, RP30 0 0 1
GUCA1B, GCAP2 0 0 3
IDH3B n.d. n.d. n.d.
IMPDH1, LCA11, RP10 0 0 10
KLHL7, RP42 n.d. n.d. n.d.
LRAT 0 0 3
MERTK 1 14 7
NRL, RP27 0 0 9
NR2E3, ESCS, PNR 2 9 23
PDE6A 1 13 8
PDE6B, CSNB3 2 10 21
PRCD, RP36 0 0 1
PROM1, PROML1 0 0 1
PRPF3, HPRP3, PRP3, RP18 0 0 3
PRPF8, PRPC8, RP13 0 0 13
PRPF31, PRP31, RP11 8 23 35
PRPH2, RDS, RP7 2 2 86
RBP3, IRBP n.d. n.d. n.d.
RDH12 1 3 29
RPE65, LCA2, RP20 8 12 67
RGR 2 29 7
RHO, OPN2, RP4 4 3 129
RLBP1, CRALBP 2 18 11
ROM1 0 0 8
RPGR, CORDX1, RP3 19 19 98
RP1, ORP1 0 0 45
RP2 5 11 46
RP9, PAP1, PIM1K 0 0 2
SAG 0 0 4
SEMA4A, CORD10, SEMAB, RP35 0 0 3
TOPORS, LUN, P53BP3, RP31 n.d. n.d. n.d.
TULP1, RP14 2 18 11
USH2A 4 6 70
cis-acting mutations
 
 
Table 3. Cis-acting splicing mutations in genes associated with retinitis pigmentosa 
For 18 out of 41 genes associated with retinitis pigmentosa (RP), splicing mutations are 
annotated in the human mutation database (http://www.hgmd.cf.ac.uk). Nevertheless, this 
database does not exclusively include mutations that are examined at the RNA level but also 
mutations that lay in the conserved consensus sequences of splice sites and thus are likely 
to interfere with splicing.  
 
Several different mutations, including deletions and insertions, have been found in PRPF31. 
The gene product mediates interactions between the U4/U6 particle and the U5 to form the 
tri-snRNP (Makarova et al., 2002). In contrast, only three mutations were found in PRPF3 
and all of them localize to highly conserved amino acids in exon 11 (Gamundi et al., 2008; 
Mordes et al., 2006; Chakarova et al., 2002). PRPF3 builds a stable complex with pre-mRNA 
processing factor 4 (PRPF4) and cyclophilin and associates with U4/U6 snRNP (Liu et al., 
2008; Horowitz et al., 1997). Nevertheless, its exact function is not yet resolved. Similar as in 
PRPF3, all mutations in PRPF8 cluster in one exon (McKie et al., 2001). The protein 
encodes a component of the U5 snRNP which is involved in formation of the catalytic core by 
bringing the BS, DS and AS in close vicinity for the transesterification reactions (Faustino 
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and Cooper, 2003; Liu et al., 2008). Only two mutations in the retinitis pigmentosa 9 (RP9) 
gene are currently known. The resulting protein PAP-1 is implicated to bind PRPF3 and the 
centromere binding factor 1 (CBF1) -interacting transcription corepressor (CIR), which is 
involved in splicing regulation and SR protein binding (Mordes et al., 2006). 
In conclusion, the complex process of splicing can influence the pathogenesis of numerous 
diseases by various ways. However, only two diseases, SMA and RP are caused by trans-
acting mutations in basal splice factors. In contrast to SMA, the role of splicing on the 
pathogenic mechanism of RP is not only restricted to trans-acting mutations, but reveals also 
several examples of tissue-specific splicing and cis-acting mutations. This indicates a 
correlation between splicing and the development of RP. Thus, insight in the function of 
splicing for the pathogenic mechanisms of RP may help to understand the genetically and 
clinical heterogeneity of the disease.  
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2. Aims of this study 
Splicing plays a critical role in the differentiation of cell types and the development of tissues. 
Thus, it is not surprising that defects of the splicing process or disturbances of its regulation 
can induce many genetic disorders. Since mutations in tissue-specific splice isoforms as well 
as cis- or trans-acting mutations have been identified to cause RP, this indicates that splicing 
is of importance for PR viability and plays a role in the disease pathogenesis. Detailed 
knowledge of the different influences of splicing on the disease development will increase the 
insight into the pathogenic mechanisms underlying RP and the clinical and genetic 
heterogeneity of the disease. Therefore, the three projects of this thesis aimed to elucidate 
the different roles of splicing in the pathogenesis of RP (Figure 12). 
 
RP and splicing
prediction of alternatively spliced
variants of RP-associated genes
characterization of a splicing
mutation and rescue of the
mutation-induced mis-splicing
functional characterization of an 
alternative exon in a RP-
associated splice factor
 
 
Figure 12. Three approaches to elucidate the role of splicing in retinitis pigmentosa. 
Illustration of the three projects which aim to improve our understanding of the relevance of 
splicing in RP.  
 
Although over 70% of the human genes are expected to be alternatively spliced, only for a 
quarter of the human RP-associated genes splice isoforms have been verified. Thus, the first 
project aimed to predict novel splice isoforms of RP-associated genes by in silico analysis of 
alternative splice patterns in expressed sequence tag (EST) databases. The results from this 
bioinformatic screening will show if RP-associated genes are prevalent targets of alternative 
splicing and which of these genes use alternative splicing to generate transcript and protein 
diversity. Furthermore, insight into alternative splicing of RP-associated genes will have 
implication on future molecular diagnostic testing of patients.  
Currently, trans-acting mutations in four splice factors (PRPF3, PRPF8, PRPF31 and PAP-1) 
are associated with RP and might affect accurate splicing of various genes. Little is known 
about the pathogenesis of RP caused by mutations in these splice factors. Thus, the second 
project aimed to increase the knowledge of the functional properties of PRPF3 and to 
characterize mutations affecting this gene.  
For a long time, human mutations were categorized according to their impact on the amino 
acid sequence. However, the detection of splice consensus and regulatory sequences 
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indicated that mutations can also disturb the expression of accurate transcripts. Therefore, 
the third part of this thesis aimed to characterize the pathogenic mechanism of a novel DS 
mutation in RHO and to develop a therapeutic strategy to treat this kind of mutations. The 
insight into functional consequences of cis-acting mutations may facilitate the understanding 
of spliceosome assembly and regulation. Moreover, the results of this part may provide a 
basis for future treatments of RP patients with cis-acting mutations. 
In recent years, splicing was found to be an important mechanism that influences protein 
function, tissue development, disease pathogenesis and therapeutic strategies. Together, 
these studies aim to increase the understanding of the coherence between splicing and RP.  
Additionally, these studies will help to understand the pathogenic processes of other 
diseases and to develop novel as well as to improve current therapeutic treatments. 
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3. Results 
3.1. Prediction of alternative splice isoforms in human and mouse 
orthologous genes associated with retinitis pigmentosa 
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3.1.1. Abstract 
Alternative splicing is highly abundant in higher vertebrates and significantly expands the 
regulatory and functional repertoire of both the transcriptome and proteome. From 
genomic large-scale screening, 60% to 70% of human and around 40% of mouse genes 
are estimated to be alternatively spliced. In recent years, some genes associated with 
retinitis pigmentosa (RP) were reported to undergo extensive alternative splicing. In 
addition, tissue-specific splicing of these genes has been discussed to be relevant for 
the pathogenesis of retina-restricted phenotypes, like of RP.  
Alignment of expressed sequence tags (ESTs) to the genomic sequences has become 
an appropriate strategy to predict alternative splicing. We screened all RP-associated 
genes for alternative splicing by EST database analyses and found that over 90% of the 
human and more than 80% of the mouse orthologous RP-associated genes are 
predicted to have novel isoforms. In approximately 60% of the human and in about a 
quarter of the mouse genes, even more than five alternative splice events were 
detected, indicating that the RP-associated genes are frequently alternatively spliced. 
Novel exons, found in about 80% of the analyzed genes, were the most frequently 
predicted splice events found in our screening. For over 55% of the genes even several 
novel exons could be predicted. Exon skipping was the second most splice event 
detected, whereas alternative start and stop exons as well as exon truncation and 
elongation were only predicted at minor frequencies. Seven novel exons and one 
skipping event were found to be conserved between the species. 
In conclusion, alternative splicing was found to be frequent in RP genes, whereas only 
12.4% of the predicted isoforms have been published so far. Further investigation of 
alternative splicing including spatial and temporal expression analyses of the predicted 
isoforms might help to explain pathogenic mechanisms leading to the complex 
phenotype of RP. 
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3.1.2. Introduction 
With the completion of the human genome sequencing project, the amount of genes 
encoded in the human genome has been reduced to an unexpected low number of 
25,000 - 30,000 genes (Faustino and Cooper, 2003; Nurtdinov et al., 2003; Kim et al., 
2007). This caused a discrepancy between the number of protein-coding genes and the 
amount of about 90,000 known proteins (Modrek and Lee, 2002; Neverov et al., 2005; 
Magen and Ast, 2005). Alternative splicing is a mechanism that selectively inserts or 
skips domains of pre-mRNA transcripts in different combinations to synthesize multiple 
mRNAs from one individual gene. Simultaneously with the increasing sequence 
information, the estimated abundance of alternatively spliced human genes has been 
increased to 60-70% (Wang and Cooper, 2007a; Xu et al., 2002; Maniatis and Tasic, 
2002; Modrek and Lee, 2002; Faustino and Cooper, 2003; Modrek and Lee, 2003; 
Neverov et al., 2005; Nurtdinov et al., 2007). The majority of these alternative splice 
events is expected to change the open reading frame (ORF). Consequently, the 
encoded proteins may show different functions, changed expression patterns and/or 
altered post-translational modulations (Wang and Cooper, 2007a; Xu et al., 2002; 
Maniatis and Tasic, 2002; Modrek and Lee, 2002; Faustino and Cooper, 2003; Modrek 
and Lee, 2003; Neverov et al., 2005; Nurtdinov et al., 2007). Hence, alternative splicing 
provides an important mechanism for protein diversification (Nurtdinov et al., 2007; 
Neverov et al., 2005; Kan et al., 2002), may modify untranslated transcript regions (UTR) 
subsequently affecting mRNA stability and/or translation efficiency, and significantly 
expands the functional and regulatory repertoire of both, the transcriptome and the 
proteome (Kwan et al., 2008; Pan et al., 2005; Xu et al., 2002; Stoilov et al., 2002; 
Faustino and Cooper, 2003; Chen et al., 2006a; Kim et al., 2007). 
Splicing may also be involved in pathological processes either through cis- or trans-
acting mutations that cause aberrant splicing of transcripts (Kwan et al., 2008; Chen et 
al., 2006a). Furthermore, isoform variations between tissues and ratios of multiple splice 
isoforms in distinct cell types are known to be tightly regulated (Xu et al., 2002; Kan et 
al., 2002; Faustino and Cooper, 2003; Yeo et al., 2005; Wang and Cooper, 2007a). 
Thus, altered splicing can not only be disease-causing but disparity of splice variant 
ratios were found to modify disease susceptibility, progression and/or severity (Wang 
and Cooper, 2007a; Xu et al., 2002; Xu et al., 2002; Kan et al., 2002; Yeo et al., 2005; 
Chisa and Burke, 2007; Faustino and Cooper, 2003). Although numerous human 
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diseases are associated with aberrant splicing, only retinitis pigmentosa (RP) and spinal 
muscular atrophy (SMA) are caused by mutations affecting components of the basal 
splicing machinery (Faustino and Cooper, 2003). 
Over 1.5 million individuals worldwide are affected by RP. Initial clinical manifestations of 
this hereditary retinopathy include night blindness and constricted visual field both 
caused by rod photoreceptor (PR) cell death. The loss of PR function and viability 
progresses over a period of many years and may range from night blindness and mild 
visual impairments to complete blindness (Kennan et al., 2005; Farrar et al., 2002; 
Mordes et al., 2006). So far, 41 different genes and ten loci are associated with RP. The 
genes have different modes of inheritance including autosomal dominant (adRP) and 
recessive (arRP), as well as X-linked (XlRP) forms (Chen et al., 2006b). Recently, 
mutations in four essential splice factors (PRPF3, PRPF8, PRPF31 and RP9) were 
exclusively associated with adRP (Martinez-Gimeno et al., 2003; Maita et al., 2004; 
Deery et al., 2002; Chakarova et al., 2002; Vithana et al., 2003; McKie et al., 2001). 
Surprisingly, these mutations cause a phenotype which is restricted to the retina 
although the splice factors are ubiquitously expressed. A dysfunction in splicing of an 
RP-associated gene is likely to underlie the pathogenesis of RP in these cases (Yuan et 
al., 2005). 
Little is known about tissue-specific splicing and its regulation, despite growing interest in 
alternative splicing. Thus, insight into alternative splice events of RP-associated genes 
may help to explain the pathogenic mechanisms of the disease.   
Here, we screened EST databases to identify splice isoforms of genes associated with 
RP and to compare frequencies and conservation of splice events between human and 
mouse. 
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3.1.3. Materials and Methods 
EST databases (http://www.ncbi.nlm.nih.gov/, http://genome.ucsc.edu/) were screened 
for alternative splicing in RP-associated genes. In order to reduce the possibility of false 
positives, e.g. computational errors or sequences from paralogous genes, we only 
considered ESTs that showed above 95% identity to the corresponding genomic DNA 
sequence. 
EST sequences were compared to the genomic reference sequence of the RP-
associated gene and in the case of mouse CNGB1, EYS and mouse PRCD to an 
mRNA. Considering that intron retention is the rarest splice event accounting for less 
than 3% of the cases, we excluded ESTs that likely represented incompletely spliced 
RNAs or genomic DNA contamination from the analysis (Neverov et al., 2005; Kan et al., 
2002; Nurtdinov et al., 2007; Kim et al., 2007).  
We distinguished the following types of splice events in this study: exon skipping, splice 
site mismatch by exon truncation and/or extension, alternative first exon, alternative last 
exon and insertion of novel exon. Cassette exons and mutually exclusive exons were not 
discriminated. For all distinguished splice events, ESTs that showed sequence similarity 
to constitutive exons were considered to be most informative. ESTs which align in 
intronic regions were considered as potential novel exons. Often, clusters of ESTs 
aligning to the same intronic regions strengthened the prediction of a novel exon. 
Predicted novel exons were named with number and letters according to their location 
between constitutive and other predicted exons (Table 6). Novel exons locating 
upstream of the first constitutive exon were referred as alternative start exon. Similarly, 
novel exons locating downstream of the last exon were named alternative stop. ESTs 
omitting a known exon were used to predict exon skipping events. Truncation and 
elongation events of constitutive exons were only included in the study if the EST 
showed splice events in other regions of the transcript. Moreover, the splice site at which 
the truncation or elongation occurred had to be spliced to another exon to be 
considered.  
To evaluate if the pattern of alternative splicing in RP-associated genes is conserved 
between species, the EST screen was compared between mouse and human 
databases. Comparison of alternative splice events between both species minimizes the 
detection of artefacts (Graveley, 2001). Conservation of EST sequences between human 
and mice was analyzed using Blast2Sequences (http://www.ncbi.nlm.nih.gov/).  
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3.1.4. Results 
Prevalence of alternative splice events in RP-associated genes 
Publicly available bioinformatic databases including over 5 million human and 3 million 
mouse ESTs provide a rich resource of information about the occurrence of novel 
alternative splicing events in human and mouse (Kan et al., 2002; Yeo et al., 2005). 
Considerable numbers of genome-wide surveys based on information of ESTs were 
performed to analyze the prevalence of alternative splicing in human and mouse genes 
(Sorek et al., 2004a; Nurtdinov et al., 2003; Kan et al., 2002; Xu et al., 2002). However, 
no such comparative analysis was performed in detail for genes associated with a 
particular disease. RP is a genetically heterogeneous disease. To evaluate the 
relevance of splicing for this disease, human and mouse EST databases were screened 
to predict alternative splice events in the so far known 41 RP-associated genes. Indeed, 
these analyses predicted 251 alternative splice events in human (Table 4), while 156 
were identified in mouse (Table 5). Considering that 41 genes were analyzed, this 
accounts for an average of over 6 predicted isoforms per gene in human and 
approximately 4 in mouse. For seventeen human and seventeen mouse genes more 
than 6 respectively 4 splicing isoforms were found. Twelve of RP-associated genes 
(PRPF8, PRPF31, RHO, SEMA4A, ABCA4, CERKL, CRB1, PDE6B, PRCD, SAG, 
TULP1 and RPGR) were predicted to have above-average frequencies of splice variants 
in both species indicating that they may be prominent targets of alternative splicing. 
The predicted isoforms were observed in 39 human respectively 34 mouse genes. Only 
5% of the human and 17% of the mouse RP-associated genes seem not to be 
alternatively spliced according to EST databases (Figure 13). However, those genes 
were different in human (FSCN2 and RDH12) than in mice (KLHL7, NR2E3, ROM1, 
CNGB1, EYS, LRAT and RBP3). The remaining 95% of the human and 83% of the 
mouse genes were predicted to express at least one alternatively spliced transcript. 
ESTs supporting the expression of one alternative splicing event were found for 10% of 
the human genes and for 17% of the mouse ones. About one third of the human and 
almost half of the mouse genes were observed to have between two and five different 
alternative splicing events. In over 60% of the human and in a quarter of the mouse 
genes even more than 5 splicing events were found in EST databases, indicating that 
the RP-associated genes are frequently alternatively spliced. Interestingly, there were 
four genes identified for which 15 or more alternative isoforms were predicted, namely 
the human crumbs homologue 1 (CRB1) and progressive rod-cone dystrophy (PRCD) 
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gene, as well as the mouse genes for prominin 1 (PROM1) and arrestin (SAG). 
Furthermore, we found indications that the human SAG, semaphorin B (SEMA4A) and 
inositiol monophosphate dehydrogenase 1 (IMPDH1) genes are prominent targets of 
alternative splicing. 
 
Distribution of splice events 
The distribution of predicted splice events to genes that are bequeathed in either 
autosomal dominant or recessive, as well as X-linked patterns was comparable in both 
organisms (Figure 14). Slightly more than half of the alternative splicing events were 
predicted in genes causing arRP. Although more genes lead to adRP, only 43% of the 
events in human and 39% of the ones in mouse were observed in adRP-associated 
genes. Solely two genes are known to cause XlRP. Thus, it is not surprising that only 
about 5% of the alternative splice events were identified in these genes.  
 
Types of alternative splicing events in RP-associated genes 
Six different forms of alternative splicing were distinguished. These comprise inclusion of 
novel exons, skipping of constitutive exons, truncation and extension of constitutive 
exons, as well as alternative start and stop exons. To discern novel exons that have the 
potential to add novel protein domains and have influence on transcript initiation and 
termination, we distinguished novel exons upstream or downstream of the constitutive 
first or last exon, respectively. These exons were referred as alternative start or stop 
exons. 
Comparing different types of alternative splicing, we found that novel exons represent 
the major form identified in RP-associated genes (Figure 15). In humans, novel exons 
account for 45% of all alternative splicing variants, whereas in mouse, this number is 
with 67% even higher. The category of novel exons was followed by exon skipping 
events. However, exon skipping is more often observed in human (34%) than in mouse 
(24%). The other four types of splice events were found to be more rarely represented in 
EST databases. Here, only alternative start exons were found in comparable levels in 
human and mouse. In contrast, alternative stop exons were exclusively predicted in 
human.  
Genes with numerous exons tend to have more novel exons and skipping events 
predicted in our study, whereas for shorter genes more alternative start or stop exons as 
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well as exon truncation and elongation events were found. It is not surprising that larger 
genes with more exons were found to have more predicted alternative splicing events. 
Interestingly, about 80% of the human and mouse RP-associated genes show at least 
one novel exon identified by the EST databases (Figure 16). Interestingly, more than 
55% of the genes revealed several novel exons. In human, exon skipping events seem 
to occur similarly often as splicing to novel exons. At least one skipping event was 
observed in 76% of the human genes and 56% of the genes were predicted to skip 
several exons. Nevertheless, a lower abundance of exon skipping was found in mouse. 
Skipping of ORF-preserving exons was reported to be much more frequent than of 
frame-shifting ones (Magen and Ast, 2005). In our analysis, only about one third of the 
predicted exon skipping incidences, 35% of the human and 33% of the mouse, were 
predicted to preserve the reading frame, whereas 57% respectively 61% did not (data 
not shown). The remaining 7% of exon skipping events in human and 6% in mouse were 
predicted to skip part of the UTR and thus would not affect the frame of the coding 
region. In humans, at least one alternative start exon was found in 24% of the human 
genes. This form of alternative splicing seems to be more abundantly predicted than 
alternative stop exons. This was similar in mouse, where the level of alternative start 
exons reached 10%, with no alternative stop exon predicted. Exon truncation and 
elongation of human genes was found at 17% and 9%, respectively. In mouse, these 
numbers were even lower accounting only for 7% and 2% of the genes. 
 
Conservation of alternative splicing events between human and mouse 
To analyze the conservation of splice isoforms, sequence comparison of alternative 
splicing events in mouse and human were performed. Alternative splicing events were 
considered to be conserved if they were predicted from both mouse and human ESTs 
independently.  Seven novel exons and two skipping event were found to be conserved 
between the species (Table 6). These correspond to 5.8% of the alternative splicing 
events found in mouse and 3.6% of the predicted ones in human. These novel exons 
were found in four adRP (CA4, GUCA1B, PRPF3 and PRPH2), two arRP (MERTK, 
TULP1) and in one XlRP (RPGR) genes. Conserved exon skipping events were 
detected in the arRP gene retinal G-protein coupled receptor (RGR) and the adRP 
isocitrate dehydrogenase 3β (IDH3B) gene.  
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3.1.5. Discussion 
Only little is known about the splicing processes in RP-associated genes. To 
complement the understanding of these processes, we analyzed the splicing of all 
known RP-associated genes by bioinformatics approaches. This survey predicted 95% of 
these genes to have novel isoforms. Similarly, the frequency of alternative splicing of 
mouse RP-associated genes was found to be 83%. Considering that databases do not 
show a complete number of alternative splicing variants, an even higher amount of splice 
isoforms may exist. From genomic large-scale screenings, approximately 60 to 70% of 
the human genes are estimated to be alternatively spliced (Faustino and Cooper, 2003; 
Nurtdinov et al., 2007; Wang and Cooper, 2007a), whereas 40% of the mouse genes are 
expected to express alternative variants (Nurtdinov et al., 2003). In addition, higher 
frequencies of alternative splicing in the human versus mouse genome has been 
previously published (Pan et al., 2005). However, our data suggest that in both species 
genes associated with RP seem to be more frequently alternatively spliced than other 
genes. From the 251 predicted alternative splicing events in human, only a few have 
been described before. Among those, two exon skipping events and a novel exon affect 
splicing of IMPDH1 (isoform b and c) (Goldstein and Colby, 1999). Furthermore, in the 
transcription factor neural leucine zipper (NRL), a novel exon has been identified 
(Wistow et al., 2002), whereas an alternative start exon and two skipping isoforms were 
reported in the ceramide kinase-like protein (CERKL) (Tuson et al., 2004). In CRB1, two 
C-terminal alternative splicing events lead to skipping of exon 12 and inclusion of exon 
12a (den Hollander et al., 2001). The skipping of exon 6 in RGR was recently been 
published and produces a protein that is deposited in Bruch’s membrane (Lin et al., 
2007a). Several isoforms of the retinitis pigmentosa GTPase regulator (RPGR) gene, 
e.g. skipping of exon 14 and 15 and alternative splicing of 9a and ORF15 have been 
published to affect RPGR (Kirschner et al., 1999). Recently, skipping of exon 42 in the 
newly identified EYS gene has been described (Collin et al. 2008). 
Tissue-specific isoforms are estimated to account for 10-30% of the alternatively spliced 
genes (Xu et al., 2002; Pan et al., 2005; Kwan et al., 2008). In addition, alternative 
splicing is expected to be more prominent in tissues with several highly differentiated 
than in those with uniform cell types (Xu et al., 2002; Ben Dov et al., 2008; Yeo et al., 
2005). Hence, it is not surprising that alternative splicing was found to be 2.4 times more 
enriched in eye and 1.8 times more frequent in brain than in other tissues (Xu et al., 
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2002). This suggests that retina-specific genes have various isoforms and/or are widely 
expressed genes which produce retina-specific transcripts. As observed in our EST 
screening, the unusually high degree of alternative splicing in RP-associated genes 
supports the notion that splicing plays a central role in the retina. 
RP-associated genes are predicted to encode an average of six isoforms per gene in 
human and four in mice. This is not surprising as general human genes are predicted to 
have between one and fifteen isoforms (Neverov et al., 2005). Only mouse PROM1 was 
observed to have more than fifteen isoforms, whereas for human CRB1 and PRCD as 
well as for mouse SAG exactly fifteen isoforms were observed. Interestingly, more 
alternative splicing events were observed in arRP genes compared to adRP ones. This 
may correlate with the higher number of exons found in arRP genes. In general, longer 
genes tend to have more predicted novel exon or exon skipping events, whereas in 
shorter genes exon truncation, elongation and alternative start or stop exons seem to be 
more frequent. Thus, we did not detect a clear correlation between mode of inheritance 
and frequency of alternative splicing. 
From the types of alternative splicing discriminated in this study, novel exons seem to be 
the most prominent form in both species. Approximately 80% of the analyzed genes 
revealed one predicted novel exon and about 55% even several. It was previously 
described that cassette exons, which are created by exonization of repetitive elements, 
are the most common form of alternative splicing (Chen et al., 2007; Yeo et al., 2005). 
These so called young exons are usually species-specific, short and expressed at low 
abundance ((Sorek et al., 2004a; Nurtdinov et al., 2007). In contrast, mutually exclusive 
exons, which are expected to have evolved from tandem duplications of adjacent exons, 
are quite rare (Sorek et al., 2004), indicating that the observed novel exons in our study 
are mainly cassette exons. Exon skipping was found to be almost as frequent as novel 
exons in human RP-associated genes, whereas only half of the mouse genes revealed 
exon skipping. Intron retention, which is the less abundant form of alternative splicing, is 
the most ancient form expected to have emerged before exon definition was enabling 
exon skipping in vertebrates (Kim et al., 2007). The remaining forms of alternative 
splicing including alternative start and stop exons as well as exon truncation and 
expansion were, as previously described (Sorek et al., 2004; Magen and Ast, 2005), also 
quite rare in our study. 
Although comparative EST database analysis is a widely used approach to predict 
alternative splicing, this method has various limitations. Low sequence coverage of ESTs 
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influences the number of findings, as genes with higher EST coverage are known to 
predict more alternative splicing (Maniatis and Tasic, 2002; Nurtdinov et al., 2003; 
Neverov et al., 2005). Furthermore, our data may support that genes with high numbers 
of exons have less coverage, e.g. usherin (USH2A) which contains 72 exons shows only 
1 predicted splice isoform. Nevertheless, the coverage may vary extremely between the 
different genes and also depends on the expression level of a gene (Graveley, 2001; 
Kan et al., 2002). Predicted transcripts which are only supported by a small number of 
ESTs may be splicing errors (Chen et al., 2006a). Splicing errors are estimated to occur 
at residual levels of 1.2% of total transcripts (Graveley, 2001; Neverov et al., 2005; Pan 
et al., 2005) and spurious alternative splicing may be found in cells used for EST 
generation (Kan et al., 2002). Similar problems may arise if cancer cell lines accumulate 
somatic mutations (Nurtdinov et al., 2003; Magen and Ast, 2005; Kim et al., 2007). On 
the other hand, exclusion of ESTs from cell lines and tumour tissues, which account for 
more than 50% of the entries in the databases (Sorek et al., 2004) would decreases the 
probability of predicting rare splice isoforms. 
Differentiation between database artefacts and expressed, biologically relevant isoforms 
in EST-based genomic surveys is highly important (Yeo et al., 2005; Ben Dov et al., 
2008). Analysis of the conservation of predicted alternative splicing events between 
species may indicate functional importance of splice variants (Kan et al., 2002). 
Therefore, conservation between human and mouse was analyzed because they share 
genomic sequence organization including constitutive exons and show comparable EST 
databases (Modrek and Lee, 2003; Sorek et al., 2004). In our evaluation, 3.6% of the 
human alternative splicing events were found to be conserved in mouse and most of 
these are novel exons. Interestingly, only skipping of RGR exon 6 is already published 
(Lin et al., 2007). Compared to other studies, 10-20% of the alternative splicing events 
were estimated to be conserved (Modrek and Lee, 2003; Pan et al., 2005; Yeo et al., 
2005; Ben Dov et al., 2008). This discrepancy between our study compared to others 
can easily been explained by the fact that we used more stringent selection criteria, e.g. 
the EST was only counted if the identity of between mouse ESTs and mouse genome 
was over 95%. Other studies even counted ESTs with identities lower than 90% (Chen 
et al., 2006a). Using EST databases, we identified in the majority of cases one novel 
exon in the respective transcript. In several other studies exon skipping was determined 
to be the most prevalent form of conserved alternative splicing in vertebrates (Kim et al., 
2007). This difference may be explained by the fact that we selected for clusters of 
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ESTs. Alternative splicing and in particular conserved alternative splicing tend not to 
disrupt protein domains and is therefore mostly frame-preserving (Chen et al., 2006a). In 
contrast, species- and tissue-specific alternative splicing is frequently frame-shifting. 
From the conserved alternative splicing in this study, only exon 3a in PRPF3 and 
skipping of exon 6 in RGR can be clearly considered as frame-preserving alternative 
splicing events. Surprisingly, skipping of frame-shifting exons in human and mouse was 
more frequent than of frame-preserving ones. This may indicate that most predicted 
skipping incidents are species-specific and/or tissue-specific and that the resulting 
transcripts have rather regulatory than protein function. But not only conserved 
alternative splicing may be interesting, many non conserved events may demonstrate a 
species-specific expression pattern (Modrek and Lee, 2003; Artamonova and Gelfand, 
2007), which may also be important for the pathogenesis of RP. About 30% of 
alternative splicing events are known to introduce premature termination codons into the 
transcripts (Wang and Cooper, 2007). These transcripts are recognized by nonsense 
mediated decay (NMD) and are degraded. Thus, frame-shifting alternative splicing may 
be underrepresented in EST databases because they are candidates for degradation by 
NMD (Artamonova and Gelfand, 2007). Transcript elimination by NMD may have 
regulatory impacts on temporal and spatial gene expression and thus may be functional 
at the transcript level (Artamonova and Gelfand, 2007).  
Investigation of alternative splicing and in particular tissue-specific splicing of RP-
associated genes will help to explain pathogenic mechanism leading to the retina-
restricted phenotype of RP. Nevertheless, the in silico predicted splicing events need to 
verify RT-PCR analysis. Usually, between 50-80% of the tested exons can be 
experimentally validated (Kan et al., 2002; Chen et al., 2006a). To chose the best 
candidates, the flanking intronic sequences of the isoforms should be checked for 
conservation of the canonical AG (acceptor) and GT (donor) dinucleotides within the 
splice site (SS) (Sorek et al., 2004). Expressed novel exons represent an interesting 
form of alternative splicing, since they insert previously non coding sequences which are 
likely to be translated into protein function (Chen et al., 2006a). Besides novel function, 
newly identified coding sequences are excellent candidates for mutation screening 
approaches. 
Altogether, this survey aimed to find alternative splicing for genes connected to RP and 
to extend previous studies that predicted alternative splicing in human and mouse 
genomes. Indeed, almost all human and mouse genes were observed to be alternatively 
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spliced and novel exons were found to be the major form of alternative splicing. These 
splice variants have the potential to influence the pathogenic mechanism of RP. 
Verification of their expression and further characterization of these isoforms may help to 
understand specific expression pattern in different tissues and/or developmental stages 
of interest. The understanding of regulation of temporal and spatial expression patterns 
of proteins might increase the knowledge of the pathogenic mechanisms leading to RP 
in patients. 
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3.1.7. Tables 
Ac Nr gene inheritance species novel exon skipping alternative start alternative stop truncation elongation total
NM_000717.2  CA4 adRP Hs 2 1 1 4
NM_000554.3 CRX adRP Hs 2 1 2 5
NM_012418.2 FSCN2 adRP Hs 0
NM_002098.4  GUCA1B adRP Hs 1 1
NM_006899.2 IDH3B adRP Hs 3 3 6
NM_000883.3 IMPDH1 adRP Hs 4 6 1 11
NM_018846.3 KLHL7 adRP Hs 2 6 8
NM_014249.2 NR2E3 adRP Hs 1 1
NM_006177.3   NRL adRP Hs 2 2 2 6
NM_004698.1   PRPF3 adRP Hs 2 4 6
NM_006445.3  PRPF8 adRP Hs 6 1 7
NM_015629.2 PRPF31 adRP Hs 3 3 1 1 8
NM_000322.3 PRPH2 adRP Hs 6 6
NM_152443.2 RDH12 adRP Hs 0
NM_000539.2  RHO adRP Hs 1 2 1 3 7
NM_000327.2  ROM1 adRP Hs 1 2 1 3 7
NM_006269.1  RP1 adRP Hs 1 2 1 2 2 8
NM_203288.1  RP9 adRP Hs 5 1 2 8
NM_022367.2 SEMA4A adRP Hs 4 5 2 11
NM_005802.2 TOPORS adRP Hs 1 1 2
NM_000350.2 ABCA4 arRP Hs 9 1 10
NM_001030311.1  CERKL arRP Hs 4 2 1 7
NM_000087.2  CNGA1 arRP Hs 1 3 4
NM_001297.3 CNGB1 arRP Hs 5 2 7
NM_201253.1 CRB1 arRP Hs 9 3 2 1 15
NM_198283.1 EYS arRP Hs 5 5
NM_004744.3 LRAT arRP Hs 2 1 1 4
NM_006343.2  MERTK arRP Hs 4 1 1 6
NM_000440.1 PDE6A arRP Hs 4 1 5
NM_000283.2 PDE6B arRP Hs 6 2 8
NM_001077620.1 PRCD arRP Hs 5 3 7 15
NM_006017.1 PROM1 arRP Hs 2 4 6
NM_002900.2 RBP3 arRP Hs 1 1
NM_002921.3 RGR arRP Hs 2 2 4
NM_000326.4 RLBP1 arRP Hs 1 3 4
NM_000329.2 RPE65 arRP Hs 1 2 3
NM_000541.3  SAG arRP Hs 8 6 14
NM_003322.3 TULP1 arRP Hs 3 5 8
NM_206933.1 USH2A arRP Hs 1 1
NM_006915.1  RP2 xlRP Hs 4 4
NM_000328.2 RPGR xlRP Hs 6 2 8
total 113 86 17 15 16 4 251  
 
Table 4. Alternative splice events identified in human retinitis pigmentosa-associated 
genes 
Reference sequence number (Ac Nr), gene name and the mode of inheritance are shown in 
the first three rows. Six different types of alternative splicing were distinguished and the 
numbers of splice events are listed. 
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Ac Nr gene inheritance species novel exon skipping alternative start alternative stop truncation elongation total
NM_007607.1 CA4 adRP Mm 6 1 7
NM_007770.4  CRX adRP Mm 2 1 3
NM_172802.2 FSCN2 adRP Mm 1 1
NM_146079.1  GUCA1B adRP Mm 1 1
NM_130884.3 IDH3B adRP Mm 1 2 3
NM_011829.2  IMPDH1 adRP Mm 2 2
NM_026448.3 KLHL7 adRP Mm 0
NM_013708.4  NR2E3 adRP Mm 0
NM_008736.2 NRL adRP Mm 1 1 1 3
NM_027541.4   PRPF3 adRP Mm 4 1 5
NM_138659.2   PRPF8 adRP Mm 4 1 5
NM_027328.3 PRPF31 adRP Mm 3 2 5
NM_008938.1  PRPH2 adRP Mm 2 1 1 1 5
NM_030017.3 RDH12 adRP Mm 1 1
NM_145383.1   RHO adRP Mm 3 3 1 7
NM_009073.3 ROM1 adRP Mm 0
NM_011283.1 RP1 adRP Mm 1 1
NM_018739.1 RP9 adRP Mm 4 4
NM_013658.2  SEMA4A adRP Mm 2 1 3 6
NM_134097.3 TOPORS adRP Mm 2 2
NM_007378.1  ABCA4 arRP Mm 5 5
NM_001048176.1 CERKL arRP Mm 4 1 5
NM_007723.2  CNGA1 arRP Mm 2 2
BC045114 CNGB1 arRP Mm 0
NM_133239.2 CRB1 arRP Mm 3 2 5
U07554 EYS arRP Mm 0
NM_023624.3  LRAT arRP Mm 0
NM_008587.1 MERTK arRP Mm 6 1 7
NM_146086.2 PDE6A arRP Mm 1 1
NM_008806.2 PDE6B arRP Mm 3 3 6
DQ390337 PRCD arRP Mm 2 2 1 5
NM_008935.1  PROM1 arRP Mm 14 4 18
NM_015745.2 RBP3 arRP Mm 0
NM_021340.3 RGR arRP Mm 2 2 4
NM_020599.1 RLBP1 arRP Mm 3 3
NM_029987.2 RPE65 arRP Mm 1 1
NM_009118.2   SAG arRP Mm 12 3 15
NM_021478.1 TULP1 arRP Mm 4 4 8
NM_021408.3  USH2A arRP Mm 1 1
NM_133669.4 RP2 xlRP Mm 1 2 3
NM_011285.1 RPGR xlRP Mm 5 1 6
total 105 38 8 0 4 1 156  
 
Table 5. Alternative splice events identified in mouse orthologous genes associated 
with retinitis pigmentosa 
The first three rows show the reference sequence number (Ac Nr), gene name and mode of 
inheritance. These rows are followed by the rows for the different types of alternative splicing 
distinguished in this study and the number of splice events observed in these groups. 
 
 
Ac Nr gene inheritance tissue novel exon exon skipping
NM_000717.2  CA4 adRP 2a
NM_002098.4  GUCA1B adRP retina 1c
NM_004698.1   PRPF3 adRP retina 3a
NM_000322.3 PRPH2 adRP retina 2b
NM_006343.2  MERTK arRP 1b
NM_003322.3 TULP1 arRP retina 13a
NM_000328.2 RPGR xlRP retina 18a
NM_002921.3 RGR arRP RPE 6
NM_006899.2 IDH3B adRP b-cells 7-11  
 
Table 6. Summary of predicted splice events that are conserved between human and 
mouse 
In the first three rows the reference sequence number (Ac Nr), the gene name and the 
inheritance are shown. The forth row indicates the tissue from which the EST was generated 
and the fifth row show predicted novel exons and the sixth row constitutive exons that are 
predicted to be alternatively skipped. 
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3.1.8. Figures 
Figure 13. Prevalence of alternative splice events in mouse and human retinitis 
pigmentosa associated genes 
The graph shows the percentage of retinitis pigmentosa associated genes which were found 
to have any, one, between two and five or more than five alternative splicing events 
predicted from EST database screening. 
 
 
 
Figure 14. Comparison of alternative splice events between the three different modes 
of inheritance found in retinitis pigmentosa-associated genes 
Proportion of predicted alternative splicing events found in retinitis pigmentosa-associated 
genes either bequeathed in autosomal dominant (adRP, n=20), recessive (arRP, n=19) or X-
linked (XlRP, n=2) patterns. 
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Figure 15. Comparison of different types of alternative splicing 
Six types of alternative splicing were distinguished. From each the prevalence of predicted 
alternative splicing events in human (n=251) and mouse (n=156) was evaluated. 
 
 
Figure 16. Prevalence of different types of alternative splicing events 
Percentage of retinitis pigmentosa-associated genes which have either no or one to several 
alternative splicing events predicted. 
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3.2. Characterization of a novel isoform of the retinitis pigmentosa-
associated splice factor PRPF3. 
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3.2.1. Abstract 
Retinitis pigmentosa (RP) is a genetic heterogeneous retinal dystrophy which leads to severe 
visual impairments in over 1.5 million patients worldwide. Recently, mutations in the pre-
mRNA processing factors 3, 8 and 31 (PRPF3, PRPF8 and PRPF31) have been associated 
with the disease. However, the PRPF3-associated pathology of RP is currently not well 
understood. In order to elucidate the function of this splice factor and the underlying 
pathogenic mechanism, we characterized its expression including a novel splice isoform. 
We identified seven novel isoforms of PRPF3 by bioinformatic screening of EST databases. 
However, only the novel exon 3a was predicted in eye and its sequence revealed high 
homology in higher vertebrates. RT-PCR and sequencing confirmed the expression of exon 
3a in various human tissues. Inclusion of exon 3a was shown to initiate nonsense-mediated 
decay (NMD) in lymphoblastoid cells. Nevertheless, the 3a isoform shows significant 
expression levels, especially in kidney, testis and retina. Interestingly, isoform 3a transcripts 
produce a novel open reading frame (ORF) which includes exon 11, the exon where all RP-
associated mutations have been identified. The resulting protein of the alternative ORF 
resembles the yeast PRPF3 and is missing a Pro-Trp-Ile (PWI) motif which is specific for 
higher vertebrates. In order to examine the effect of the truncated protein on the human 
T494M mutation, evaluation of intracellular protein distribution was performed in cell culture. 
Compared to wildype proteins, reduced nuclear localization of T494M-mutated PRPF3 was 
observed. The truncated protein derived from the alternative ORF revealed an increased 
level of cytoplasmic localization. The combination of mutation and alternative ORF showed 
no additional effect on protein translocation. 
Together, our data show that exon 3a is a widely expressed alternative exon of PRPF3 
producing an NMD-sensitive transcript that is likely to be expressed as an N-terminally 
truncated protein. The high conservation of exon 3a suggests a regulatory function in higher 
vertebrates probably influencing the expression ratio of the two protein variants. Reduced 
nuclear localization of T494M mutated and truncated proteins indicate that inefficient 
translocation into the nucleus may be part of the pathogenic mechanisms of PRPF3-
associated RP. 
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3.2.2. Introduction 
Alternative splicing is a mechanism which separates and reconnects exons of the pre-mRNA 
to produce alternative mRNA transcripts. These transcripts often result in diverse protein 
isoforms with distinct functions. At least 70% of human genes are estimated to be 
alternatively spliced (Stoilov et al., 2002; Faustino and Cooper, 2003;). Approximately 80% of 
these splicing events alter the corresponding open reading frames (ORFs) and thus expand 
the proteomic diversity. The remaining 20% modify untranslated regions (UTRs) and may 
regulate mRNA stability and/or translation efficiency (Wang and Cooper, 2007). Additionally, 
alternatively spliced transcripts are often expressed in precisely regulated temporal and 
spatial patterns. Thus, it is not surprising that defective splicing is a frequent mechanism 
leading to diseases and/or modifications of disease courses (Stoilov et al., 2002; Faustino 
and Cooper, 2003). Cancer, myotonic dystrophy, and Parkinson’s disease are a few 
examples of disorders which are caused by mutations inducing aberrant splicing (Wang and 
Cooper, 2007). However, so far only two diseases are caused by mutations in genes 
encoding splice factors (Faustino and Cooper, 2003). One of them is retinitis pigmentosa 
(RP), a disorder that belongs to the group of rod-cone dystrophies. Worldwide, about 1.5 
million patients suffer from this degenerative disease. Night blindness and constriction of the 
visual field are the first manifestations. These symptoms are caused by progressive loss of 
rod photoreceptor function and viability, which first manifests in the periphery of the retina. 
Due to secondary effects on cone photoreceptors viability the degeneration progresses to the 
central retina and may ultimately lead to complete blindness (van Soest et al., 1999; Kennan 
et al., 2005). So far, mutations in 41 different genes and ten loci are identified to be 
associated with RP (http://www.sph.uth.tmc.edu/retnet/). Their inheritance patterns include 
autosomal dominant or recessive as well as X-linked modes. The genetic and clinical 
heterogeneity of RP makes it difficult to establish clear genotype-phenotype correlations. No 
treatment is known to effectively cure RP. The RP-associated genes can be grouped 
according to their function in phototransduction, visual cycle, photoreceptor and tissue 
maintenance, and transcriptional regulation (Kennan et al., 2005).  
During the last eight years, mutations in four splice factors were identified to cause 
autosomal dominant RP (McKie et al., 2001; Chakarova et al., 2002; Deery et al., 2002; 
Martinez-Gimeno et al., 2003; Vithana et al., 2003; Maita et al., 2004). One of them is the 
pre-mRNA processing factor 3 (PRPF3) that maps on chromosome 1q21.1 and covers 
31.80kb. Its mRNA transcript is 2428bp long and consists of 16 constitutive exons (Horowitz 
et al., 1997; Heng et al., 1998). Only three missense mutations in PRPF3 were shown to 
cause autosomal dominant RP type 18, two in the adjacent amino acids P493S and T494M, 
and one (A489N) four amino acids upstream (Chakarova et al., 2002; Gamundi et al., 2008). 
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The T494M was observed in several independent RP families worldwide (Chakarova et al., 
2002; Gonzalez-Santos et al., 2002). All RP-associated splice factors are essential 
components of the spliceosome and are associated with the same spliceosomal subunit, the 
tri-small nuclear ribonucleoprotein (tri-snRNP) complex (Anthony et al., 1997; Lauber et al., 
1997). The PRPF3 protein is known to undergo three protein-protein interactions suggested 
to mediate tri-snRNP recruitment. The central part binds pre-mRNA processing factor 4 
(PRPF4) and splicing factor 30 (SPF30), whereas the C-terminal region is responsible for the 
binding of the proto-oncogene serine/threonine kinase 1 (PIM-1) associated protein (PAP-1) 
(Anthony et al., 1997; Lauber et al., 1997; Gonzalez-Santos et al., 2002; Maita et al., 2005; 
Little and Jurica, 2008). The N-terminus of PRPF3 encodes an invariant Pro-Trp-Ile (PWI) 
motif which provides weak interactions with nucleic acids.  
Despite the ubiquitous expression of the splice factors, mutations in these genes cause a 
phenotype that is restricted to the retina. Retina-specific phenotypes caused by mutations in 
splice factors are usually explained by the extremely high metabolic activity in the retina. This 
requires a high protein turnover and thus, the retina may be more sensitive to rate-limiting 
effects in splicing. In conclusion, correct and rapid splicing seems to be of high importance 
for photoreceptor viability (Martinez-Gimeno et al., 2003). Dysfunction in splicing may cause 
RP, but its precise role in the pathogenic mechanism underlying the disease is not yet 
understood. 
The main objective of the present study was to characterize alternative splice events in the 
RP-associated splice factor PRPF3 and to evaluate their role in the pathogenesis of RP.  
Gaby-Gerda Tanner  General Discussion 
 72
3.2.3. Materials and Methods 
Prediction of alternative splicing in PRPF3  
Expressed sequence tag (EST) databases (http://www.ncbi.nlm.nih.gov/, 
http://genome.ucsc.edu/) were analyzed for alternative splicing in PRPF3. Alignments of 
ESTs were compared to the genomic reference sequence (RefSeq NM_004698) of human 
PRPF3. ESTs in intronic regions as well as ESTs skipping constitutive exons indicated novel 
isoforms. To exclude false positives, ESTs were only included if they show a minimum 
identity of 95% at the nucleotide level in comparison to the corresponding genomic 
sequence. Spliced ESTs as well as clusters of more than five overlapping ESTs were 
estimated to have a higher probability to be expressed. Percent identity plot (PIP) 
(http://pipmaker.bx.psu.edu/pipmaker/) was used to analyze the conservation of the novel 
exons and localization of repetitive elements in the genomic sequence of PRPF3 (Schwartz 
et al., 2000). 
 
Expression analysis of exon 3a 
To verify the expression of the novel exon 3a of PRPF3, reverse transcription polymerase 
chain reaction (RT-PCR) was performed on total RNA from cells as well as from mouse and 
human retina. Cell pellets were homogenized with QIAshredder columns (Qiagen, 
Hombrechtikon, Switzerland), whereas a rotor-stator homogenizer (ULTRA-TURRAX T8; IKA 
Werke, Staufen, Germany) was used for retina. Total RNA was extracted with RNeasy 
extraction kits (Qiagen, Hombrechtikon, Switzerland) according to the protocol. 
Complementary deoxyribonucleic acid (cDNA) was synthesized with superscript III reverse 
transcriptase (Invitrogen, Basel, Switzerland) using random hexamers (GE Healthcare, 
Otelfingen, Switzerland). Primers and conditions for RT-PCR are summarized in 
supplementary tables 1 and 2. All polymerase chain reaction (PCR) products were subcloned 
into the vector TOPO TA (Invitrogen, Basel, Switzerland) and sequenced (Genetic Analyzer 
ABI Prism 3100; Applied Biosystems, Rotkreuz, Switzerland). Tissue-specific expression was 
analyzed on commercially available human total RNA (Becton Dickinson Bioscience, 
Allschwil, Switzerland). 
Quantitative RT-PCR analysis was performed with the ABI Prism 7900 TaqMan using minor 
groove binder (MGB) probes (Applied Biosystems, Rotkreuz, Switzerland). The respective 
probes span the splice junctions of different exons (3-4 and 3-3a). The expression of the 
alternative splice junction (3-3a) was compared relative to the constitutive splice junction (3-
4). 
 
Gaby-Gerda Tanner  General Discussion 
 73
Mutational screening of genomic DNA from RP patients   
From blood samples of 169 (84 female, 85 male) Swiss RP patients referred to us for genetic 
diagnosis, genomic DNA (gDNA) was extracted (Chemagic Magnetic Separation Module I; 
Chemagen AG, Baesweiler, Germany). From all patients informed consent was obtained 
prior to genetic testing. Direct sequencing of PCR products of coding regions and flanking 
intronic sequences (Genetic Analyzer ABI Prism 3100; Applied Biosystems, Rotkreuz, 
Switzerland) was performed to screen for disease-associated sequence changes in PRPF3 
(GenBank RefSeq NM_004698). Primers and PCR conditions for the screening procedure 
are summarized in supplementary tables 1 and 3. Nomenclature of the sequence alteration is 
based on cDNA with the A of the translation start site corresponding to position +1 
(www.hgvs.com).  
 
Cloning of expression constructs 
PRPF3 expression constructs were cloned into vector pcDNA4/V5-HisC (Invitrogen, Basel, 
Switzerland). For the wildtype construct, the PRPF3 ORF was amplified from RZPD clone ID 
IRAUp969F0118D6 (Deutsches Ressourcenzentrum für Genomforschung GmbH, Berlin, 
Germany) by ProofStart polymerase (Qiagen, Hombrechtikon, Switzerland). The primers 
included EcoRI and XhoI restriction sites for directional cloning. Primer sequences and PCR 
conditions are summarized in supplementary tables 1 and 4. For T494M constructs, the 
mutation was introduced by site-directed mutagenesis (QuikChange-II site-directed 
mutagenesis kit, Stratagene, Switzerland) using primers with the corresponding nucleotide 
exchange. The isoform 3a ORF1 insert was amplified from cDNA of human retina with 
primers including BamHI and XhoI sequences, whereas RT-PCRs for the ORF2 insert were 
performed with primers containing EcoRI and XhoI restriction sites. To generate isoform 3a 
constructs, the ORF1 and ORF2 inserts were cut with EcoNI and BamHI (Fermentas, 
Nunningen, Switzerland) before cloning. A fragment containing the T494M mutation was 
transferred from the mutant construct using Van91I and ApaI restriction sites. All constructs 
were confirmed by sequencing and compared to the reference sequence (NM_004698). 
 
Cell culture, cycloheximide treatment and transient transfection 
COS7 cells were cultured in MEM with Earle’s Salt, HEK 293T and ARPE-19 cells in 
Dulbecco’s modified Earle’s medium (DMEM), and eppstein-bar-virus (EBV) transfected 
lymphoblasts in RPMI 1640 media with glutamine. All media were additionally supplemented 
with 10% fetal calf serum, 1.2% penicillin/streptomycin and 1.4% glutamine (LabForce, 
Nunningen, Switzerland). 
For cycloheximide treatment, the absolute number of lymphoblast cells was counted 
(Casyton: Schärfe Systems, Reutlingen, Germany). 1 x 106 cells/ ml were transferred to a 
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75cm2 flask and cycloheximide (Sigma-Aldrich, Steinheim, Germany) was added to obtain a 
final concentration of 30µg/ml. After 4 hours of incubation at 37°C and 5% CO2, cells were 
harvested by centrifugation at 2000g for 10 minutes at 4°C. The cell pellets were frozen and 
stored at -80°C. 
Cells were transfected either in six-well plates containing coverslips (COS 7 and HEK293T: 4 
x 105 cells/ well, ARPE-19: 2.5 x 105 cells/ well) or 75ml flasks. In six-well plates, transfection 
was performed at 60-80% confluence with 4.8µg of PRPF3 expression constructs. DNA was 
diluted in 150mM NaCl and mixed with branched polyethylenimine (PEI, Sigma-Aldrich, 
Steinheim, Germany) in a ratio of 8 amino to one phosphate group. Transfection in flasks 
was performed in 4 fold higher scale for transfection reagents and DNA than in six-well 
plates. After 30 minutes of incubation at room temperature, the DNA-PEI mixture was applied 
to the cells. Before incubation at 37°C and 5% CO2, the six-well plates and flasks were 
centrifuged for 5 minutes at 280g. The cells were harvest after 48 hours of incubation. 
 
Protein extraction and Western blot analysis 
Proteins were extracted in RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 0.2% Nonidet P40 
(Roche, Rotkreuz, Switzerland) and 1mM EDTA) supplemented with complete protease 
inhibitor (Roche, Rotkreuz, Switzerland) with a glass homogenizer. The protein amount was 
measured using BCA assay according to the manufacturer’s instruction (Bio-Rad, Reinach, 
Switzerland) and BSA served as standard. SDS polyacrylamide gels (10 or 12%) were 
loaded with 50ug protein extract. After protein transfer to a nitrocellulose membrane (Hybond 
ECL; GE Healthcare, Otelfingen, Switzerland) by semi-dry blotting, blocking with 10% milk in 
PBS was performed. Then, the blots were incubated overnight at 4°C with the first antibody 
in PBS containing 10% respectively 5% milk powder (1:5000 dilution of anti-V5 mouse IgG; 
Invitrogen, Basel, Switzerland or 1:5000 dilution of anti-PRPF3 rat IgG; Labforce, Nunningen, 
Switzerland). After washing in PBST and PBS, blots were incubated for 2 hours at room 
temperature with horseradish peroxidase-conjugated secondary antibody in PBS with 5% 
milk (1:3000 dilution of HRP-anti-mouse IgG; Invitrogen, Basel, Switzerland or 1:3000 
dilution of HRP-anti-rat IgG; Invitrogen, Basel, Switzerland). Blots were developed with ECL 
solution (Perkin Elmer, Schwerzenbach, Switzerland). 
 
Immunocytochemistry 
Cells were first fixed with 4% para-formaldehyde (Merck, Zug, Switzerland) and then 
permeabilized with 0.2% triton X 100 in phosphate buffered saline (Roth, Reinach, 
Switzerland). For staining, two incubation steps of 1 hour each at room temperature were 
performed, first using 1:500 diluted anti-V5 antibodies followed by incubation with Cy3-
conjugated anti-mouse IgG (1:500, Dianova, Hamburg, Germany). Cells were again fixed in 
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para-formaldehyde and mounted in vectashield medium containing DAPI (Reactolab, 
Servion, Switzerland). Images were taken with Axioplan 2 imaging microscope and 
ApoTome, AxioCam MmR and Axiovision 4.6 software (Carl Zeiss AG, Feldbach, 
Switzerland). For the protein localization studies, 100 cells per slide were analyzed in 
triplicates for three independent transfections (n=900). Statistical analysis using 95% 
confidence intervals was performed without continuity correction (Newcombe, 1998) 
(http://faculty.vassar.edu/lowry/prop1.html). 
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3.2.4. Results 
Novel splice isoforms of PRPF3 predicted using bioinformatic approaches 
Expressed sequence tags (ESTs) databases were screened to identify alternative splicing of 
PRPF3. Seven putative splicing variants were observed by comparison of EST sequences to 
the genomic reference sequence of PRPF3 (RefSeq NM_004698, Figure 17A). Five isoforms 
were predicted to skip constitutive exons and are represented by only few ESTs (Table 7). In 
contrast, the expression of the two novel exons referred as exons 3a and 4a was supported 
by 31 and 9 ESTs, respectively (Tables 8 and 9). Exon 3a was conserved in different species 
suggesting a functional relevance of this PRPF3 isoform. 
Conservation of the putative exons 3a and 4a was examined in higher vertebrates. Exon 4a, 
which is embedded in a region of short interspersed nuclear elements (SINEs) known as Alu 
repeats, was observed to be over 70% conserved between human and chimpanzee (Figures 
17B and 19). On the nucleotide level even an identity of 98% was found between the species 
(Figure 18B). While exon 4a is only conserved in chimpanzee, at least 70% identity between 
human and all analyzed species was observed for exon 3a (Figure 17B). Nucleotide 
sequence alignments even revealed complete identity between human, chimpanzee and 
dog, 99% between human, mouse and rat, as well as 71% between human and chicken 
(Figure 18A). In contrast to exon 4a locating in an Alu repeat, exon 3a resides in a predicted 
CpG island (Figure 19). Together with the high conservation, this suggests a functional role 
of exon 3a in higher vertebrates. Moreover, the inclusion of exon 3a is predicted by an EST 
from eye tissue (BU156605) indicating that this splice isoform might have a functional 
relevance in the retina. In contrast, localization and restricted conservation of the other 
predicted isoforms of PRPF3 may indicate a less pronounced functional relevance. 
 
Exon 3a is widely expressed in human tissues 
Prompted by EST database screening and the high evolutionary conservation, we verified 
the expression of the PRPF3 isoforms including exon 3a. Using cDNA of human and mouse 
retina as well as of HeLa and ARPE-19 cells, RT-PCR was performed and a double band 
was observed by gel electrophoresis (Figure 20A). Sequencing revealed that the lower band 
represents the constitutive PRPF3 transcript containing exons 2 through 6. The upper band 
includes 96 additional nucleotides that perfectly correspond to the EST sequence of 
BU156605. Thus, exon 3a encodes exactly 32 amino acids and inclusion of exon 3a does 
not lead to frame shift. However, exon 3a includes a premature termination codon (PTC).  
Since all RP-associated mutations in PRPF3 have so far been identified in exon 11, exon 3a 
must be part of the same transcript to have an influence on the mutations and consequently 
on the pathogenesis of RP. RT-PCR on human retina and subsequent sequencing verified 
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the expression of a transcript including exon 3a followed by all constitutive exons up to exon 
13 (Figure 20B). This shows that the alternative transcripts include exons 3a and 11. 
Furthermore, the RT-PCR analysis did not show any other splice isoform of PRPF3, 
suggesting that the additionally predicted transcripts are either tissue-specific or less 
abundantly expressed compared to 3a. 
Mutations in novel exons can help to understand pathogenic mechanisms underlying the 
disease. Therefore, gDNA of 169 Swiss RP patients was screened for mutations in 
constitutive PRPF3 exons and alternative exon 3a. Besides six known polymorphisms, the 
screening revealed five novel intronic sequence changes and one novel exonic alteration in 
exon 6 (Supplementary table 5). Although the basepair exchange in exon 6 (c.1032 A>G) is 
not changing the amino acid sequence it may interfere with accurate recognition of the splice 
donor site located 4 bp downstream. However, no mutation was identified in exon 3a and in 
its flanking intronic regions.  
The expression of exon 3a was examined in different human tissues and was confirmed in all 
cDNAs tested (brain, lung, liver, kidney, retina and testis) (Figure 20C). Thus, not only the 
constitutive PRPF3 is widely expressed among human tissues, but also isoform 3a. 
However, in all tissues the expression of exon 3a seemed to be lower compared to the 
constitutive transcript. To determine the expression levels in more detail, quantitative RT-
PCR was performed. Probes spanning the different splice sites were used to relatively 
compare the constitutive and alternative exon junctions. The expression of the constitutive 
PRPF3 varies between the tissues with highest amounts in testis and lowest in liver (Figure 
20D). In contrast, the ratio between exon 3a and constitutive PRPF3 isoforms was highest in 
kidney, followed by retina and liver. Of note, these are also the tissues in which the 
expression of constitutive PRPF3 is lowest. 
 
Isoform 3a transcripts undergo nonsense-mediated decay 
Inclusion of the novel exon introduces a PTC in exon 3a which is followed by an alternative 
start signal in exon 4. Thus, two alternative ORFs referred as ORF1 and ORF2 are 
generated (Figure 21A). Interestingly, ORF2 resembles the yeast PRPF3 and lacks the first 
three exons including the PWI domain. This suggests that in humans ORF2 might be used to 
produce an alternative protein missing this domain, which is a conserved type of RNA and 
DNA binding motif. To evaluate if translation of the ORF2 is probable, the initiation sites of 
human and yeast were compared to the consensus sequences of eukaryotes (Kozak, 1987). 
The essential AUG triplet and the important position -3 are conserved in all ORFs (Figure 
21B). In contrast, the forth nucleotide at position +4 known to have an impact on translation 
efficiency was only found to be conserved in the start signal of PRPF3 exon 2. Nevertheless, 
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the alternative start signal in exon 4 is predicted to serve as an adequate consensus 
sequence for protein expression (Figure 21B) (Kozak, 1987). 
Frequently, inclusion of an alternative exons induces frameshift and PTC (Sorek, 2007). In 
addition, over 30% of the isoforms containing PTCs are found to elicit nonsense-mediated 
decay (NMD) (Lejeune and Maquat, 2005). Translation inhibition by cycloheximide also 
inhibits the co-translational process of NMD. Following cycloheximide treatment, the negative 
and loading control of RNA polymerase II transcripts showed no alteration in expression 
(Figure 21C). In contrast, NMD inhibition caused increased amounts of isoform 3a transcripts 
in lymphoblasts. Quantitative RT-PCR measurements confirmed the significant accumulation 
of isoform 3a transcripts in cycloheximide-treated cells (Figure 21D).  
 
Reduced nuclear localization of mutant and alternative protein 
Exon 3a seems not to encode any known domain (data not shown). Nevertheless, alternative 
splicing may cause changes in the protein domain composition by e.g. removal of signal 
peptides which in turn affect protein localization (Magen and Ast, 2005). PRPF3 has two 
predicted nuclear localization signals (NLS), an N-terminal and a C-terminal one. The 
alternative ORF2 generated by exon 3a inclusion contains only one NLS. Expression 
constructs of the putative proteins may show which of the NLS is functional or whether both 
signals are necessary for correct protein translocation into the nucleus. The fact that isoform 
3a transcripts of PRPF3 include exon 11 raises the possibility that the mutation also affects 
isoform 3a at the protein level. To analyze this hypothesis, PRPF3 constructs carrying the 
T494M mutation and different 3a ORFs were cloned for expression studies and examination 
of intracellular protein localization in cell culture (Figure 22A). Preliminary results from 
western blot analysis of transfected HEK 293T cells revealed protein expression from 
wildtype (Wt), mutant (T494M) and both ORF2 constructs by V5 staining (Figure 22B). In 
contrast, no signals were observed from isoform 3a and ORF1 constructs, while the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control shows similar protein loadings 
for all tested cells. However, expression of endogenous PRPF3 protein could be detected in 
these cells with a PRPF3 antibody. The intracellular localization of the different PRPF3 
proteins was detected by immunocytochemistry. The protein distribution of these isoforms in 
the nucleus, the cytoplasm or in both compartments was distinguished. Nuclear localization 
was found in 84% of the cells transfected with Wt PRPF3 constructs (Figure 22C). 
Remaining cells (16%) showed localization in both compartments. In contrast, T494M-mutant 
and isoform 3a PRPF3 revealed significant lower number of cells with nuclear localization 
and more cells showing protein distribution in both compartments. Compared to T494M 
mutated proteins, a more pronounced loss of nuclear localization was observed for ORF1 
and ORF2 proteins, all containing only one NLS. ORF1 proteins revealed almost exclusive 
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localization in the cytoplasm, whereas ORF2 proteins localize predominantly in both 
compartments and only a minor proportion of the cells showed nuclear localization. No 
significant changes were observed between 3a proteins containing or lacking the T494M 
mutation. 
 
Expression of exon 3a is not autoregulated by overexpression of PRPF3 proteins 
Some splicing factors like transformer2-β1 (Tra2-β1), polypyrimidine tract binding protein 
(PTB) and serine/arginine-rich 2 protein (SC35) autoregulate their expression by NMD 
through a negative feedback loop (Sureau et al., 2001; Stoilov et al., 2004; Wollerton et al., 
2004; Lejeune and Maquat, 2005; Ni et al., 2007; McGlincy and Smith, 2008). Protein binding 
to their own pre-mRNA enhances splicing of NMD-sensitive transcripts by skipping or 
inclusion of ultraconserved elements (UCEs). Interestingly, NMD of positively acting splicing 
factors as serine/arginine rich (SR) proteins is regulated by splicing activation, whereas for 
negatively acting factors like hnRNP proteins NMD is activated by splicing repression (Ni et 
al., 2007; McGlincy and Smith, 2008). This polarity in the homeostatic control of RNA-binding 
protein expression may be highly important for the balance in splicing regulation (Ni et al., 
2007). The finding that the highly conserved exon 3a of splice factor PRPF3 induces NMD 
suggests that this exon may function as an autoregulatory element. In order to test 
autoregulation of PRPF3 expression, quantitative transcript analysis was performed in cells 
overexpressing different PRPF3 proteins. The results show clear overexpression of Wt and 
T494M transcripts in cells transfected with the Wt and T494M expression constructs (Figure 
23). Nevertheless, the expression level of 3a containing isoforms was not altered. Of note, 
the level of overexpression of constitutive PRPF3 after transfection was higher in ARPE-19 
than in HEK293T cells, although the transfection efficiency in HEK293T was higher (36%) 
than in ARPE-19 cells (24%). Interestingly, isoform 3a ORF2 Wt overexpression does 
significantly increase the amount of constitutive PRPF3 transcripts in HEK293T, but not in 
ARPE-19 cells. However, expression of isoform 3a remains constant in all tested cell lines.  
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3.2.5. Discussion 
Two novel exons, 3a and 4a, and five putative isoforms showing exon skipping were 
predicted upon EST databases screening. We confirmed the expression of exon 3a-
containing PRPF3 transcripts in several tissues, but did not find other isoforms. This 
indicates that the other isoforms showing exon skipping are either rare or tissue-specific. The 
predicted exon 4a of PRPF3 locates to an Alu element. Interestingly, over 5% of the 
alternatively spliced exons in humans include parts of Alu repeats (Sorek et al., 2002; Lev-
Maor et al., 2003; Krull et al., 2007). These primate-specific elements are also frequently 
found in mRNAs and ESTs and may thus serve as a source of false postitives in EST 
database screening. Nevertheless, these repetitive elements were shown to have a 
considerable influence on evolution of alternative splicing and thereby enhancing regulatory 
and coding capacity of the genome (Gotea and Makalowski, 2006). Of note, the isoforms 
skipping constitutive exons were not observed by ESTs derived from eye or retina.  
We could confirm the expression of exon 3a in retina, the tissue affected by RP. In addition, 
exon 11, to which the RP-associated mutations of PRPF3 locate, is included in isoform 3a 
transcripts. Novel exons may carry unidentified mutations and are thus candidates for 
mutational screening in patients. Screening of PRPF3 revealed five novel intronic and one 
exonic sequence alteration (Supplementary table 5). Disease-causing effects of these 
variations must be investigated be further analysis. However, no mutation in exon 3a was 
found in our RP patient panel. Since residual PRPF3 activity and binding to PRPF4 was 
shown to be essential for survival of non-photoreceptor cells (Ayadi et al., 1998; Gonzalez-
Santos et al., 2005), mutations in PRPF3 may rather affect fine-tuning of protein function 
than eliminating the entire activity. This is supported by the fact that all three mutations 
identified so far locate to the same region probably affecting the same functional domain. 
This may explain why all PPPF3 mutations cause rather mild RP phenotypes in patients 
(Gonzalez-Santos et al., 2008). Furthermore, rate-limiting effects on splicing processes might 
explain the tissue-restricted phenotype observed with PRPF3 mutations.  
Typically, PTCs wich are more than 50-55bp downstream of a splice site are proposed to 
induce NMD (Lejeune and Maquat, 2005). The PTC in exon 3a induces NMD despite closer 
localization (34bp) to the splice site than predicted. This may suggest that NMD in this 
transcript is not elicited by the co-translational removal of the downstream exon junction 
complexes (EJC), but is rather initiated by an alternative pathway using an unknown splicing 
generated signal. Such a pathway has been described for β-globin. Here, a sequence has 
been postulated to functionally substitute the EJC in recruiting NMD factors after the splicing 
process (Zhang et al., 1998; Lejeune and Maquat, 2005). Currently, there is little information 
about gene- or tissue-specific efficiency of NMD. We have determined NMD-induced 
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transcript reduction in the range of 1.5 to 3 fold. Similar values were described for mutations 
in the optic atrophy 1 (OPA1) and in the breast cancer 1 (BRCA1) gene (Schimpf et al., 
2008). A variability of NMD efficiency may also explain the milder phenotype of Becker’s 
muscular dystrophy (BMD) in some patients carrying the same PTC in the dystrophin gene 
as other patients suffering from the more severe Duchene muscular dystrophy (DMD) (Linde 
et al., 2007). Thus NMD efficiency may play an important role as a genetic modifier in 
disease pathologies influencing the expression level of truncated proteins that either cause 
gain-of-function or dominant-negative effects (Bateman et al., 2003; Linde et al., 2007; 
Schimpf et al., 2008). 
Preliminary results of western blot analysis showed clear overexpression of Wt and T494M-
mutated PRPF3. Furthermore, the expression of both isoform 3a ORF2 proteins indicate that 
the translation initiation site in exon 4 can indeed serve as an adequate alternative start 
signal for protein expression producing a protein lacking the PWI domain. Interestingly, the 
PWI motif which is expected to facilitate the formation of subcomplexes within the 
spliceosome was found in mammalian PRPF3 but not in yeast and C. elegans orthologous 
(Szymczyna et al., 2003). This indicates that it may exclusively be used in splice processes 
in higher eukaryotes (Blencowe and Ouzounis, 1999; Gonzalez-Santos et al., 2002; 
Szymczyna et al., 2003). Although the loading control showed similar protein levels of all 
cells no isoform 3a and ORF1 proteins could be detected on the western blot. Since these 
are preliminary results, protein expression analysis must be repeated to clearly show that Wt, 
T494M and ORF2 constructs express proteins while ORF1 and isoform 3a constructs do not.    
Protein misfolding and aggregate formation due to two mutations in the RP-associated splice 
factor PRPF31 were found to substantially inhibit subcellular translocation of the protein into 
the nucleus (Deery et al., 2002). Hence, a similar mechanism could underlie the 
pathogenesis of PRPF3-induced RP.  Recently, Gonzalez-Santos et al. described that no 
differences have been observed in nuclear localization of PRPF3 Wt and T494M (Gonzalez-
Santos et al., 2008). Earlier, localization of deletion constructs missing the central region was 
observed in both, nucleus and cytoplasmic compartments (Gonzalez-Santos et al., 2002). 
However, in neither of these protein localization studies a statistical evaluation was 
published. In contrast, we observed significant differences between PRPF3 Wt and T494M 
with high cell numbers (n = 900 cells). The effect on protein translocation by T494M may not 
be obvious without statistic evaluation. Thus, we show for the first time that a reduced 
nuclear localization caused by the T494M mutation may be part of the pathogenic 
mechanism. PRPF3 was shown to be a substrate but also a direct interacting partner for 
casein kinase II (CKII). The interaction involves the central region of PPRF3 and influences 
the splicing activity triggered by defective association with PRPF4 and U4/U6 snRNAs. This 
suggests that PRPF3 targets CKII to the spliceosome (Lehnert et al., 2008). Although the 
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T494M-mutated protein was found to be less phosphorylated, controversial results on the 
functionality of the position 494 as a recognition motif for CKII are published so far 
(Gonzalez-Santos et al., 2008; Lehnert et al., 2008). Since altered phosphorylation states are 
known to control localization of various proteins, a reduced phosphorylation of T494M may 
also correlate with the reduced nuclear protein translocation observed in our study.  
A similarly decreased level of nuclear localization was found for isoform 3a Wt indicating that 
not only the mutation, but also the inclusion of exon 3a affects the nuclear protein import.  
Since isoform 3a ORF1 proteins almost exclusively locate to the cytoplasm this suggests that 
the N-terminal NLS is not sufficient to translocate PRPF3 proteins into the nucleus.  Isoform 
3a ORF2 localized preferentially in both compartments indicating that other elements besides 
the C-terminal NLS may be necessary for a correct protein transport. No additive effect on 
localization was observed in cells expressing isoform T494M or isoform 3a ORF2 T494M 
compared to their wildtype proteins. Of note, the central region of PRPF3 which is part of the 
PRPF4 binding domain has been shown to be important for protein translocation (Gonzalez-
Santos et al., 2002). This raises the hypothesis that PRPF4 binding may have an influence 
on protein localization. Additionally, analysis of the intranuclear localization revealed 
aggregation of T494M proteins in the nucleolus upon photoreceptor differentiation, while Wt 
proteins remain co-localized with snRNPs in speckles (Comitato et al., 2007). The 
accumulation induced redistribution of other splice factors. This leads to the hypothesis that 
in conditions of elevated splicing activity, as expected during outer segment renewal, 
recycling of T494M PRPF3 may be rate-limiting for the splicing process and may trigger 
apoptosis of photoreceptor cells after their differentiation (Comitato et al., 2007). Together 
with our observation this highly suggests that loss of protein function due to insufficient 
functional protein amounts caused by cytoplasmic retention or accumulation in the nucleolus 
is the pathogenic mechanism underlying PRPF3-induced RP.  
UCEs are genomic regions longer than 200 bp with over 90% conservation between human, 
mouse, rat and dog (Bejerano et al., 2004). Interestingly, UCEs were predominately found in 
RNA-binding proteins and splicing factors and inclusion of these non-protein coding exons 
frequently generates NMD-sensitive transcripts (Bejerano et al., 2004; Ni et al., 2007; 
Saltzman et al., 2008). This strongly implies regulatory functions of these UCEs (Ni et al., 
2007; Saltzman et al., 2008). Recent studies of UCEs showed that their location in core 
splicing components autocontrol and regulate their expression by alternative splicing coupled 
to NMD (Saltzman et al., 2008). Negative-feedback loops limit the expression of the proteins 
and prevent overaccumulation. This control loop was found to either reduce noise of gene 
expression maintaining low expression variability between cells as found for Tra2-β1 or to 
produce oscillatory gene expression (McGlincy and Smith, 2008). High cellular concentration 
of splice factor 2 (SF2/ASF) were shown to accelerate the degradation process of NMD-
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sensitive transcripts by influencing the translation efficiency (Sato et al., 2008). This indicates 
that alterations of expression levels of splicing factors not only influence the expression of 
the particular gene but influences the expression of all genes with NMD-sensitive transcripts. 
Since exon 3a is highly conserved in the respective species and locates to a non-protein 
coding CpG island this may indicate transcript degradation by NMD although not predicted. 
Although expression of PRPF3 isoform 3a seems not to be autoregulated by a negative 
feedback loop sensing the own overexpression, this does not exclude that such a 
mechanisms may be only activated in particular situations as during photoreceptor 
differentiation or in certain tissues. Furthermore, the regulatory function may be relevant not 
for PRPF3 itself but for other splice-relevant transcripts. 
In conclusion, our results show the wide expression of the alternative exon 3a among human 
tissues. Furthermore, inclusion of exon 3a generates NMD-sensitive transcripts and allows 
the expression of a truncated protein lacking the PWI. Thus, precisely regulated expression 
of exon 3a might change the ratio of the two protein isoforms. The reduced nuclear 
localization of mutated PRPF3 suggests that these processes might be part of the 
pathogenic mechanism leading to RP. Furthermore, expression of exon 3a might reduce the 
protein levels available for the nuclear splicing process. Other possible influences on the 
disease pathology remain to be tested. This might include tissue-specific NMD efficiencies 
similar as described in the pathogenesis of Schmid metaphyseal chondrodysplasia (SMCD). 
In SMCD, PTC-introducing mutations in collagen X elicit NMD in cartilage but not in non-
cartilage cells explaining the tissue-restricted phenotype of the disease caused by a widely 
expressed gene (Bateman et al., 2003). Thus, a tissue-specific NMD efficiency of 
photoreceptors on PRPF3 transcripts would explain the retina-restricted phenotype of RP. 
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3.2.8. Tables  
 
accession 
number
tissue species % identity to 
human genome
length of EST 
(in exons)
skipped exons
1 DB282736 uterus Hs 100 2 - 7 3 - 5
2 DB027156 testis Hs 100 1 - 7 3 - 5
3 DA060010 cerebellum Hs 100 1 - 10 6 - 9
4 DA966915 stomach Hs 100 1 - 8 5 - 6
5 AA992923 n/a Hs 100 6 - 16 8 -15
6 CA541475 trophoblast 
stem cells
Mm 90 1- 6 4 -5
 
 
Table 7. Predicted isoform skipping constitutive exons of PRPF3 
Summary of the expressed sequence tags (ESTs) supporting skipping of constitutive exons of 
PRPF3 shown by five human (Hs) and one mouse (Mm) EST. The EST accession number and 
the tissue as well as the species in which the EST was identified are shown in columns 1 to 3. 
Additionally, the identity between EST and human genome, the length of the supporting EST in 
exons and the skipped exons are shown in the following columns.  
 
 
accession 
number
tissue species % identity to 
human genome
length of EST 
(in exons)
1 BQ707849 spleen Hs 100 4a
2 CN267512 embryonic stem cells Hs 100 4a
3 BQ709466 spleen Hs 99 4a
4 EL595215 epidermis Hs 99 4a
5 BF849707 n/a Hs 98 4a - 8
6 BQ708572 spleen Hs 98 4a - 7
7 AV688506 hepatocellular carcinoma Hs 98 4a
8 BM007670 spleen Hs 98 4a
9 AV684043 hepatocellular carcinoma Hs 97 4a  
 
Table 8. Expressed sequence tags predicting expression of PRPF3 exon 4a 
Summary of human (Hs) expressed sequence tags (ESTs) predicting the expression of PRPF3 
exon 4a. Accession numbers, tissue and species in which the EST was identified are shown in 
columns 1 to 3. Additionally, the identity to the human genome and the length of the supporting 
EST are shown in the following columns. 
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accession 
number
tissue species % identity to 
human 
genome
length of 
EST (in 
exons)
1 DA954117 spleen Hs 100 1 - 5
2 DA100787 cerebellum Hs 100 1 - 4
3 DA127943 cerebellum Hs 100 1 - 4
4 DA200903 brain Hs 100 1 - 4
5 DA286242 corpus callosum Hs 100 1 - 4
6 DA489159 brain Hs 100 1 - 4
7 DA819741 n/a Hs 100 1 - 4
8 DA920350 small intestine Hs 100 1 - 4
9 DB179746 kidney Hs 100 1 - 4
10 DB254751 uterus Hs 100 1 - 4
11 DC378225 n/a Hs 100 1 - 4
12 BU948384 insulinoma Hs 100 2 - 5
13 DA343914 substantia nigra Hs 100 2 - 4
14 BI907004 leukocyte Hs 100 2 - 4
15 BP352247 n/a Hs 100 2 - 4
16 CN284215 embryonic stem cells Hs 100 2 - 4
17 DB136590 thymus Hs 100 1 - 3a
18 CA487158 n/a Hs 99 2 - 7
19 BU156605 eye Hs 99 2 - 5
20 BQ932459 brain Hs 99 2 - 5
21 BU558311 breast Hs 98 2 - 6
22 AW176122 breast Hs 98 2 - 3a
23 CV369848 marrow Hs 98 3a
24 EE365371 skin Bt 94 2 - 6
25 EH181146 ascending colon Bt 94 2 - 6
26 DY097993 blood Bt 94 3a - 4
27 EE355102 skin Bt 93 2 - 4
28 BU614500 whole brain Mm 94 2 - 6
29 CA540124 whole embryo Mm 92 2 - 3a
30 CB585756 n/a Rn 92 2 - 5
31 CB767094 n/a Rn 92 2 - 3a  
 
Table 9. Expressed sequence tags predicting inclusion of PRPF3 exon 3a 
Numerous expressed sequence tags (ESTs) predict inclusion of PRPF3 exon 3a in human (Hs), 
mouse (Mm), rat (Rn) and ox (Bt) tissue. Accession numbers of ESTs, the tissue as well as the 
species are shown in columns 1 to 3. The EST observed in eye is marked by bold letters. 
Additionally, the identity and the length of the EST are shown in the following columns. 
 
Gaby-Gerda Tanner  General Discussion 
 91
3.2.9. Figures 
 
 
Figure 17. Prediction of novel isoforms in PRPF3 and their conservation 
(A) Schematic representation of putative novel PRPF3 isoforms in human. Black bars show 
constitutive exons and orange bars novel exons. Isoforms were shown for regions covered by 
ESTs. (B) The overview shows the conservation of genomic PRPF3 sequences of different 
species (Pt: NC_006468.2, chimpanzee, Cf: NC_006599.2, dog, Mm: NC_000069.5, mouse, Rn: 
NC_005101.2, rat and Gg: NC_006112.1, chicken) to human PRPF3 (RefSeq NM_004698). The 
top row shows the positions of constitutive human exons (blue) and novel exons (orange) in the 
genomic region coding for PRPF3. The sequences of the ESTs BU156605 (exon 3a) and 
BF849707 (exon 4a) were used to mark the regions of the novel exons. Aligned regions in the 
different species are shown in green and regions with at least 70% nucleotide identity in red. 
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Figure 18. Sequence alignments of exon 3a and 4a from different species 
 (A) and (B) show sequence alignments of exon 3a  and exon 4a genomic regions (red letters) 
from different species (Pt: NC_006468.2, chimpanzee, Cf: NC_006599.2, dog, Mm: 
NC_000069.5, mouse, Rn: NC_005101.2, rat and GgFehler! Textmarke nicht definiert.: 
NC_006112.1, chicken) to human PRPF3 (Hs: RefSeq NM_004698).  
 
 
 
 
Figure 19. PIP-blot of repetitive elements in genomic sequence of PRPF3 
Repetitive elements are indicated by bars and triangles. Constitutive exons are marked in blue 
and novel exons in orange. 
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Figure 20. Expression of alternative exon 3a in PRPF3 
(A) Verification of exon 3a expression by RT-PCR of cultured cells as well as of mouse 
and human retina. Gray lines indicate the positions of the primers. (B) RT-PCR revealed 
that exon 3a and exon 11, containing the three known RP-associated mutations, are 
part of the same transcript. (C) Constitutive transcripts and transcripts including exon 3a 
are clearly expressed in all tested human tissues. PCR was performed with the primers 
indicated in panel A. (D) Quantitative analysis revealed fluctuating expression levels of 
constitutive PRPF3 transcripts (blue) with highest expression in testis and lowest in 
liver. The ratio between the isoform 3a (violet) and the constitutive PRPF3 is highest in 
kidney, followed by retina and liver (small figure). The error bars show 95% confidence 
intervals. 
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Figure 21. Alternative open reading frames of isoform 3a and nonsense-mediated decay 
(A) Inclusion of exon 3a induces a premature stop codon in exon 3a (stop is shown by 
an asterisk). This generates two novel open reading frames (ORFs) named ORF1 and 
ORF2 indicated by arrows. (B) Comparison of the Kozak consensus sequences of the 
two translation initiation sites in isoform 3a and the yeast consensus. (C) Inhibition of 
the translation by cycloheximide treatment of EBV cell lines indicates that the transcript 
including exon 3a undergoes nonsense-mediated decay (NMD), whereas RNA 
polymerase II expression remains constant in both treatments and all cell lines. (D) 
Quantitative RT-PCR of the cycloheximide treated cells reveals significantly increased 
exon 3a levels due to NMD inhibition. The error bars show 95% confidence intervals. 
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Figure 22. Protein expression and intracellular localization of PRPF3 isoforms 
(A) Seven expression constructs of PRPF3 were cloned for protein localization studies. 
Positions of nuclear localization signals are indicated by NLS, gray bars represent the 
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inclusion of exon 3a and V5 marks the tag. Numbers indicate translation start (1) and 
the construct length in amino acids. Position of the human mutation is indicated by 
T494M. (B) Western blot with anti-V5 shows protein expression in HEK 293T cells 
transfected with wildtype (Wt), mutant (T494M) and a slightly smaller product from both 
ORF2 constructs. No protein expression from ORF1 or isoform 3a constructs was 
observed. Equal loading amount were seen using GAPDH as a control. An anti-PRPF3 
antibody revealed endogenous protein expression for isoform 3a, mock and ORF1 
transfected cells as well as a mixture of endogenous and overexpressed protein from 
Wt, T494M or ORF2 constructs. (C) To study intracellular localization of PRPF3 
isoforms, nuclear, cytoplasmic and the localization in both compartments were 
distinguished. 100 cells from triplicates of three independent transfections (n=900 cells) 
were analyzed. Error bars show 95% confidence intervals. The results showed reduced 
relative nuclear localization of T494M proteins and isoform 3a proteins. Isoform 3a 
ORF1 proteins predominantly localized to the cytoplasm, whereas increased localization 
of the ORF2 proteins was found in both compartments - nucleus and cytoplasm.  
 
 
 
 
Figure 23. Autoregulation of PRPF3 expression 
To study autoregulation of PRPF3 3a isoforms, five replicates (n=5) of HEK293T and 
ARPE-19 cells transfected with different PRPF3 protein expression constructs were 
analyzed for expression of constitutive and isoform 3a PRPF3 transcripts. Error bars 
show 95% confidence intervals Transcript analysis show clear overexpression of the 
constitutive transcripts in cells transfected with Wt and T494M constructs. Interestingly, 
the overexpression is higher in ARPE-19 than in HEK293T although the transfection 
efficiency in ARPE-19 cells was with 24% lower compared to 36% in HEK293T cells. 
Transfection of HEK293T cells with ORF2 Wt isoform does lead to a clear 
overexpression of the constitutive transcripts compared to non- or mock-transfected 
cells, whereas this was not the case in APRE-19 cells. This suggests that isoform 3a 
ORF2 Wt expression may enhance the expression of constitutive PRPF3 variants. 
However, the expression of exon 3a remains constant in all tested cell lines. This 
indicates that no regulatory effect of exon 3a inclusion upon protein overexpression 
exist in PRPF3.  
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3.2.10. Supplementary material 
Supplementary table 1. Primer sequences 
 
Primers for expression verification 
hPRP3Ex2dnGT  GTGGGGAAGGGCATGGACAAG 
hPRP3BU156605upGT  GGTGGTAGGCTTTGGGTGACATCC 
hPRP3Ex6up1GT  GCCTGGGAGGGCTGAATAGTG 
hPRPF3Ex13up  GTCAGGTACAGTTGCCCA 
mPRP3Ex2dnGT   AGCCATGGATAGAGAAGACGGTGAA 
mPRP3Ex6upGT  GCCGATGGGAAGTCGCTCTGGTTG 
 POL2A FOR   GCACCACGTCCAATGACAT 
 POL2A REV   GTGCGGCTGCTTCCATAA 
 
Primers for mutational screening   
hPRPF3_5UTRdn2_new GGTGTAGTATTGAGTCCTG 
hPRPF3Int1up   CTTAGGTGACTCAGTATGGTAGC 
hPRPF3Int1dn   CAGGGCAAGGTCATTTAGTGTA 
hPRPF3Int2up   CACTAATTCATCTCTCCTACTCTA 
hPRPF3Int2dn2  GTGACTACATTGGGTGGG 
hPRPF3Int2up2  ATCAAACAATGGAAACTCAAAT 
hPRPF3Int2dn   GCAAGGTTGTGTCATATTCCCC 
hPRPF3Int3up   CCACAATAAATACAGACCCATGCA 
hPRPF3Int3dn   GCAGGCAGAATGTGGTATAGTC 
hPRPF3Int5up   GCCAGATCAGTAACATTCAAAGG 
hPRPF3Int5dn   CCACGCCTGGCTTTATTTTG 
hPRFP3Int6up   CCTAGAACACAGAGATTTAAC 
hPRPF3Int6dn   CTGTTTTCTATGACTCCAATTTATC 
hPRPF3Int7up   GTACCATCCTTCCCACTAAAACC 
hPRPF3Int7dn   CAAGCACAAGAACCCATTATAG 
hPRPF3Int8up   GCACTTAAAATGTATGTTCACTG 
hPRPF3Int8dn2  ATGTATTCTTACTGCTTTGG 
hPRPF3Int9up3  GATGTTAAAGTTCCTCCAG 
hPRPF3Int9dn   GTTATTGGAGGAAGTGAGTTTAG 
hPRPF3Int11up  GCTCTTGATCCACACTAGGG 
hPRPF3Int11dn  GCATTCATCATTTGTTTACTCCAG 
hPRPF3Int13up  GGAGGCTCAAAGTCTAAACGGG 
hPRPF3Int13dn  GAGCAACAGAAAAGAGAACAC 
hPRPF3Int14up  AGCACTGTCCACGACTTC 
hPRPF3Int14dn  GTCTCACAAATGTTACTAGGT 
hPRPF33’UTRup  GGGGTTGGGAAATAGAATAAGTG  
 
Primers for cloning  
PRP3EcoRI-IF-dn  CCGAATTCGGGGCTGAAGTTTGTGAGGT 
newPRP3-XhoI-IFup   CTCCTCGAGAATCAGTGGACTCTAACACAG 
PRP3-T494M-mid-dn   CTGTTCAAGACCCCATGAAGGTAGAAGCCC 
PRP3-T494M-mid-up   GGGCTTCTACCTTCATGGGGTCTTGAACAG 
PRPF3_5’UTR_BamHI  GCGGGATCCGAAGTTTGTGAGGTGTAGTATTG 
PRPF3_Estup1XhoI   CCGCTCGAGAGGAGGGCTCGTGTTTTGC 
PRPF3_Est4dnEcoRI   GGAATTCCAGGAAGCGCTCGCCCCTGGCCG 
hPRPF3Ex16upStopXhoI CCGCTCGAGAATCAGTGGACTCTAACACAG 
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forward primer reverse primer annealing temperature elongation time
hPRP3Ex2dnGT hPRP3Ex6up1GT 64°C 2 minutes
mPRP3Ex2dnGT mPRP3Ex6upGT 64°C 2 minutes
hPRP3BU156605upGT hPRPF3Ex13up 60°C 4 minutes
RNA poly II dn RNA poly II up 58°C 2 minutes  
 
Supplementary table 2. Primer combinations and  RT-PCR conditions 
Total reaction volume of RT-PCR was 25µl and contained 3µl primers (5µM; Microsynth, 
Balgach, Switzerland), 0.5µl dNTPs (10mM), 3µM MgCl2, 0.25µl Hotfire polymerase 
(5U/µl) and 50ng cDNA as template. All RT-PCR ingredients except primers were from 
Solis BioDyne (Tartu, Estonia). RT-PCR reaction was started with 15 minutes activation 
of the Hotfire at 95°C. This step is followed by 35 cycles of 1 minute denaturation at 
95°C, 1 minute annealing at the temperature indicated above and elongation at 72°C for 
the time listed above. The reaction is finished with 10 minutes additional elongation time 
at 72°C.   
 
 
forward primer reverse primer MgCl (uM) Q annealing temperature elongation time
hPRPF3_5UTRdn2_new hPRPF3Int1up 1,5 - 60°C 2,5 minutes
hPRPF3Int1dn hPRPF3Int2up 3 - 56°C 2,5 minutes
hPRPF3Int2dn2 hPRPF3Int2up2 1,5 - 52°C 2 minutes
hPRPF3Int2dn hPRPF3Int3up 1,5 - 56°C 2,5 minutes
hPRPF3Int3dn hPRPF3Int5up 1,5 - 58°C 2,5 minutes
hPRPF3Int5dn hPRFP3Int6up 1,5 - 56°C 2,5 minutes
hPRPF3Int6dn hPRPF3Int7up 3 - 54°C 2,5 minutes
hPRPF3Int7dn hPRPF3Int8up 3 + 54°C 2,5 minutes
hPRPF3Int8dn2 hPRPF3Int9up3 3 - 55°C 2,5 minutes
hPRPF3Int9dn hPRPF3Int11up 3 - 58°C 2,5 minutes
hPRPF3Int11dn hPRPF3Int13up 3 - 58°C 2,5 minutes
hPRPF3Int13dn hPRPF3Int14up 3 - 58°C 2,5 minutes
hPRPF3Int14dn hPRPF33’UTRup 3 - 58°C 2,5 minutes  
 
Supplementary table 3. Primer combinations and  PCR conditions 
Total reaction volume of PCR was 25µl and contained 2µl primers (5µM; Microsynth, 
Balgach, Switzerland), 0.5µl dNTPs (10mM), 0.125µl Hotfire polymerase (5U/µl) and 
70ng gDNA as template. MgCl2 concentration and Q-solution added are listed above. All 
PCR ingredients were from Solis Biodyne (Tartu, Estonia). PCR reaction was started 
with 15 minutes activation of the Hotfire at 95°C. This step is followed by 30 cycles of 1 
minute denaturation at 95°C, 1 minute annealing at the temperature indicated above 
and elongation at 72°C for the time listed above. The reaction is finished with 10 
minutes additional elongation time at 72°C.   
 
 
forward primer reverse primer annealing temperature elongation time
PRP3EcoRI-IF-dn newPRP3-XhoI-IFup 60°C 5 minutes
PRPF3_5’UTR_BamHI PRPF3_Estup1XhoI 60°C 1.5 minutes
PRPF3_Est4dnEcoRI hPRPF3Ex16upStopXhoI 60°C 4 minutes  
 
Supplementary table 4. Primer combinations and ProofStar PCR conditions 
Total reaction volume of ProofStar PCR was 50 µl and contained 6µl primers (5µM; 
Microsynth, Balgach, Switzerland), 3µl dNTPs (10mM), 1,5µM MgCl2, 1µl ProofStar 
polymerase (5U/µl) and 50ng cDNA as template. All ProofStar PCR ingredients were 
from Qiagen (Hombrechtikon, Switzerland). RT-PCR reaction was started with 5 
minutes activation of the Proofstar at 95°C. This step is followed by 35 cycles of 1 
minute denaturation at 95°C, 1 minute annealing at the temperature indicated above 
and elongation at 72°C for the time listed above. The reaction is finished with 10 
minutes additional elongation time at 72°C.   
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position number of patients DNA number polymorphism Average Heterozygosity comments
c.146 - 17 G>A 33 rs11205362 n.d.
c.146 - 16 C>T 1 22225
Intron 2 c.277 - 52 T>C 107 rs834225 0.482 +/- 0.093
Exon 6 c.1032 A>G; p.T344T 1 18259 4bp upstream of the DS
Intron 7 c.1202 + 25 A>C 24 rs11806171 0.061 +/- 0.163
Intron 9 c 1427- 62 A>G 13 rs17648533 0.094 +/- 0.195
22461
11981
22461
11981
Intron 13 c.1837- 65 C>G 11 rs16836186 0.131 +/- 0.220
c.1899 + 104 T>G 2 rs3737319 0.094 +/- 0.195
c.1899 + 191 G>C 1 22353
23656
23655
Intron 1
Intron 11
Intron 14
2c.1899 + 205 T>C
c.1633 + 65 G>A 2
c.1633 + 66 C>A 2
 
 
Supplementary table 5. Nucleotide substitutions observed in PRPF3 in retinitis pigmentosa 
patients 
Screening for mutations in PRPF3 revealed no variations in exon 3a, whereas the 
occurrence of six known polymorphisms was observed in the patient panel (n=169). 
Five intronic substitutions were found in several patients. One silent exchange in exon 6 
was observed to locate 4 nucleotides (bp) upstream of the donor splice site (DS). The 
influence of the exonic mutation on splice site recognition can not be ruled out. Control 
individuals should be sequenced to analyze if unclear variations represent rare 
polymorphism.  
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3.3. Therapeutic strategy to rescue mutation-induced exon skipping 
in rhodopsin by adaptation of U1 snRNA. 
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3.3.1. Abstract 
Retinitis pigmentosa (RP) is a degenerative retinopathy leading to visual impairment 
in more than 1.5 million patients worldwide. Splice site mutations cause various 
diseases including RP. Most exonic donor splice site mutations are reported at the 
last nucleotide of an exon and over 95% of them are predicted to result in mis-
splicing. 
A novel human mutation at the last nucleotide of exon 4 in rhodopsin (RHO, 
c.936G>A) is shown to generate two mis-spliced transcripts in COS 7 cells and retinal 
explants. One of these transcripts skips exon 4 whereas the other activates a cryptic 
donor splice site. Both are predicted to result in truncated RHO, explaining the 
pathogenic mechanism underlying the patients’ RP phenotype. 
U1 snRNA mediated donor splice site recognition is a key step in the splicing 
process. As a therapeutic strategy, U1 snRNAs was adapted to the novel RHO 
mutation and tested for its potential to revert mis-splicing. The rescue efficiency for 
mis-spliced transcripts of RHO was examined by quantitative RT-PCR. Using 
mutation-adapted U1 snRNA, we observed significantly reduced exon skipping that 
reached wildtype levels. Nevertheless, activation of the cryptic splice site was still 
detected. To test the feasibility of the strategy for mutations which only cause exon 
skipping, we inactivated the cryptic splice site. Indeed, adapted U1 snRNA was able 
to rescue over 95% of mis-spliced transcripts. 
This study shows that modified U1 snRNAs constitute a promising therapeutic 
strategy to treat donor splice site mutations. Our findings have implications on various 
diseases caused by similar mutations. 
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3.3.3. Introduction 
Retinitis pigmentosa (RP) represents one of the most prevalent retinopathies and 
affects 1 in 3000 - 4000 individuals. Worldwide, about 1.5 million patients are 
diagnosed with RP. The disease leads to visual handicap or even complete blindness 
(Farrar et al., 2002; Kennan et al., 2005; Chen et al., 2006; Mordes et al., 2006). So 
far, no cure is available for this type of retinal degeneration. 
First disease manifestations constitute night blindness and constriction of peripheral 
vision, which are caused by progressive retinal degradation initially starting in rod 
photoreceptors (Kennan et al., 2005; Chen et al., 2006; Hartong et al., 2006). During 
disease progression, attenuation of retinal vessels, accumulation of intra-retinal 
pigment deposits, and reduced cone cell viability occur. In later stages, atrophy of the 
retinal tissue and severe visual impairments are found (Farrar et al., 2002; Kennan et 
al., 2005; Chen et al., 2006; Mordes et al., 2006). Occasionally, RP patients can 
develop posterior subcapsular cataracts, cystoid macular oedema and waxy optic 
nerve pallor (Chen et al., 2006). 
RP is a clinically variable disorder with respect to disease severity, age of onset, and 
rate of progression. Moreover, the disease is genetically heterogeneous and involves 
more than 35 genes with different modes of inheritance (Kennan et al., 2005; Chen et 
al., 2006; Hartong et al., 2006). Autosomal dominant inheritance seems to occur in 
the majority of RP families, whereas recessive, X-linked and sporadic cases are less 
frequent (Chen et al., 2006). 
Rhodopsin (RHO, OMIM 180380) was the first gene to be associated with autosomal 
dominant RP and accounts for most of these cases (up to 25%) (Mordes et al., 2006). 
More than 100 RHO mutations have been described so far (Deretic et al., 2005). On 
the protein level, the mutations affect protein folding, chromophore binding, G-protein 
activation, or cellular trafficking, all causing a disruption of the phototransduction 
cascade (Schuster et al., 2005; Chen et al., 2006; Hartong et al., 2006; Shinohara et 
al., 2008). RHO is localized within the disc membranes of the rod outer segments, 
where it accounts for approximately 70% of the total protein (Liang et al., 2004; 
Kennan et al., 2005). 
Point mutations are the most common cause of RP and the majority (84%) of them is 
reported as missense or nonsense mutations. Interestingly, the impact of point 
mutations on splicing received more attention in recent years and about 15% of the 
single nucleotide substitutions are currently expected to cause or modify human 
genetic diseases through mis-splicing (Faustino and Cooper, 2003; Baralle and 
Baralle, 2005; Lopez-Bigas et al., 2005; Chen et al., 2006; Wang and Cooper, 2007).  
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The splice process requires recognition of splice sites (SS) and spliceosome 
assembly. The assembly is initiated by formation of stable complexes of U1 small 
nuclear RNA (U1 snRNA), pre-mRNA and splice factor proteins (Puig et al., 2007). 
Donor splice sites (DS) are recognized by the U1 complex through complementary 
base pairing of the U1 snRNA to the pre-mRNA, a process assisting in exon 
recognition and definition. In later stages of splicing, U1 snRNA dissociates from the 
DS and is subsequently replaced by U6 snRNA to initiate the transesterification 
reactions necessary to join the exons (Zhuang and Weiner, 1986; Sahashi et al., 
2007). 
The consensus sequence of DS includes the last 3 nucleotides of an exon (position -
3, -2, and -1) and the first 6 nucleotides of an intron (positions +1 to +6) (Shapiro and 
Senapathy, 1987; Roca et al., 2005). The last exonic position (-1 in respect to the SS) 
is found to be a G in 78%, whereas an A accounts for 10% of all cases (Shapiro and 
Senapathy, 1987). 
The importance of DS and acceptor splice site (AS) for correct splicing is reflected by 
the fact that 10% of the point mutations locate to these regions and have been 
reported to result in one or a combination of splice anomalies, namely exon skipping, 
cryptic splice site (CS) activation, and intron retention. DS mutations are more 
frequently reported than AS mutations. In particular, 64% of the DS mutations are 
situated in the first two intronic base pairs (Sironi et al., 2001; Krawczak et al., 2007). 
This may be due to the fact, that the GT dinucleotide is almost exclusively found at 
this position (98.5%) and only a minor proportion of splice sites use GC (1%) or AT 
(0.4%) dinucleotides (Stoilov et al., 2002). In addition, DS mutations are often found 
at positions -1, and +5 of the splice junction (Krawczak et al., 2007). However, the 
molecular mechanisms for accurate SS selection remains controversial and 
incompletely understood (Sironi et al., 2001; Borensztajn et al., 2006). 
In this report, we describe a novel exonic SS mutation in RHO which is associated 
with the ocular phenotype of RP. Different minigene constructs were used to analyze 
the impact of this mutation on the recognition of DS in cell culture and in mouse 
retinal explants. Our results show that mutation-induced exon skipping of RHO can 
be rescued by adaptation of U1 snRNA to the mutation. Additionally, we could show 
that a GC 4bp upstream of the constitutive DS serves as CS. Inactivation of this 
position improved accuracy of SS recognition following U1 snRNA-mediated rescue. 
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3.3.4. Material and Methods 
Mutation analysis  
Genomic DNA from 78 Swiss RP patients referred to us for genetic diagnosis was 
extracted from blood samples (Chemagic Magnetic Separation Module I; Chemagen 
AG, Baesweiler, Germany). From all patients informed consent was obtained prior to 
genetic testing. Screening for disease-associated sequence alterations in RHO 
(GenBank RefSeq NM_000539.3) was performed by direct sequencing of PCR 
products of coding regions including flanking intronic sequences (Genetic Analyzer 
ABI Prism 3100; Applied Biosystems, Rotkreuz, Switzerland). The screening 
procedure has previously been published (Neidhardt et al., 2006). DNA mutation 
nomenclature is based on cDNA sequence with the A of the translation initiation site 
corresponding to position +1 (www.hgvs.com) (den Dunnen and Antonarakis, 2000). 
 
Clinical examination  
The patient was examined including funduscopy, best corrected visual acuity and slit-
lamp examination. Visual fields were evaluated by Goldmann kinetic perimetry. Full-
field electroretinography was performed according to the standard protocol of the 
International Society for Clinical Electrophysiology of Vision (LKC UTAS 3000®, LKC 
Technologies Inc. Gaithersburg, MD, USA) (Marmor and Zrenner, 1998; Gerber et al., 
2003). A Goldmann-Weekers adaptometer (Haag-Streit, Köniz, Switzerland) was 
used for dark adaptometry measurements. 
 
Cloning of minigene and expression constructs 
To generate minigene constructs, genomic sequences spanning a region from intron 
2 to 4 of RHO were cloned into pSPL3 vector (Church et al., 1994). This region was 
amplified by PCR from patient DNA using primers including BamHI and XhoI 
restriction sites (Rho-Ex4-upBamHI, Rho-Ex3-dnXhoI, Supplementary table 6). 
ProofStart polymerase (Qiagen, Hombrechtikon, Switzerland) was used at an 
annealing temperature of 65°C and 4.5 min extension time. All PCR products were 
verified by direct sequencing. PCR fragments derived from the non-mutated allele 
were used to generate control minigene constructs (mini-wt), whereas fragments from 
the mutated allele resulted in minigenes containing the novel mutation c.936G>A in 
exon 4 of RHO (mini-mut). The mutated allele also included a known polymorphism 
(c.936+307A>T; rs2855557) in intron 4. 
The sequence variation c.933G>A in exon 4 of RHO was introduced into minigenes 
by mutagenesis and resulted in mini-wt_c and mini-mut_c constructs. For 
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mutagenesis, two overlapping PCR fragments were amplified using primers 
containing a nucleotide mismatch (MW_crypt_dn, MW_crypt_up, MM_crypt_dn, 
MM_crypt_up, Rho-Ex4-upBamHI, Rho-Ex3-dnXhoI, Supplementary table 6). 
Subsequently, these two PCR products were used as templates in the secondary 
PCR and cloned into the vector pSPL3. 
The derivate pG3U1 of pHU1 (Lund and Dahlberg, 1984; Pagani et al., 2002) was 
used to express U1 snRNA (U1-Wt). The sequence variations of the different mutated 
U1 constructs (U1-Mut, U1-RHO_Wt, U1-RHO_Mut) were introduced by mutagenesis 
as described above. PCR reactions were performed with proofreading polymerase 
and the following primers: pGU1Mutfwd, pGU1Mutrev, pGU1RhoWTfwd, 
pGU1RhoWTrev, pGU1RhoMutfwd, pGU1RhoMutrev (Supplementary table 6). All 
constructs were verified by sequencing. 
 
Cell culture, transfection and retinal explants 
COS 7 cells were cultured in 6-well plates using Dulbecco’s modified Earle’s medium 
DMEM supplemented with 10% FCS, 1.4% glutamine and 1.2% 
penicillin/streptomycin (LabForce, Nunningen, Switzerland). At a confluence of 60-
80%, transfection was performed with 2.4µg minigene plasmid and either 0.5µg or 
2.4µg U1 construct. DNA was diluted in 150mM NaCl and mixed with branched 
polyethylenimine (Sigma-Aldrich, Steinheim, Germany) in a ratio of N/P of 8. After 30 
minutes incubation at room temperature, the mixture was added to the cells. 
Centrifugation of the 6 well plates (280g, 5 minutes, room temperature) increased the 
transfection efficiency. Two days after transfection, cells from 2 wells were harvested 
and pooled before RNA extraction. 
Preparation, electroporation and culturing of explant cultures were carried out 
according to published protocols (Matsuda and Cepko, 2004; Kiang et al., 2005). 
Briefly, 12–14 retinae were dissected from newborn C57 mouse pups and 
electroporated with mini-wt and mini-mut minigene constructs. Electroporated retinas 
were cultured in vitro for 14 days before RNA extraction. 
 
RNA extraction and RT-PCR analysis 
Cell pellets and retinal explants were homogenized with either QIAshredder columns 
(Qiagen, Hombrechtikon, Switzerland) or rotor-stator homogenizer (ULTRA-TURRAX 
T8; IKA Werke, Staufen, Germany). Total RNA was extracted with RNeasy extraction 
kit according to the manufacturer’s protocol (Qiagen, Hombrechtikon, Switzerland). 
RNA quality was controlled by electrophoresis, UV spectrometric measurement 
(Nanodrop, Witec AG, Littau, Switzerland), and analysis with the bioanalyzer 2220 
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(RNA 6000 Nano kit; Agilent, Basel, Switzerland). Single-stranded cDNA synthesis 
was performed with superscript III reverse transcriptase (Invitrogen, Basel, 
Switzerland) according to manufacturer’s instruction using the vector-specific primer 
SA2 (Supplementary table 6).  
RT-PCR analyses of transfected COS 7 cells or retinal explants were performed 
according to the manufacturer’s protocol (Exon trapping system, Invitrogen, Basel, 
Switzerland). Briefly, two nested PCR reactions were performed with Hotfire 
polymerase (Solis Biodyne, Tartu, Estonia). PCR products from the primary reaction 
(primers SA2 and SD6, Supplementary table 6) were digested with BstXI restriction 
enzyme (Fermentas, Nunningen, Switzerland) to specifically remove splice products 
derived from the vector backbone. The secondary PCR was performed with 5µl 
digested PCR reaction as template and nested primers dUSA4 and dUSD2 
(Supplementary table 6). Secondary PCR products were analyzed by agarose gel 
electrophoresis, sequencing and fragment analysis. 
 
Quantification of transcripts 
For fragment analysis, minigene-derived transcripts were amplified using a FAM-
labeled dUSD2 primer and analyzed with a Genetic Analyzer ABI Prism 310 (Applied 
Biosystems, Rotkreuz, Switzerland). ROX1000 (Applied Biosystems, Rotkreuz, 
Switzerland) served as size standard.  
Quantitative RT-PCR analyses were performed on the ABI Prism 7900 HT SDS with 
Assay by Design MGB probes (Applied Biosystems, Rotkreuz, Switzerland). These 
probes were designed to compare splice events either including RHO exon 3 to 4 or 
RHO exon 3 to pSPL3. Ratios of both transcript levels were calculated to relatively 
quantify the skipping of RHO exon 4. The efficiency of the MGB probes was validated 
according to the manufacturer’s instructions. Statistical analysis was performed by 
SDS2.2 software (Applied Biosystems, Rotkreuz, Switzerland) using automatic 
outlayer removal (n=4-5) and calculation of the error as 95% confidence interval. 
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3.3.5. Results 
Identification of a novel rhodopsin mutation in an RP patient 
Sequencing of exonic and flanking intronic regions of RHO in 78 RP patients revealed 
a novel mutation in one individual. We detected a heterozygous G to A exchange 
c.936G>A (p.Gln312Gln) which affects the last base of RHO exon 4 (Figure 24A). 
The deduced protein sequence is not altered by this nucleotide change, but the 
mutation affects the donor splice site (DS) of exon 4. Hence, the novel mutation is 
predicted to interfere with splicing and/or exon definition. 
 
Clinical characterization of the RP patient 
The patient was examined at the age of 42 to confirm a suspected diagnosis of RP. 
The patient’s primary complaint was night blindness. Visual acuity was 20/20 in both 
eyes. Additionally, slight myopia was present in both eyes: -1 diopters in the right eye 
and -2.75 diopters in the left eye. Besides slight bilateral posterior subcapsular 
cataract, anterior segment morphology was normal. Intraocular pressure was 12 
millimetres of mercury in both eyes. Fundus examination revealed slightly pale discs 
in both eyes as well as rarefied and attenuated vessels. Pigment mottling and bone 
spicules in the periphery were present. Both maculae exhibited a fine epiretinal gliosis 
and an atrophic aspect of the retina. A subtle cystoid macular oedema was detected 
in the left eye. Dark adaptometry showed a loss of rod sensitivity of about 2 log units 
while cone sensitivity was still within normal ranges. Goldmann kinetic perimetry 
revealed a concentric constriction of the visual field (Figure 24B). Full-field 
electroretinography showed extinguished rod-driven signals. Cone-driven signal 
amplitudes and implicit times were severely impaired. Signals could only be recorded 
in single flash stimulation (Figure 24C - F). Together, the results of the clinical 
examination confirmed the diagnosis of RP. 
 
Mis-splicing of RHO induced by the novel mutation c.936G>A 
To analyze the effect of the mutation c.936G>A on splicing of RHO, minigenes of the 
normal (mini-wt) and mutant (mini-mut) patient’s alleles, including the genomic region 
from intron 2 through 4, were cloned and tested in cell culture assays (Figure 25A).  
RT-PCR analysis of RNA from COS 7 cells, which were transfected with mini-wt, 
showed a single band at 554bp. Sequencing confirmed that this amplicon contained 
correctly spliced exon 3 and 4 of RHO (Figure 25B and C). In contrast, RT-PCR 
analysis of mini-mut revealed aberrant splicing with three products at 310, 550, and 
670bp (Figure 25B). The product at 310bp represents transcripts that skip exon 4 of 
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RHO (r.697_936del). Furthermore, splice products found at 550bp show a 4bp 
deletion at the end of exon 4 leading to a shift in the open reading frame 
(r.933_936del, Figure 25C). The 670bp product contains a cryptic exon derived from 
vector pSPL3 and thus is considered to be unspecific for RHO splicing. 
To analyze the splicing of RHO minigenes in photoreceptor cells, the minigenes were 
transfected into mouse retinal explants. RT-PCR showed a similar splice pattern as 
observed in COS 7 cells (Supplementary figure 1). Sequencing verified these results. 
In conclusion, weakening of the DS by the novel RHO mutation (c.936G>A) is leading 
to both exon skipping and frameshift (r.[697_936del, 933_936del]). Thus, mis-splicing 
is likely to be the disease mechanism causing RP in the patient described herein. 
 
Relative quantification of mutation-induced exon skipping in RHO 
We performed fragment analysis of RT-PCR products and confirmed the splice 
pattern generated by mini-wt and mini-mut. Moreover, fragment analysis revealed that 
even mini-wt generated residual levels of transcripts skipping exon 4 (310bp) and 
transcripts including the unspecific pSPL3 exon at 670bp (Figure 25E). 
Quantitative RT-PCR was used to determine the expression levels of transcripts 
skipping or including exon 4 and to calculate their ratios (310/554bp and 310/550bp). 
Compared to mini-wt, we detected a significant increase of exon 4 skipping in mini-
mut samples by a factor of about 5 (Figure 25D). This shows that the novel RHO 
mutation is interfering with DS recognition and definition of exon 4. 
Together, the mutation c.936G>A, although not directly changing the amino acid 
sequence, is deleterious at the level of post-transcriptional processing and induces 
mis-splicing of RHO (r.[697_936del, 933_936del]). 
 
Rescue of mutation-induced exon skipping by U1 snRNA adaptation 
Disturbed base pairing of U1 snRNA with the mutated DS of RHO exon 4 may explain 
why exon skipping or activation of the CS causes RP in the patient. We postulated 
that adaptation of U1 snRNA to the mutation may reduce skipping of exon 4 and 
increase the amount of correctly spliced transcripts. To test this hypothesis, we 
cotransfected RHO minigenes together with expression constructs coding for adapted 
U1 snRNA into COS 7 cells and assessed exon 4 skipping by quantitative RT-PCR. 
Relative quantification was performed as described above. Adapted U1 snRNAs (U1-
Mut and U1-RHO_Mut) were modified to match either the mutation or both the 
mutation and the sequence surrounding of the exon 4 DS (Figure 26A). To control for 
the effect of the adaptations, U1 snRNA expression constructs (U1-Wt or U1-
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RHO_Wt) were generated that show the wild type sequence at the position of the 
mutation (Figure 26A).  
Splicing of mini-wt was not altered by any of the U1 expression constructs including 
the adapted ones (Figure 26B). In contrast, skipping of exon 4 in mini-mut was 
significantly reduced by cotransfection with U1-RHO_Wt (Figure 26C and Table 10). 
The quantitative RT-PCR of cotransfections with mutation-adapted U1 snRNAs (U1-
Mut and U1-RHO_Mut) showed that exon 4 skipping can be diminished to a residual 
level found in mini-wt (Figure 26C and Table 10). For quantification, the ratio between 
transcripts that either skip or include exon 4 was compared by real-time RT-PCR. 
Overexpression of U1-Wt in cells transfected with mini-mut showed no beneficial 
effect on splicing. Two different transfection concentrations of U1 constructs (0.5 and 
2.4µg) were tested and showed comparable results (data not shown). 
Our data demonstrate that the adaptation of U1 snRNA can rescue exon skipping in 
mis-spliced transcripts. Nevertheless, sequencing of the PCR products revealed that 
the rescued transcripts from mini-mut still use the CS in exon 4 and thus show a 4bp 
deletion, even in those cases which were cotransfected with U1-RHO_Mut (Figure 
26D). Hence, adaptation of U1 snRNA can efficiently reverse exon skipping, although 
activation of CS is not rescued in the case studied.  
 
Inhibition of the cryptic splice site confirms the rescue potential of U1 snRNA 
In addition to exon 4 skipping, the RHO c.936G>A mutation leads to an activation of a 
CS. Interestingly, this CS is characterized by a GC dinucleotide at the beginning of 
the intron instead of the more conserved GT.  
The strength of the different DS were calculated based on consensus values as 
suggested by Shapiro and Senapathy (Shapiro and Senapathy, 1987). This 
calculation indicates that the novel mutation causes a decrease in the consensus 
value of the constitutive DS from 71 (mini-wt) to 58.6 (mini-mut, Figure 27A). 
Simultaneously, this mutation increased the value for the CS from 58.6 (mini-wt) to 
69.3 (mini-mut). These data support that the mutation causes activation of the CS 4 
base pairs upstream of the consensus DS.  
We further aimed to test the feasibility of the U1 snRNA rescue approach for 
mutations that do not show activation of a near CS. To inactivate the CS in our 
minigenes, we exchanged the CS-derived G with an A (c.933G>A, Figure 27A). 
Supportively, the calculated consensus values for this exchange predicted that the 
CS will be inactivated (value of 51.1) and the mutated DS might be preferred again 
(value of 58.6) by the splice machinery. RT-PCR and fragment analyses of cells 
transfected with wildtype minigenes that contained the mutated CS (mini-wt_c) 
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revealed the complete splice product including exons 3 and 4 of RHO. In contrast, the 
inactivation of CS in mutant minigenes (mini-mut_c) led to a significant increase in 
exon 4 skipping (Figures 27B and C). Compared to mini-wt_c, mini-mut_c showed a 
3000 fold higher ratio of exon skipping. Thus, the inactivation of the CS led to a 
drastic increase in exon skipping. 
These newly generated minigenes provide the experimental basis to study the 
influence of the U1 rescue approach on mutation-induced exon skipping events that 
lack an activation of a CS. Comparable to wildtype minigenes, splicing of mini-wt_c 
was not altered by cotransfection with any of the four U1 snRNAs (data not shown). 
Interestingly, mini-mut_c cotransfected with U1-Wt and U1-Mut did not reverse 
skipping of exon 4. In contrast, exon 4 inclusion was observed with U1-RHO_Wt and 
U1-RHO_Mut (Figure 27C). As confirmed by sequencing, the rescued transcripts 
contained the complete exon 4 also including the last 4 bp (Figure 27D). 
Quantification confirmed that exon 4 skipping is indeed drastically reduced by 
cotransfection with U1-RHO_Wt and U1-RHO_Mut. We found that up to over 90% of 
mis-spliced transcripts are rescued (Figure 27C and Table 10). These data indicate 
that SS mutations that cause exon skipping without activation of CS can be efficiently 
rescued by adapted U1 snRNA. This confirms its strong potential for therapeutic use, 
which may help to reduce or stop disease manifestations in patients suffering from 
DS mutations. 
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3.3.6. Discussion 
In this report, we describe the identification and characterization of a novel exonic DS 
mutation in RHO and the evaluation of a therapeutic strategy to treat this type of 
mutation. 
The novel mutation affects the last base of exon 4 and changes the DS consensus 
sequence. Interestingly, most RHO mutations that lead to splice defects are located 
to intron 4. One of these mutations also affects the DS, causes a G to T exchange at 
the first intronic position (c.936+1G>T), and was predicted to activate a CS (Macke et 
al., 1993). Additional mutations were reported to change the consensus sequence of 
the AS of exon 5 (Bell et al., 1994; Reig et al., 1996). 
The recognition of the DS is one of the key events during splice processes. Mutations 
that destroy the natural DS sequence often cause skipping of the respective exon 
(Buratti and Baralle, 2004). With the exception of the intronic GT dinucleotide, most 
nucleotide substitutions affecting DS are predicted to locate to the same position 
where we have found the novel RP-associated mutation in RHO. Furthermore, over 
95% of these exchanges are predicted to affect pre-mRNA splicing (Sahashi et al., 
2007). We used minigene constructs to verify the impact of the novel RHO mutation 
on splicing and detected two mis-spliced transcripts. None of these transcripts use 
the constitutive DS. Thus, the nucleotide substitution can be considered as a loss-of-
function mutation caused by aberrant splicing.  
Minigenes have been shown to reliably predict splice defects (Schneider et al., 2007) 
and represent a suitable tool to analyze aberrant splicing. This is particularly relevant 
for transcripts with tissue-specific gene expression like RHO. Furthermore, minigenes 
can be studied in different cell culture systems and conditions. We identified the 
mutation-induced aberrant RHO transcripts in both, transfected COS 7 cells and 
mouse retinal explant cultures. In the retinal explants, photoreceptors, which are the 
target of the diseases, represent approximately 80% of the transfected cells. This 
indicates that the observed splice defects of RHO are similar in different cell types. 
Nevertheless, photoreceptors may contain specific splice factors that influence the 
severity of the splice defects. Furthermore, our minigene studies showed that a 
vector-derived exon may also be spliced into the transcript. Although this vector-
derived exon is not present in RHO, we cannot exclude that similar processes occur 
in photoreceptors of the patient. 
Mutation-induced skipping of exon 4 truncates parts of the seven trans-membrane 
domains of RHO including the visual pigment binding site. This is likely to result in 
structurally and functionally unstable RHO (Mendes et al., 2005). Due to CS 
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activation, the second mis-spliced transcript shows a 4bp deletion leading to a 
frameshift and a termination codon after 48 amino acids. The corresponding protein is 
predicted to contain several RHO-unrelated amino acids at the C-terminal end. The 
C-terminus of RHO is known to code for a sorting signal. Mutations in this region have 
been shown to lead to protein mis-localization and accumulation in the golgi 
apparatus (Deretic et al., 2005; Mendes et al., 2005). Unstable proteins as well as 
reduced RHO concentration in the rod outer segments induce rod photoreceptor cell 
death and explain the RP phenotype observed in the patient described herein 
(Deretic et al., 2005; Mendes et al., 2005). 
To the best of our knowledge, we demonstrate for the first time the feasibility of a 
therapeutic strategy to treat DS mutations affecting the last exonic position. Our data 
indicate that manipulation of U1 snRNA can reverse deleterious effects of DS 
mutations and lead to increased levels of exon recognition. Quantitative assessment 
of the ratio between transcripts that either include or exclude exon 4 showed that 
exon skipping can be rescued by the U1 snRNA approach. The highest rescue of 
exon skipping was observed when the amount of mis-spliced transcripts was low (as 
observed with mini-mut constructs). The rescue reached over 95% with the mini-
mut_c constructs. This suggests that the potential of adapted U1 snRNA as a 
therapeutic agent depends on the strength of the DS that is affected by the mutation. 
Supportively, our experiments showed that depending on the sequence surrounding 
of the DS the adaptation of U1 snRNA needs to be optimized.  
Two different concentrations of U1 (0.5 and 2.4µg) were found to produce similar 
rescue levels. It is unclear whether higher or lower U1 concentrations may have 
beneficial effects on the rescue approach. It will be a matter of further investigations 
to determine an adequate dose-response curve and to estimate an optimal U1 
concentration for future therapeutic strategies.  
The novel RHO mutation activated a CS which was not rescued by adapted U1 
snRNAs. This may be explained by the fact that the mutation is not only weakening 
the constitutive DS, but simultaneously activating the CS. Consequently, U1 snRNA 
predominantly recognizes the stronger SS. This hypothesis was confirmed by our 
results and the calculation of consensus values (Shapiro and Senapathy, 1987). 
Activation of unexpected CS as well as intron retention was also seen in U1 rescue 
experiments published by other groups. Exon skipping due to a deletion of DS 
positions +5 to +11 in albumin was partially rescued by manipulation of U1 snRNA, 
but in addition novel splice isoforms were produced by CS activation (Hitomi et al., 
1998). In the TCIRG1 gene, mis-splicing caused by a substitution in DS at position +4 
could be rescued. In addition, mutations at position +5 resulted in increased intron 
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retention or CS activation (Susani et al., 2004; Pinotti et al., 2008), indicating that SS 
recognition does not only depend on consensus sequences. In the alternatively 
spliced tau exon 10, secondary hairpin formation is described to modulate SS 
selection (Buratti and Baralle, 2004; Garcia-Blanco, 2006). Furthermore, competition 
between alternative SS can be altered by numerous different proteins acting on splice 
regulatory sequences. Together, these findings indicating that the prediction of CS 
activation or the processes leading to SS recognition constitute challenges in the U1-
mediated splice rescue approach (Thanaraj and Clark, 2001; Buratti and Baralle, 
2004; Buratti et al., 2006; Puig et al., 2007). 
Cell-type independent mechanisms for accurate recognition of DS have been shown 
to result from 5’ to 3’ oriented scanning of the pre-mRNA (Borensztajn et al., 2006). 
This mechanism predicts that DS mutations lead either to skipping of the mutated 
exon or to an activation of CS that correspond to the first suitable DS consensus 
sequence encountered by the spliceosome (Borensztajn et al., 2006). Nevertheless, 
a strong putative CS in the exon must be combined with a strong authentic AS to 
preferably induce CS recruitment instead of exon skipping (Wimmer et al., 2007). 
Consequently, our findings suggest that the CS, which was activated by the RHO 
mutation, is not strong enough to completely prevent exon 4 skipping. In addition, GC 
dinucleotides are often found in DS of alternatively spliced exons (Thanaraj and 
Clark, 2001; Stoilov et al., 2002; Sahashi et al., 2007). Positions 4bp upstream and 
downstream of the constitutive DS are most often found to serve as CS. Surprisingly, 
46% of the CS that locate 4bp upstream of the dominant SS contain GC instead of 
the canonical GT nucleotides (Dou et al., 2006). Our data show that elimination of this 
GC, in combination with the U1 snRNA rescue approach, helps to recognize the 
constitutive DS. Inhibition of the CS by site directed mutagenesis not only corrected 
the SS recognition, but also confirmed the potential of the U1 therapeutic approach to 
rescue mis-spliced transcripts affected by exon skipping. 
Besides conventional pharmaceuticals, oligonucleotide-mediated gene therapeutics 
were discussed as agents to treat a variety of diseases (Stoilov et al., 2002; Garcia-
Blanco, 2006). Anti-sense oligonucleotides have been shown to induce skipping of 
cryptic exons by sterical inhibition of the spliceosome. Recently, anti-sense 
treatments in different mutated genes were compared and showed efficiencies that 
vary from 10% to 95% (Uchikawa et al., 2007). In contrast to the anti-sense 
oligonucleotide approach, the rescue method discussed in this report rather aims to 
strengthen mutated constitutive DS. A combination of blocking CS by anti-sense 
oligonucleotides and strengthening constitutive DS by an U1-mediated intervention 
may lead to an improved rescue. 
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Our experiments showed that mis-splicing of mutant minigenes can be reversed by 
modified U1 snRNA constructs in cell culture. Interestingly, injection of recombinant 
adeno-associated virus (AAV) to the subretinal space has been shown to successfully 
deliver ciliary neurotrophic factor to mouse retina. The survival of photoreceptors in 
the rhodopsin knockout mouse could be prolonged by this method (Liang et al., 
2001). Even more significantly, AAV-mediated delivery of RPE65 to human retina 
improved retinal function of patients suffering from leber congential amourosis without 
showing any significant adverse effect (Bainbridge et al., 2008; Maguire et al., 2008). 
Together, these studies suggest that AVV-mediated delivery of adapted U1 to the 
retina of animal models may be a future approach to further test the U1 therapeutic 
strategy in vivo.  
A rescue efficiency of over 95%, as observed in our splicing assay with adapted U1 
snRNAs, is likely to cure or reduce progression of many diseases. It is not clear 
whether even this high efficiency may be enough for a dominantly inherited disease, 
particularly when the protein is as abundantly expressed as RHO in the retina. 
Therefore, the U1 snRNA rescue approach may preferably been used for DS 
mutations causing recessive diseases. However, it is known that the severity of the 
disease often correlates with the relative level of correctly spliced isoforms as 
described for tau exon 10 (Garcia-Blanco, 2006). Thus, rather subtle differences in 
the splicing pattern can lead to striking effects on the disease phenotype particularly 
in neuronal tissues (Nissim-Rafinia and Kerem, 2005; Garcia-Blanco, 2006). Hence, a 
rescue of over 95% may result in reduction or stagnation of RP progression. 
In conclusion, we show that the adaptation of U1 is a powerful tool to rescue exon 
skipping induced by mutations that affect the last exonic nucleotide. Our studies will 
help to improve strategies to treat DS mutations in patients.  
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3.3.9. Tables 
RQ CI RQ CI RQ CI RQ CI RQ CI
+ 1.14 + 0.88 + 0.30 + 0.64 + 0.51 
- 0.91 - 0.75 - 0.22 - 0.52 - 0.30
+ 808.30 + 1792.68 + 819.24 + 61.53 +12.17
- 438.44 - 768.59 - 471.36 - 33.83 - 8.94
minigene 
constructs
mini-mut
mini-mut_c
4.60
2874.50
5.00
4036.20
0.84
3330.17 33.66
2.77
75.15
0.76
   U1-RHO_Mut
U1 snRNA constructs
           mock          U1-Wt        U1-Mut     U1-RHO_Wt
 
 
Table 10. Relative quantification of exon 4 skipping in minigene transcripts 
RHO (NM_000539.3) exon 4 skipping (r.697_936del) of different minigene constructs 
cotransfected with either empty vector (mock) or different U1 snRNA constructs was calculated 
from quantitative RT-PCR measurements (n=4-5). For relative quantification, wild type levels 
were set to 1. RQ: relative quantification; CI: confidence interval of 95%. 
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3.3.10 Figures 
 
 
Figure 24. Identification of a novel RHO mutation and clinical characterization of the RP 
patient 
(A) Sequencing of RHO (NM_000539.3) in 78 index RP patients revealed a novel heterozygous 
mutation at the last nucleotide position of exon 4 (c.936G>A). (B) Significant constriction of the 
visual field was detected with test target I4e in both temporal regions of the patient. (C to F) 
Electroretinographic (ERG) recordings confirm the diagnosis of RP. Rod-driven signals are 
almost extinguished in scotopic ERGs with (C) dim white flash and (D) bright white flash. (E) 
Signals from cones could only be recorded during photopic conditions using a single flash. (F) 
Photopic cone-driven signals registered with 30Hz flicker are highly reduced.  
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Figure 25. The novel RHO mutation interferes with splicing 
(A) Schematic drawing of minigenes used to analyze RHO (NM_000539.3) splicing. We 
compared splicing of RHO control (mini-wt) and mutated (mini-mut) alleles and cloned intron 2 
through 4 into the multiple cloning site (MCS) of vector pSPL3. The asterisk indicates the 
position of the novel mutation c.936G>A at the last nucleotide of exon 4, arrows show binding 
sites of nested primers used for RT-PCR analysis, and V_exon1 or V_exon2 denote vector 
derived exons. (B) RT-PCR analyses of transfected COS 7 cells revealed a single transcript 
(554bp) for mini-wt and three bands (310bp, 550bp, and 670bp) for mini-mut. Note that the 
670bp band is vector-derived and thus is considered to be unspecific for RHO splicing. (C) 
Scheme of different splice isoforms identified by sequencing. The mini-wt 554bp isoform 
includes complete exons 3 and 4, whereas the mini-mut 550bp isoform contains a 4bp deletion 
at the end of exon 4 (r.933_936del). The mini-mut 310bp isoform skips exon 4 (r.697_936del). 
(D) Quantitative RT-PCR showed a significant increase of exon 4 skipping in mini-mut 
compared to mini-wt. The error bars represent 95% confidence intervals (n=4). (E) Fragment 
analysis of RT-PCR products showed that both, 310bp and 670bp isoforms, are also produced 
from mini-wt at residual levels. Additionally, fragment analysis confirmed the 4bp deletion in 
RHO exon 4. 
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Figure 26. Rescue of RHO exon 4 skipping by adaptation of U1 snRNA  
(A) U1 small nuclear RNA (snRNA) contributes to correct exon definition and binds conserved 
splice consensus sequences of the donor splice site (DS). Different U1 snRNA constructs were 
generated to analyze their therapeutic potential by cotransfection of COS 7 cells with minigene 
constructs: wildtype U1 (U1-Wt), U1 adapted to the human mutation c.936G>A (U1-Mut), and 
U1 additionally modified to perfectly match the DS of RHO (U1-RHO_Wt and U1-RHO_Mut). 
(B) RT-PCR revealed that constitutive splicing of wildtype minigenes (mini-wt) is not altered by 
cotransfection with the different U1 snRNA construct. (C) In contrast, mis-splicing of mutated 
minigenes (mini-mut) was rescued by cotransfection with adapted U1 snRNAs. Overexpression 
of U1-Wt did not alter the splice pattern. The quantification showed a significant rescue of 
mutation-induced exon 4 skipping by adapted U1 snRNAs. Error bars represent 95% 
confidence intervals (n=4-5). (D) Sequencing of the 550 bp band confirmed that the 4bp 
deletion in RHO exon 4 is not rescued by cotransfection with adapted U1 snRNAs.  
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Figure 27. Efficiency of the U1 snRNA rescue in minigenes lacking the activation of 
cryptic splice donor sites  
(A) An additional nucleotide exchange (c.933G>A) was introduced into the minigene constructs 
(mini-wt_c and mini-mut_c) to inhibit the activation of the cryptic splice site (CS). Splice site 
strength as consensus values were calculated for the CS and donor splice site (DS) of the 
different minigenes. (B) RT-PCR showed that splicing of mini-wt_c was not altered by the 
additional nucleotide exchange and produced the expected transcript including complete exon 3 
and 4. In contrast, mini-mut_c only produced transcripts skipping exon 4 of RHO 
(NM_000539.3, 310bp). (C) Rescue of exon 4 skipping was observed in transcripts from mini-
mut_c that were cotransfected with adapted U1 snRNA. Relative quantification demonstrated a 
significant reduction of isoforms skipping exon 4 upon cotransfection with U1-RHO_Wt and U1-
RHO_Mut. Note that overexpression of wildtype (U1-Wt) or cotransfection with mutation-
adapted U1 snRNA (U1-Mut) does not affect the splicing pattern. The error bars represent 95% 
confidence intervals (n=4-5). (D) Sequencing confirmed the inclusion of the complete exon 4 in 
transcripts of mini-wt_c and mini-mut_c. 
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3.3.11 Supplementary material 
Supplementary table 6. Primers used for cloning and RT-PCR 
Rho-Ex4-upBamHI:  5'-GCGGGATCCAGCGCCCCATCCACTCAAATC-3' 
Rho-Ex3-dnXhoI:  5'-CCGCTCGAGGGCCCGTCCACTGTCACCAAT-3' 
M13forward:  5'-GTAAAACGACGGCCAGTG-3' 
M13 revers: 5'-GGAAACAGCTATGACCAT-3' 
MW_crypt_dn: 5'-CTATATCATGATGAACAAACAGGTGCCTAC-3'  
MW_crypt_up:  5'-GTAGGCACCTGTTTGTTCATCATGATATAG-3’  
MM_crypt_dn:  5'-CATGATGAACAAACAAGTGCCTACTGCGGG-3’  
MM_crypt_up:  5'-CACCCGCAGTAGGCACTTGTTTGTTCATCA-3' 
pGU1Mutfwd:  5'-CGAAGATCTCATACTTACTTGGCAGGGGAGATACC-3'  
pGU1Mutrev:  5'-CGGACTAGTACCATAGAGGGGACGGTTCATTCAT-3'  
pGU1RhoWTfwd:  5'-CGAAGATCTCATAGGCACCTGCCAGGGGAGATA-3'  
pGU1RhoWTrev:  5'-CGGACTAGTACCATAGAGGGGACCGTCCACGGAT-3'  
pGU1RhoMutfwd:  5'-CGAAGATCTCATAGGCACTTGCCAGGGGAGATAC-3'  
pGU1RhoMutrev:  5'-CGGACTAGTACCATAGAGGGGACCGTTCACGGTA-3' 
T7: 5'-TAATACGACTCACTATAGGG-3' 
SP6:  5'-ATTTAGGTGACACTATAG-3' 
SD6: 5'-TCTGAGTCACCTGGACAACC-3' 
SA2: 5'-GCTCACAAATACCACTGAGAT-3' 
dUSA4: 5'-CGACCAATTCACTCCTCAGGTG-3' 
dUSD2: 5'-GTGAACTGCACTGTGACAAGC-3' 
 
 
 
Supplementary figure 1. Interference of the novel RHO mutation with splicing in 
photoreceptors 
RT-PCR analyses of transfected retinal mouse explants revealed a single transcript (554bp) for 
wildtype minigene (mini-wt) and three bands (310bp, 550bp, and 670bp) for mutant minigene 
(mini-mut) in transfected explants. This splice pattern is similar as observed in COS 7 cells. 
Sequencing confirmed that the mini-wt 554bp isoform includes exons 3 and 4. In contrast, the 
mini-mut 550bp isoform contains a 4bp deletion at the end of exon 4 (r.933_936del). The mini-
mut 310bp isoform skips exon 4 (r.697_936del), whereas the 670bp band includes a vector-
derived exon and thus is considered to be unspecific for RHO splicing. 
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4. General Discussion 
The mechanism of alternative splicing has been proposed shortly after the identification of 
exon-intron structures of the adenovirus in 1977 (Sambrook, 1977; Gilbert, 1978). In the 
1980s, already the first alternatively spliced genes have been described (Early et al., 1980; 
Rosenfeld et al., 1982; Modrek and Lee, 2002). With the new millennium, it became more 
and more obvious that alternative splicing is highly prevalent and must be considered as a 
general mechanism that influences biological studies, molecular diagnostics, disease 
pathogenesis as well as the development of novel therapies. Three mechanisms how 
alternative splicing can be involved in disease pathogenesis can be distinguished. First of all, 
mutations can locate to tissue-specific splice variants and may thus explain tissue-restricted 
disease manifestations. Second, the so called trans-acting mutations, which can be found in 
splicing factors, might influence splicing of various genes. Third, cis-acting mutations in 
regulatory or conserved consensus sequences can disturb splicing of the respective gene. 
Since all three have been detected to cause RP, this suggests that splicing is of importance 
for retinal maintenance and survival of photoreceptors (PRs). Therefore, this work aimed to 
improve the understanding of the different roles of splicing in the pathogenesis of human 
diseases, with a special focus on RP. 
4.1. Large scale genomic surveys for prediction of alternative splicing 
The prevalence and importance of alternative isoforms was recently shown by comparing 
variations in whole gene expression profiles to expression changes due to alternatively 
spliced isoforms. Interestingly, alterations in isoform expression levels were found to be 
much more frequent in human genes (Kwan et al., 2008). Moreover, in about 20% of the 
alternatively spliced genes, isoform expression was found to be influenced by single 
nucleotide polymorphisms (SNPs) (Kwan et al., 2008). Thus, SNP dependent differences in 
isoform expression may be responsible for phenotypic variation and disease susceptibility. 
Since some mutations in the alternatively expressed exon ORF15 of the RPGR gene are 
responsible for the retina-restricted phenotype of RP, tissue-specific splicing may also 
underlie the pathogenesis of other RP-associated genes. The prediction of alternative splice 
variants of RP-associated genes from EST databases can estimate the prevalence of 
alternative splicing and provide a basis to analyze tissue-specific expression of these genes. 
Our bioinformatic study suggested enrichment of alternative splicing in human RP-associated 
genes as well as in mouse orthologous genes. According to the results of this thesis, 95% of 
human and 83% of mouse genes appeared to be alternatively spliced, whereas other studies 
estimated approximately 70% of the human and 40% of the mouse genes to be alternatively 
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spliced (Faustino and Cooper, 2003; Nurtdinov et al., 2003; Nurtdinov et al., 2007; Wang and 
Cooper, 2007). The higher frequency of alternative splicing in human genes was previously 
described and can be partially explained by the recent origin of many species-specific splice 
isoforms (Nurtdinov et al., 2003). Furthermore, the discrepancy between our high level of 
alternative splicing and the lower ones described by other researchers may explained on two 
ways. On one hand, growing information in EST databases through high-throughput 
sequencing of the human genome and computational evaluation of EST sequences is 
available and allow more accurate predictions. Many publications documented this trend, e.g. 
in the early 1980s alternative splicing was only known for several genes (Early et al., 1980; 
Rosenfeld et al., 1982), whereas in the 1990s already 5% of the human genes were 
expected to be alternatively spliced (Sharp, 1994). With the bioinformatic based large-scale 
discovery of alternative splicing, the frequency of alternatively spliced human genes 
increased from 35 to 59% (Mironov et al., 1999; Brett et al., 2000a; Croft et al., 2000; Kan et 
al., 2001; Modrek et al., 2001). Similarly, the amount of known alternatively spliced mouse 
genes increased from 33 to 41% (Brett et al., 2000b; FANTOM Consortium and the RIKEN 
Genome Exploration Research Group Phase I and II Team, 2002). On the other hand, the 
high level of alternative splicing in RP-associated genes might suggest that splicing may be 
more frequently involved in retinal disorders than in other hereditay diseases. Furthermore, 
ubiquitously expressed RP-associated genes may cause a retina-restricted phenotype by 
mutations in retina-specific splice isoforms. 
Up to now, large scale genomic surveys have not been used to predict isoforms of disease-
associated genes, but were mainly performed to increase the understanding of alternative 
splicing in terms of its evolution and functionality. In this way, intron retention has been found 
to be the rarest, but the most ancient form of alternative splicing (Ast, 2004; Kim et al., 2007). 
This is not surprising, since the emergence of short introns in yeast genes first allowed 
alternative splicing. Splicing of these genes is thought to be performed by intron recognition 
through binding of U1 and U2 RNPs components to the splice site (SS) (Figure 28A). In this 
so called intron definition model, SR proteins are not involved in SS recognition, but 
mediated spliceosome assembly in a sequence-independent manner. In contrast to intron 
retention, we and others found alternative exons to be the major form of alternative splicing 
(Ast, 2004; Sorek et al., 2004; Kim et al., 2007). The accumulation and elongation of introns 
from yeast to vertebrates provided a prerequisite for exonization of intronic regions to 
generate alternative exons. Recent surveys showed that the large number of alternative 
exons also permits alternative splicing by loss of exons (Modrek and Lee, 2003; Pan et al., 
2005; Chen et al., 2006). Although longer introns produce higher levels of alternative 
splicing, they complicate SS recruitment according to the intron definition model. This and 
the detection of splicing regulatory elements suggested that alternative splicing in vertebrates 
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is rather meditated by exon recognition through SR proteins that recognize ESEs (Ast, 2004; 
Kim et al., 2007). Regulatory and sequence-specific exon definition can either directly 
stimulate SS selection in a SR domain-dependent manner (Figure 28B) or indirectly by 
inhibiting ESSs bound antagonistic hnRNP proteins by an SR domain-independent way 
(Figure 28C). A novel model proposes random activation and fixation of cryptic splice sites 
(CS) as an evolutionary process involved in exon truncation and elongation (Nurtdinov et al., 
2007). Repetitive elements and mutations affecting SS or regulatory elements provide a rich 
source of CS that can modulate exon length (Ast, 2004; Sorek et al., 2004; Ben Dov et al., 
2008). Nurtidov et al. 2007 suggested that the probability of exon truncation by a CS 
increases proportional with the exon length (Nurtdinov et al., 2007). In contrast, exon 
elongation by CSs is expected to be proportional to the distance to the next downstream stop 
codon. In this way, the mechanism of random activation and fixation of CS truncates or 
elongates exons until the two processes are equally strong and the exon length get fixed 
(Nurtdinov et al., 2007). 
 
 
 
Figure 28. Intron and exon definition models 
Intron and exon definition models can explain the evolution of different form of alternative 
splicing which developed from yeast to vertebrates. Panel A shows the sequence unspecific 
model of intron definition. This mechanism is expected to be the most ancient form regulating 
splicing in yeast. In this model, donor splice site and acceptor splice site are recognized by 
components of the U1 (pink), U2 snRNP (green) and SR proteins (dark violet) which mediate 
spliceosome assembly. If the splice sites are not recruited, this mechanism allows alternative 
splicing by intron retention. In contrast, exon definition (B+C) needs the sequence-specific 
binding of SR proteins to exonic splicing enhancers (ESEs) and is expected be a more recent 
mechanism evolved in invertebrates and vertebrates. Two different ways of exon definition can 
be distinguished: either binding of U1 and U2 snRNP components is mediated directly by SR 
proteins in a SR domain dependent manner (B) or indirectly in a SR domain independent way 
(C). Here, the SR protein inhibits the negative acting hnRNP protein on the exonic splicing 
silencer (ESSs). Figure adapted from Hastings and Krainer, 2001, and Maniatis and Tasic, 
2002.  
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An often used approach to select for functional alternative splicing events is to analyze the 
conservation between species (Sorek et al., 2004; Magen and Ast, 2005; Yeo et al., 2005). 
Because alternative splicing in mammals is expected to evolve fast, it is not surprising that 
half of the human genes are estimated to express isoforms not conserved in e.g. mice (Kan 
et al., 2002; Pan et al., 2005; Chen et al., 2006). This suggests that alternatively spliced 
isoforms are evolutionary important to establish species-specific proteomic diversity. 
Considering the rather small number of conserved alternative splicing events predicted in 
RP-associated genes, our findings indicate that the retina may be a tissue with pronounced 
species-specific gene expression.  
Alternative splicing is expected to preferentially insert or remove entire protein domains. This 
correlates with the finding that conserved alternative exons are more often frame-preserving 
(Kriventseva et al., 2003; Sorek et al., 2004; Magen and Ast, 2005). In contrast, skipping of 
species-specific alternative exons was frequently found to generate NMD sensitive 
transcripts with potential regulatory function (Magen and Ast, 2005; Pan et al., 2005; 
Nurtdinov et al., 2007). Moreover, species-specific splicing is highly abundant in genes 
important for tissue development, transcription and RNA processing (Xu et al., 2002; Gupta 
et al., 2004; Yeo et al., 2005). This suggests that these processes need alternative splicing to 
generate physiological switches to regulate cell type differentiation (also compare to the later 
discussed molecular switch relevant for neuronal differentiation (Figure 30). Since the RP-
associated genes include several transcription and splicing factors as well as genes involved 
in cell or tissue development and maintenance, it is not surprising that our study predicted 
many species-specific isoforms in these genes.  
4.1.1. Limitations of expressed sequences tag-based prediction studies 
Although EST information has been growing in recent years, incompleteness of EST libraries 
is still a problem of in silico surveys (Nurtdinov et al., 2003; Lee and Roy, 2004; Chen et al., 
2006). The level of EST coverage determines the reliability of computational prediction 
studies and different levels of database completeness between genomes complicates 
conservation analysis of alternative splicing events between species (Nurtdinov et al., 2003; 
Pan et al., 2005). In addition to the low EST coverage of genomes, the libraries may contain 
artifacts, misaligned sequences and not processed RNAs (Nurtdinov et al., 2003; Neverov et 
al., 2005). One should be aware, that EST databases also include sequences from cancer 
cells that may contain splicing errors (Nurtdinov et al., 2003; Magen and Ast, 2005) and that 
species-specific splice variants, which are often expressed in a precisely regulated tissue- or 
stage-dependent manner, are rather rare transcripts and thus underrepresented in the 
databases (Gupta et al., 2004; Sorek et al., 2004). Since ESTs are generated either from the 
5’ or 3’ end of the transcripts, the libraries have also a bias towards underrepresentation of 
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exons locating in the middle of particularly long transcripts (Lee and Roy, 2004; Sorek et al., 
2004). This leads to underestimated occurrence of alternative splicing in long genes. 
Moreover, also isoforms which are eliminated by NMD are underrepresented in the 
databases (Artamonova and Gelfand, 2007). In general, transcripts are expected to be 
produced from one single gene, but newer findings indicate that so-called transcription-
induced chimeras exist. These chimeras are typically formed by intergenic splicing of two 
distinctly annotated, but adjacent genes with same orientation and transcription into one 
single mRNA (Akiva et al., 2006; Parra et al., 2006). This suggests that genes can no longer 
be regarded as isolated transcription units (Sammeth et al., 2008). After splicing the 
transcripts contains exons of both genes and in this way, domains from the original proteins 
can be fused into a new protein and/or the protein expression regulation can be changed. 
Thus, transcription-induced chimeras are a further possibility to increase protein diversity.  
About hundreds of such transcription-induced chimeras are estimated to exist and at least a 
subset of these are expected to be functional (Akiva et al., 2006; Parra et al., 2006). 
Furthermore, retroposition of these chimeras may result in fusion genes (Akiva et al., 2006). 
The growing description of these chimeras complicates in silico prediction of alternatively 
spliced isoforms. Therefore, full awareness of all of these difficulties as well as stringent 
criteria for alternative splicing prediction is important (Kan et al., 2002). Nevertheless, 
advantages of the EST databases screening clearly prevail over possible difficulties. EST 
databases have been shown to reliably annotate expression patterns of transcripts (Gupta et 
al., 2004). Furthermore, they provide a huge resource of expression information and easy 
accessible platform to analyze and compare transcriptomes and thus to predict differences in 
species-specific alternative splicing. Hence, computational studies based on EST information 
are the most frequently used approach to predict alternative splicing. Combined with 
experimental validation, EST-based surveys can even provide an accurate set of tissue-
specific and functional alternative isoforms (Gupta et al., 2004; Sorek et al., 2004; Neverov et 
al., 2005). 
4.1.2. Verification of in silico predicted isoforms 
Computational analysis of bioinformatic EST information may generate significant amounts of 
data. In vivo expression of the respective ESTs remains to be confirmed to assess the 
reliability and accuracy of our survey. RT-PCR approaches and successive sequencing of all 
predicted splicing events is cost-intensive and time-consuming. Only a limited number of 
tissues can be tested simultaneously. Therefore, a very important issue in analyzing 
alternative splicing by RT-PCR concerns the tissue to be tested. Regarding retinal tissue, 
RNA from human retina pooled from several donors is commercially available. Another more 
difficult question is which developmental stage or physiological condition to examine. 
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However, RT-PCR and subsequent sequencing of the amplicons is currently the 
preferentially used method to validate the results of database screening (Gupta et al., 2004; 
Sorek et al., 2004; Chen et al., 2006), because the technique is reliable and well established.  
Another strategy to confirm gene expression is based on high-density microarrays. Two 
different types of microarray platforms exist. For oligonucleotide arrays, short probes are 
directly synthesized on the platform, whereas the conventional glass platform uses 
mechanically spotted probes (Mockler and Ecker, 2005). While oligonucleotide arrays 
consists of millions of probes and are rapidly produced according to customer’s wishes, the 
conventional arrays contain much lower probe density (Mockler and Ecker, 2005). However, 
both types of large-scale microarrays allow the simultaneous examination of an immense 
number of isoforms and are able to detect rare transcripts due to their high sensitivity 
(Johnson et al., 2003; Mockler and Ecker, 2005).  
Microarray approaches were originally designed to analyze gene expression and not to 
discriminate splice isoforms (Wang et al., 2003; Lee and Roy, 2004; Mockler and Ecker, 
2005). Hence, commercially available splicing arrays at the moment cover only known 
alternative splicing events. Therefore, a microarray confirming predicted alternative splicing 
in RP-associated genes would have to be designed by customers’ advices. Probes spanning 
exon boundaries are necessary to measure the expression of SS junction. These probes 
underlie a trade-off between specificity and sensitivity. Longer oligos tend to have lower 
specificity, whereas shorter ones decrease the problem of half junction hybridization, but 
increases the possibility of false positives by cross-hybridization (Johnson et al., 2003; 
Modrek and Lee, 2002; Srinivasan et al., 2005). Additional probes in exons and introns can 
serve as standard and help to detect cross- or half-junction hybridization artifacts (Johnson et 
al., 2003; Lee and Roy, 2004; Srinivasan et al., 2005). Exon-intron spanning probes are 
necessary to detect exon truncation, elongation and intron retention. Interpretation of the 
splicing array data are demanding because the quantitative output represents an alteration of 
isoform expression ratios (Castle et al., 2003; Wang et al., 2003; Lee and Roy, 2004). 
However, accurate quantification was shown to be possible if considering EST-based 
prediction of isoform mixtures (Fehlbaum et al., 2005). This indicated that computational 
surveys together with microarrays are powerful tools to verify a large number of novel 
alternative splicing RP-associated isoforms.  
4.1.3. Impact of tissue-specific splicing 
Approximately 40% of the RP-causing sequence variations remain unknown (Daiger et al., 
2007). Comprehensive knowledge of alternative protein coding or regulatory sequences may 
thus allow the detection of further mutations in RP patients. Since for 33 out of 36 RP-
associated genes novel coding regions or regulatory elements were predicted, a huge source 
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of sequences to screen for novel mutation remains. Beside the importance for diagnostic 
purposes, tissue-specific spliced isoforms may help to elucidate alternative function of the 
corresponding protein. This in turn may provide insight into tissue-specificity of pathogenic 
mechanisms as it was found for COL2A1. Mutations in this gene typically cause null-alleles 
by disturbing the production, processing or assembly of collagen molecules. This affects the 
integrity of connective tissues and cause Stickler syndrome with ocular and extraocular 
manifestations. However, mutations in exon 2 of COL2A1 reduce exon recognition and 
expression of the eye-specific isoform including exon 2. This leads exclusively to ocular 
manifestations in the affected Stickler patients (McAlinden et al., 2008). 
Interestingly, 30% of the RP-associated genes are known to be widely expressed. These 
include the four splicing factors PRPF3, PRPF8, PRPF31 and RP9, as well as TOPORS, 
MERTK, SEMA4A, RPGR, IMPDH1, USH2A and LRAT. For all of these eleven genes the 
pathogenic mechanism is not yet understood and remains to be resolved. Tissue-specific 
isoform expression of their predicted splicing events or PR-specific protein function may be 
one explanation how mutations in these genes lead to retina-restricted RP manifestations. 
Knowledge about alternative splice isoforms not only increases understanding of cell-type-
specific functions and specific sensitivities to mutations, but may also be important for 
therapeutic drug design. Different protein isoforms can be specifically inhibited by isoform-
specific molecules. Nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. diclofenac, inhibit 
the two cytochrome c oxidase enzymes, COX-1 and COX-2. In contrast, selective COX-2 
inhibitors lead to much less gastrointestinal side effects than NSAIDs. However, COX-3, an 
alternative splice isoform of COX-1 predominantly expressed in the cerebral cortex, seems to 
be selectively inhibited by the NSAIDs, phenacetin and acetaminophen. These drugs show 
low inflammatory effects in most tissues, but exhibit high COX inhibition in rat brain extracts 
(Garcia-Blanco et al., 2004). Several examples of splice isoforms are known to function in 
antagonistic or even opposite apoptotic processes (Cuperlovic-Culf et al., 2006). 
Furthermore, knowledge of isoform expression ratios can be an important diagnostic marker 
to determine pathophysiological mechanisms resulting in disease susceptibility and severity. 
Thus, detailed understanding of the exon-intron structure and an accurate picture of tissue-
specific gene expression is indispensable for future diagnostic purposes. 
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4.2. Pathogenic mechanisms of retinitis pigmentosa-associated splice 
factors 
Analysis of splice factors and their isoforms may increase the knowledge about the general 
regulation of the spliceosome and may show retina-specific characteristics. Based on the 
prediction of alternative splicing events, a highly conserved alternative exon in the RP-
associated splice factor PRPF3 has been detected. Experimental confirmation showed that 
this exon is expressed in various tissues and generates a transcript that undergoes NMD. 
Interestingly, similar NMD inducing alternative exons have been identified in ultraconserved 
elements (UCEs) of other splice factors (Bejerano et al., 2004; Yeo et al., 2005; Ni et al., 
2007). Although these exons do not encode protein domains, they underlie strong negative 
selection. This suggests that alternative inclusion of these exons may be a common 
regulatory mechanism. Indeed, all human SR proteins and some hnRNP proteins have been 
found to autoregulate their protein expression levels by NMD (Lareau et al., 2007; Saltzman 
et al., 2008) and the PRPF3 interaction partner, splicing factor 30 (SPF30), is expected to 
have similar alternative splicing-coupled regulatory function (Little and Jurica, 2008). Protein 
binding to their pre-mRNAs probably triggers alternative splicing. In addition, all the NMD 
coupled alternative splicing events of SR proteins have been described to be conserved in 
mouse indicating that this is a common mechanism to balance protein expression (Lareau et 
al., 2007; Ni et al., 2007; Saltzman et al., 2008). Interestingly, SR proteins have also been 
found to increase regulatory NMD of other splice factors and of a subset of splicing unrelated 
genes (Lejeune and Maquat, 2005; Coutinho-Mansfield et al., 2007; Ni et al., 2007). 
Together, the knowledge of NMD coupled alternative splicing in splice factors strongly 
indicates that PRPF3 isoform 3a may also have an auto- or crossregulatory function.  
4.2.1. Pathogenesis of splice factor mediated retinitis pigmentosa 
It is of importance to uncover the pathogenic mechanisms of RP, since this provides a 
prerequisite for accurate treatment of the disease. Currently, five different mechanisms are 
proposed to be responsible for the pathogenesis of splice factor mediated RP (Mordes et al., 
2006). These models include haploinsufficiency, rate-limiting defects in PRs due to 
alterations in the splicing process or hypoxia, PR-specific splicing factors and dominant-
negative effects of splice factors (Figure 29). All these models are also discussed for the RP-
associated splice factor PRPF31. Considering that large deletions of PRPF31 have been 
found to lead to RP, this indicates that haploinsufficiency can be the pathogenic mechanism 
(Figure 29A) (Abu-Safieh et al., 2006). In line with this model is the finding that most PRPF31 
mutations initiate NMD. These mutations generate null alleles and cause insufficient protein 
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expression levels (Rivolta et al., 2006; Rio et al., 2008b). Recently, an expression 
quantitative trait locus which includes transcription factors and genes essential for retinal 
development and maintenance has been identified on chromosome 14q21-23 (Rio et al., 
2008a). The locus has been shown to influence the expression level of mutant and wildtype 
PRPF31 transcripts with equal strength (Rio et al., 2008a). This may explain the reduced 
penetrance of PRPF31 which correlates significantly with changes in wildtype expression 
levels between patients and control individuals and asymptomatic carriers (Rivolta et al., 
2006). 
 
 
 
Figure 29. Models of PRPF31–associated pathogenic mechanisms 
Five different models are discussed to be involved in the PRPF31-induced pathogenesis of 
RP. Haploinsufficiency (A) is considered since large PRPF31 deletions were found to be RP 
causing in patients (Abu-Safieh et al., 2006). Since all RP-associated splice factors are 
involved in the tri-snRNP assembly, kinetic effects of the mutation on this critical step may be 
rate-limiting for splicing in photoreceptors (PR) (B) (Deery et al., 2002; Makarova et al., 2002; 
Martinez-Gimeno et al., 2003; Vithana et al., 2003; Wilkie et al., 2008) . Some hypoxia-induced 
genes were identified to be interaction partners of RP-associated splice factors. Mutation in 
splice factors may thus interfere with hypoxia-regulated protein expression (C) (Schmidt-
Kastner et al., 2008). PR-specific splice factors may be essential for splicing of retina-specific 
transcripts (D) (Faustino and Cooper, 2003; Mordes et al., 2006). Gain-of-function mutations in 
RP-associated splice factors were found to disturb accurate splicing of other RP-associated 
genes causing a dominant-negative effect on PR survival (E) (Yuan et al., 2005; Mordes et al., 
2007). Figure adapted according to Mordes et al., 2006, and Schmidt-Kastner et al., 2008. 
 
Haploinsufficiency alone does not explain how mutations in ubiquitously expressed genes 
can cause tissue-restricted RP phenotypes. A related model considers PR-specific rate-
limiting defects on the splicing activity (Figure 29B) (Faustino and Cooper, 2003; Martinez-
Gimeno et al., 2003). All RP-associated splice factors are known to be involved in tri-snRNP 
assembly. PRPF31 depletion has actually been shown to inhibit this step (Makarova et al., 
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2002). This suggests that reduced protein levels may limit splicing kinetics and compromise 
both PR function and survival. The maintenance of the extensive PR metabolism due to 
continuous disc renewal may explain the extreme susceptibility to insufficient splicing activity 
(Vithana et al., 2003; Mordes et al., 2006). Two PRPF31 mutations which reduce nuclear 
protein translocation are representative examples for the mechanism of kinetic limitations in 
the splicing process (Deery et al., 2002; Wilkie et al., 2008). Structural analysis of these 
mutations predict stronger interaction of PRPF31 with PRPF6 and U5 snRNP, probably 
inhibiting further rearrangements necessary to form catalytically active spliceosomes (Liu et 
al., 2008; Wilkie et al., 2008). 
A third mechanism proposed to be involved in the pathogenesis of RP may be hypoxia 
during dark adaptation (Figure 29C) (Schmidt-Kastner et al., 2008). Screening for ischemia-
hypoxia regulated genes identified Pim1, genes known to cause RP (CNGB1, SEMA4A) and 
genes of the tri-snRNP complex (PRPF4, LSM8) (Schmidt-Kastner et al., 2008). PRPF4 and 
Pim1 are interaction partners of RP-associated splice factors. In addition, hypoxia has been 
described to be responsible for the variable clinical manifestations of RP1 mutations 
(Schmidt-Kastner et al., 2008). These findings provide links between hypoxia and the 
pathogenic mechanism of RP. Although speculation, mutations in RP-associated splice 
factors have been discussed to reduce tri-snRNP function under hypoxic conditions due to 
alternating haploinsufficiency mediated by hypoxia-regulated changes of gene expression 
(Schmidt-Kastner et al., 2008). Furthermore, this effect is speculated to steadily increase 
retina-specific vulnerability by circadian dark adaptation resulting in diurnal hypoxia which in 
turn may reduce oxygen concentration in the outer retina under a critical threshold 
concentration for normal gene expression. Thus, hypoxia-induced pathogenesis might exert 
slow progressive damage of the PRs resulting in late onset RP.  
Occurrence of PR-specific splice factors represents the forth model that may underlie the 
pathogenesis of RP (Figure 29D) (Faustino and Cooper, 2003). The neuron-specific splice 
factors of the Nova family have been identified to trigger alternative splicing in neural tissues. 
This raises the possibility that also PR-specific factors may exist and modulate alternative 
splicing in the retina (Faustino and Cooper, 2003; Mordes et al., 2006).  
The fifth model considers dominant-negative effects of splice factors (Figure 29E) (Mordes et 
al., 2006). In support of this model, overexpression of two frameshift mutated PRPF31 
proteins have been shown to cause intron retention in RHO, RDS and FSCN2 minigenes 
(Yuan et al., 2005; Mordes et al., 2007). The resulting mis-splicing was observed in presence 
of the endogenous PRPF31 protein suggesting that the function of the protein seems to be 
blocked by the mutated proteins and is therefore considered as dominant-negative effect 
(Yuan et al., 2005; Mordes et al., 2007).  Furthermore, the resulting reduction of RHO 
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expression induced apoptosis (Yuan et al., 2005) is demonstrating a retina-specific gain-of-
function toxicity of mutated PRPF31 proteins. 
4.2.2. Pathogenesis of PRPF3  
Expression of the highly conserved exon 3a in PRPF3 has been shown to generate NMD-
sensitive transcripts. This fact unravels two novel potential mechanisms involved in the 
pathogenesis of PRPF3 mutations: tissue-specific NMD efficiency and auto- or 
crossregulation of PRPF3 expression by alternative splicing-coupled NMD.  
The efficiency of NMD has been described to vary between patients, mutations, transcripts, 
and also among cell lines and tissues (Linde et al., 2007; Schimpf et al., 2008). This 
suggests that variable NMD activity is a general phenomenon that must be precisely 
regulated probably by tissue-specific expression of exon junction complex (EJC) proteins and 
other NMD associated factors (Bateman et al., 2003). In addition, increased intracellular 
concentration of the splice factor SF2/ASF has been shown to enhance NMD activity in a 
cell-specific manner (Sato et al., 2008). The variability of NMD efficiency may cause 
interindivual phenotypic differences, disease susceptibility, incomplete penetrance and 
tissue-restricted disease manifestations. Tissue-specific NMD has also been shown to be 
involved in the disease pathogenesis of Schmid metaphyseal chondrodysplasia (SMCD). 
The disease causing mutations have been found to produce NMD sensitive transcripts. 
These undergo complete degradation exclusively in cartilage tissue where they lead to 
haploinsufficiency (Bateman et al., 2003). The results show that tissue-specific NMD exist 
and suggests that similar mechanisms can be involved in the pathogenesis of other disease, 
e.g. in the PRPF3-associated pathogenesis of RP.  
The second mechanism which might be involved in the PRPF3-associated pathogenesis of 
RP is auto- and crossregulation of splice factor expression by alternative splicing-coupled 
NMD. This mechanism has been described to be controlled by the NMD efficiency in a 
tissue- and developmental stage-dependent manner (Saltzman et al., 2008). Changes in 
alternative splicing of many genes are highly important for neuronal development. 
Interestingly, these changes have been found to be regulated by the global splicing repressor 
pyrimidine tract binding (PTB) protein (McGlincy and Smith, 2008). This gene is expressed 
and autoregulates itself in neural precursor cells (fig 30A), glia and other non neuronal cells. 
In contrast, its paralog, the neuronal pyrimidine tract binding (nPTB) protein, is specifically 
expressed in neurons and repressed in non neuronal cells. This repression is mediated by 
PTB-induced exon 11 skipping and subsequent transcript elimination through NMD 
(Grabowski and Black, 2001; Boutz et al., 2007; Fairbrother and Lipscombe, 2008). During 
neuronal differentiation, the microRNA miR-124 has been shown to silence PTB expression 
(Figure 30B). This in turn disrupts the repression and induces substitution of PTB by nPTB 
Gaby-Gerda Tanner  General Discussion 
 139
which consequently alters splicing of many genes (Boutz et al., 2007; Coutinho-Mansfield et 
al., 2007; Fairbrother and Lipscombe, 2008). The genes affected by this quick transition 
mainly represents transcripts important for neurite outgrowth and synapse development 
(Boutz et al., 2007; Grabowski, 2007). 
 
PTB nPTB
 
Figure 30. Regulatory transition of the pyrimidine tract binding protein and the neuronal 
pyrimidine tract binding protein expression during neuronal development 
In neural progenitor cells and glial cells (A), pyrimidine tract binding (PTB) protein expression 
(blue) autoregulates its own protein level by alternative skipping of PTB exon 11 which 
generates transcripts that are degraded by nonsense-mediated decay (NMD). Simultaneously, 
PTB proteins inhibit the expression of the paralogous gene neural pyrimidine tract binding 
(nPTB) protein (magenta) by a crossregulatory mechanism inducing skipping of nPTB exon 10 
and inclusion of a premature stop codon (PTC) which elicits NMD. During neural differentiation 
(B), the microRNA miR-124 binds the 3’ untranslated region (UTR) of PTB transcripts (blue), 
but not of nPTB and silences PTB expression. This stops the inhibitory influence on nPTB 
(magenta) and allows autoregulated protein expression. 
 
Recent research on PRPF3 showed that the protein expression is elevated during PR 
differentiation (Comitato et al., 2007). This indicates that the developmental stage of 
neuronal transition needs a higher PRPF3 amount. Interestingly, mutant proteins have been 
found to form nucleolar aggregates and cause intra-nuclear redistribution of other splice 
factors (Comitato et al., 2007). This suggests that mutated PRPF3 itself is not effectively 
recruited and inhibits the assembly of other factors during PR differentiation. Therefore, this 
defect has been proposed to cause dominant negative effects compromising the retina 
(Comitato et al., 2007). However, accumulation of mutant proteins in stages of higher protein 
demand may also cause rate-limiting defects of the splicing process during retinal 
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development. Eitherway, the pathogenic mechanism of PRPF3 seems to require a 
physiological or molecular switch during differentiation. The global change of alternative 
splicing due to nPTB expression may be such a transition. Furthermore, developmental 
stage-specific physiological changes might affect exon 3a inclusion and a potential auto- or 
crossregulatory function of exon 3a might be involved in the PRPF3-associated pathogenesis 
of RP.  
 
Gaby-Gerda Tanner  General Discussion 
 141
4.3. Characterization of mutations and gene therapeutic approaches 
Mutations in RHO are among the most common causes of RP. C-terminal sequence 
alterations have been described to affect Golgi trafficking resulting in protein mis-sorting 
(Mendes et al., 2005). Most RHO mutations locate to the transmembrane and cytoplasmic 
domains. These mutations abolish protein folding and may lead to protein retention in the 
ER. The protein accumulation induces unfolded protein response (UPR) to enhance protein 
folding by chaperones. Finally, the continuous production of mis-folded protein provokes 
stress-induced apoptosis (Galy et al., 2005; Ryoo et al., 2007; Shinohara et al., 2008). Other 
mutations have been found to interfere with the recycling of activated RHO, weaken protein 
stability and disturb posttranslational modifications. Some mutations interacting with the 
chromophore binding site have been shown to produce constitutively active RHO. 
Interestingly, most of these mutations do not cause RP, but CSNB (Mendes et al., 2005). 
Beside this classification, novel studies showed that characterization of mutations on 
transcript level is important to elucidate interference with the splicing process. In recent 
years, even numerous SNPs have been found to elicit mis-splicing if they are embedded in 
splicing consensus or regulatory sequences (Tazi et al., 2005). So far, no treatment for RP is 
commercially available. However, comprehensive assessment of consequences of RP 
causing mutations on PR survival is fundamental for the development of novel and the 
adaptation of existing therapeutic strategies to cure RP. 
4.3.1. Traditional therapeutic strategies 
Classical therapies for human hereditary diseases include pharmacological treatments and 
operative interventions. Several invasive strategies have been considered to treat RP. Most 
of them, including implantation of lenses to eliminate secondary effects of RP like cataracts, 
rather delay the progression than cure the disease (Hamel, 2006). Recently, human fetal 
retinal transplants have been described to improve the visual acuity of patients probably by 
trophic effects on cones (Radtke et al., 2008). Furthermore, injection of retinal progenitor 
cells in RHO knockout mice has been shown to increase ganglion cell responses and 
papillary reflexes (Radtke et al., 2008). Newest research considers implantation of an 
artificial retina. These electrical devices form a microphotodiode array which should improve 
visual perception of patients (Hamel, 2006; Radtke et al., 2008).  
Nutritional supply of vitamin A and E have been observed to slow down RP progression 
(Mendes et al., 2005; Hamel, 2006; Hartong et al., 2006). Protective effects from oral 
administration of the omega-3 fatty acid docosahexaenoic acid (DHA), which is a component 
of the PR membranes, have also been described (Hartong et al., 2006).  
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Since most RHO mutations cause protein misfolding, several types of chaperones have been 
tested for beneficial effects on protein folding. Molecular and chemical chaperones including 
DMSO are known to stabilize protein structure and their administration has been shown to 
decrease protein aggregation. But this approach had no influence on the dominant negative 
effect of trafficking wild type RHO (Mendes and Cheetham, 2008). Pharmacological 
chaperones are derivates of protein ligands which preferentially bind mutated proteins to 
block their activity. Application of non-isomerasable retinoids as pharmacological chaperones 
has been found to decrease protein mis-folding and increase the translocation rate by 
stabilizing the protein (Mendes et al., 2005; Mendes and Cheetham, 2008). 
All RP-associated mutations finally elicit apoptosis of PRs. Upregulation of anti-apoptotic 
factors has been successfully tested to inhibit apoptosis and delay retinal degeneration in a 
mouse model (Kociok, 2005; Wenzel et al., 2005). Comparably, administration of ciliary, 
brain- and glial-derived neurotrophic factors has been shown to preserve retinal maintenance 
in RHO knockout mice (Liang et al., 2001; Farrar et al., 2002; Kermer and Bahr, 2005; 
Mendes et al., 2005).  
4.3.2. Conventional gene therapy 
Conventional gene therapy focuses on gene replacement in diseases caused by null alleles 
(Hartong et al., 2006). Such an approach has recently been tested for RPE65 mutations. 
These mutations cause loss of functional proteins and lead to 11-cis retinal deficiency in 
human patients and in a naturally occurring dog animal model. Gene delivery has been 
performed by subretinal injection of a recombinant adeno-associated virus (AAV) vector 
containing an RPE65 construct under an RPE-specific promoter. In the animal model, this 
intervention has been shown to improve visual perception in low light conditions (Aceland et 
al., 2001; Narfström et al., 2003a; Narfström et al,. 2003b; Le Meur et al., 2007). Enhanced 
light sensitivity and increased papillary reflexes have also been found to improve visual 
function in dim light conditions in patients with advanced PR degeneration. Six months after 
the treatment, no adverse effect like vector diffusion or inflammation has been reported 
(Bainbridge et al., 2008; Maguire et al., 2008). However, more patients and longer evaluation 
times are necessary to control the safety and efficacy of RPE65 replacement. 
4.3.3. RNA-based gene therapy 
Research on RNA-based methods focus on three main types: antisense oligonucleotides, 
trans-splicing and RNA interference. These therapies including our U1 snRNA-mediated 
rescue of RHO mis-splicing are powerful tools to prevent the production of mutant proteins. 
In contrast to other therapies, RNA-based approaches can eliminate or modulate mutant 
transcripts through RNA processing, mRNA repair or transcript silencing without changing 
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the endogenous gene expression (Mendes et al., 2005; Wood et al., 2007). Therefore, these 
methods are suitable to treat mutations causing dominant negative effects and cell-type 
specific disease manifestations (Mitchell and McGarrity, 2005). Thus, RNA-based 
approaches can overcome the limitations of conventional gene therapy in terms of transgene 
size and expression regulation (Yang and Walsh, 2005; Wood et al., 2007). Disadvantages 
of RNA-based gene therapies include non-specific sequence binding and the problem that 
every mutation needs to be treated by an individual RNA oligonucleotide. Nuclease mediated 
degradation of the oligonucleotides may be prevented by modification like 2’-O-methyl or 
morpholine groups enhancing their stability (Garcia-Blanco et al., 2004; Aartsma-Rus and 
van Ommen, 2007; Morcos, 2007). Furthermore, the rescue effect of RNA-based methods is 
often transient and needs re-application of the components. This may require an highly 
efficient and tissue-specific expression and delivery system (Tazi et al., 2005; Yang and 
Walsh, 2005; Wood et al., 2007). However, simultaneous administration of tissue-specific 
peptides or hormones has been found to increase the tissue-specific oligonucleotide delivery 
rate (Aartsma-Rus and van Ommen, 2007). U7 snRNA regulated expression has been 
described to provide a more prolonged if not permanent effect (Marquis et al., 2007). 
Lentiviral and AVV-mediated delivery has been successfully used for delivery, but no long 
term studies analyzing the potential side effect has been performed (Garcia-Blanco et al., 
2004; Wood et al., 2007). 
 
Antisense oligonucleotides 
Antisense oligonucleotides (AOs) have initially been used to knock down gene expression by 
blockage of promoter sequences (Aartsma-Rus and van Ommen, 2007; Wood et al., 2007). 
Today, applications of AOs focus on the manipulation of SS recognition by masking 
consensus or regulatory sequences (Figure 31). Blocking SS of internal exons has been 
described to result typically in exon skipping, while targeting 5’ or 3’ SS of a transcript often 
leads to intron retention (Morcos, 2007). The concept of AOs has been first used to block the 
recruitment of a CS and thus re-direct accurate splicing in β-globulin (Figure 31A) (Gong et 
al., 2000; Stoilov et al., 2002; Vacek et al., 2003). This CS was activated by a mutation which 
leads to β-thalassemia in patients.  
Frameshift inducing mutations in the dystrophin gene cause Duchenne muscular dystrophy 
(DMD). In contrast, frame-preserving mutations lead to the milder form of Becker’s muscular 
dystrophy (BMD). This suggested that removal of mutated, but not essential exons from the 
dystrophin gene could be a therapeutic approach to reduce disease severity. Blockage of SS 
or ESEs has been successfully tested to skip mutated exons in a mouse model (Figure 31B). 
Moreover, first studies in humans using AOs for intramuscular injection are promising 
(Stoilov et al., 2002; Garcia-Blanco et al., 2004; Aartsma-Rus and van Ommen, 2007). 
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Spinal muscular atrophy (SMA) is caused by mutations in SMN1, but the severity can be 
modified by protein expression from the paralogous SMN2 gene. However, this gene skips 
exon 7 in the majority of transcripts due to a defective ESE and consequently produces 
truncated and nonfunctional proteins missing the C-terminus (Faustino and Cooper, 2003). In 
order to enhance exon inclusion, an AO containing an ESE element recruiting SF2/ASF 
binding has been tested. This AO has been found to efficiently correct exon recognition in 
cell culture (Figure 31C) (Aartsma-Rus and van Ommen, 2007; Marquis et al., 2007; Wood et 
al., 2007).  
 
 
 
Figure 31. Antisense oligonucleotide mediated therapy 
Antisense oligonucleotides (red) can be used to block cryptic splice sites, constitutive splice 
sites or to mediate SR protein (SF2/ASF, violet) binding by exonic splicing enhancer (ESE) 
sequences (yellow). Mutations can activate cryptic splice site and thereby lead to inclusion of 
alternative exons (green) which may disrupt the reading frame by introduction of a premature 
termination codon (PTC). Binding of an antisense oligonucleotide (red) to the cryptic splice site 
can block the recruitment and thus inhibit its inclusion (A). Similarly, a mutation (C>T) in a 
constitutive exon may lead to a PTC and thus produce a truncated protein which can cause 
severe disease manifestation in patients (B). Antisense oligonucleotides can mediate exon 
exclusion by blocking splice site usage and consequently produce near full-length proteins 
which cause much milder disease phenotype. Mutation in a ESE can disrupt SR protein 
binding and subsequently lead to exon exclusion (C). Antisense oligonucleotides with ESE 
sequences can mediate protein binding and thus inhibit exon exclusion. Figure adapted from 
Wood et al., 2007. 
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Trans-splicing mediated therapies 
RNA trans-splicing is a natural occurring process which joins exons from two separate 
transcripts to generate a chimeric mRNA (Yang and Walsh, 2005). Trans-splicing between 
different copies of estrogen receptors or cytochrome oxidases has been described in 
humans (Mitchell and McGarrity, 2005). The identification of this mechanism allowed the 
development of novel therapeutic strategies. Two main methodologies are currently using 
trans-splicing: spliceosome-mediated RNA (SMaRT) and ribozyme mediated trans-splicing 
(Figure 32) (Stoilov et al., 2002; Wood et al., 2007). The SMaRT method can repair 
transcripts by substitution of 5’, internal or 3’ parts of the mutated transcript. A pre-mRNA 
trans-splicing molecule (PTM) is used which contains the sequence to be replaced (Figure 
32A). Moreover, the PTM has a trans-splicing and a DNA-binding sequence that specifically 
targets the mutant transcript. Both, binding and splicing domain, are excised after 
spliceosome-mediated trans-splicing (Stoilov et al., 2002; Yang and Walsh, 2005; Wood et 
al., 2007). SMaRT has been found to reach significant repair levels in cell lines and primary 
cell cultures (Yang and Walsh, 2005). In the factor VIII hemophilia A knockout mouse model, 
the neomycin cassette has been successfully replaced by SMaRT (Yang and Walsh, 2005). 
 
 
 
Figure 32. Therapeutic approaches using trans-splicing 
Spliceosome mediated trans-splicing (SMaRT) and ribozyme mediated trans-splicing use the 
annealing of two independent transcripts to generate a chimeric product. A pre-mRNA trans-
splicing molecule (PTM, green) including an antisense binding domain is used to substitute the 
mutated (red stars) transcript in the SMaRT method (A). Ribozyme mediated trans-splicing is 
mainly used to replace elongated toxic expansion (yellow) at the 3’ untranslated region of 
transcripts (B).Again an antisense sequence is used to bind the ribozyme with the normal 
expansion length to the transcripts so that the enzyme can catalyze the trans-splicing reaction. 
Figure adapted from Wood et al., 2007. 
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Trans-splicing ribozymes are derived from self-splicing introns. They consist of a guide 
sequence binding the transcript, a catalytic domain and a trans-spliced region which includes 
the sequence to be repaired (Figure 32B) (Wood et al., 2007). Elongated repeats in the 
3’UTR of the DMPK gene cause myotonic dystrophy (DM). The ribozyme has been used to 
substitute the pathogenic repeat with a 3’UTR of normal length. Although this study in 
mammalian cells revealed low rescue efficiency, it provides the proof of principle (Wood et 
al., 2007). 
 
RNA interference 
About one decade ago, the occurrence of double-stranded small interfering RNAs (siRNAs) 
has been detected to trigger post-transcriptional gene silencing by RNA interference (RNAi). 
In order to induce silencing, the siRNAs bind target sequences and are subsequently 
recognized by an RNA-induced silencing complex (RISC). Depending on the sequence 
complementarity and the targeting position of the siRNAs, the RISC mediates either 
transcript cleavage, translational inhibition or transcriptional silencing if affecting the 
methylation of the genomic DNA (Stoilov et al., 2002). The advantage of RNAi is the extreme 
sequence specificity allowing silencing of alternative splice variants and even different alleles 
(Wood et al., 2007). Isoform-specific siRNAs have been shown to exclusively degrade one 
vascular endothelial growth factor (VEGF) isoform involved in tumor angiogenesis (Figure 
33A) (Wood et al., 2007). Comparably, allele-specific siRNAs can target SNPs or small 
deletions (Figure 33B) as it has been done for a trinucleotide deletion in the torsin A gene 
that cause dystonia (Wood et al., 2007).  
Recently, three novel silencing approaches has have been described. The first method uses 
5’ mutated U1 snRNAs that basepairs at the 3’ terminal exon of a target gene. It inhibits 
polyadenylation and silences gene expression by a mechanism not yet understood (Abad et 
al., 2008). In contrast to conventional RNAi, this method is much more efficient in silencing 
gene expression (Abad et al., 2008). The second strategy combines RNAi with gene 
replacement to achieve a mutation independent approach. This strategy overcomes the 
problem of the extreme heterogeneity of RHO mutations as all mutated RHO transcripts can 
be replaced by the same therapeutics. Therefore, allele unspecific RNAi of both mutant and 
wild type transcripts is coupled with gene replacement using a construct that is resistant to 
the silencing due to a wobble basepair. This method has been successfully tested in 
transgenic RHO mice (Kiang et al., 2005; O'Reilly et al., 2007; O'Reilly et al., 2008). Similarly, 
the third approach couples doxycycline induced RNAi with AO expression to achieve a 
precisely regulated, reversible splicing correction (Marquis et al., 2008).  
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Figure 33. RNA interference as therapeutic strategy 
RNA interference (RNAi) can elicit isoform or allele specific degradation of transcripts. Double 
stranded small interfering RNAs (siRNA) which are specific for a certain exon junction (violet-
green) can recruit an RNA-induced silencing complex to the corresponding transcript isoform 
mediating its degradation (A) Analogous allele-specific siRNAs mediate the recognition and 
degradation of the corresponding allele by the silencing complex (B). Figure adapted from 
Wood et al., 2007. 
 
Other RNA-based therapeutic strategies 
In recent years, many low molecular weight drugs have been identified to interfere with 
alternative splicing. Interferon for example has been described to increase exon 7 inclusion 
in SMN2 probably by a response element in the promoter (Garcia-Blanco et al., 2004). 
Comparably, application of the histone deacetylases, sodium butyrate and valproic acid, as 
well as of the topoisomerase II inhibitor aclarubicin have been shown to reduce exon 7 
skipping by enhancing SR protein binding (Stoilov et al., 2002; Garcia-Blanco et al., 2004; 
Hagiwara, 2005; Tazi et al., 2005). In contrast, overexpression of the SR protein-
phosphorylating cdc2-like kinase has been described to restore the abnormal tau isoform 
ratio by facilitating exon 10 skipping (Stoilov et al., 2002; Hagiwara, 2005). However, also 
cytokines are known to change splicing patterns by influencing the phosphorylation status of 
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SR proteins. Insulin-dependent changes of splice factor arginine/serine rich 5 (SFRS5; 
SRp40) phosphorylation for example has been found to trigger exon inclusion in the protein 
kinase C (Hagiwara, 2005).  
Other genes are alternatively spliced upon extracellular signals. Neural depolarization is 
known to suppress exon inclusion of the voltage-gated K+ channel by a Ca2+/calmodulin-
dependent protein kinase (CaMK) responsive RNA element (Blaustein et al., 2007). 
Administration of a CaMK inhibitor to neuronal cells can increase exon inclusion (Hagiwara, 
2005). Analogously, exon inclusion of CD44 gene has been observed to be prevented by 
interruption of the signaling pathway through inhibition of the mitogen-activated protein 
kinase (MAPK) (Hagiwara, 2005).  
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4.4. Concluding remarks 
With the new millennium, it became more and more obvious that the role of splicing in the 
pathogenesis of numerous diseases is highly versatile. However, in most of these diseases 
the role of splicing in the pathogenic mechanism only covers one or two of the three possible 
aspects: tissue-specific splicing, trans- or cis-acting mutations. Since the pathogenesis of RP 
includes all three aspects, this suggests that the connection between RP and splicing is 
especially complex. Tissue-specific splicing has been associated with tissue-restricted 
disease manifestations and trans-acting mutations in splice factors as well as cis-acting 
mutations are known to be able to cause the disease. Together, this suggests that splicing is 
of most importance for the maintenance of the retina and the survival of PRs. Therefore, this 
study aimed to contribute to the understanding of the different roles of splicing in the 
pathogenesis of RP (Figure 34). Prediction of alternative isoforms indicated that most of the 
RP-associated genes express novel splicing variants, but the exact gene structure and the 
expression levels needs to be confirmed. Functional characterization of a novel splice 
isoform of PRPF3 elucidated the importance of physiological NMD and suggested an auto- 
or crossregulated expression control of PRPF3. Finally, the identification and 
characterization of a novel cis-acting mutation in RHO was used to develop a novel strategy 
to rescue donor splice site mutation-induced mis-splicing.  
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Figure 34. Implications of this study on the research of the pathogenesis of retinitis 
pigmentosa and the development of future diagnostic tools and therapies 
The three parts of this study all aimed to elucidate the pathogenesis (yellow boxes) of 
retinitis pigmentosa (RP). However, research on the pathology is always connected to the 
investigation of gene expression and protein function (light green boxes) and provides the 
basis for development of future treatments (red boxes). 
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Together, all three parts of this study contributed to increased understanding of the role of 
splicing in the pathogenesis of RP and thus provide a basis for further diagnostic 
improvements and development of therapeutic strategies to treat RP. These may in turn 
have implications on the research of other diseases associated with splicing.  
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5. Summary (English) 
Currently, about 70% of the human genes are expected to use alternative splicing to express 
multiple, sometimes tissue-specific, isoforms. Furthermore, it is well known that splicing can 
influence disease pathogeneses in three major ways: either by mutations that interfere with 
accurate splice site recognition or by mutations located in splice factors as well as in tissue-
specifically expressed sequences. Retinitis pigmentosa (RP) is a degenerative retinopathy 
that causes severe visual impairments or even complete blindness in about 1.5 million 
patients worldwide. In contrast to other diseases, splicing is involved in the pathogenesis of 
RP through all three major ways. Nevertheless, the detailed pathogenic mechanism is not 
well understood and no approved treatment available to cure classical RP. In recent years, 
many novel therapeutic possibilities have been developed. However, also the best therapy is 
not effective, if the underlying mutation is not identified, the protein function not known or the 
pathogenic mechanism not fully understood. Therefore, this study investigated the impact of 
splicing on the pathogenesis of RP through the prediction of gene structures and mutational 
screening. Functional characterization of a novel mutation and an alternative exon as well as 
the development of a therapeutic strategy to treat splice site mutations in rhodopsin (RHO) 
complemented this study. 
Alternative isoform prediction was performed from bioinformatic EST database searches and 
expression of splice variants could be predicted for almost all RP-associated genes. This 
indicates that these genes undergo more often alternative splicing than other groups of 
genes. Expression of one novel exon in the splice factor PRPF3 could be confirmed in 
human and mouse retina. However, the question remains how mutations in widely expressed 
splice factors can result in retina-specific symptoms of RP. Therefore, the function of the 
novel exon has been analyzed and the inclusion of the novel exon has been found to 
introduce a premature termination codon which induces nonsense-mediated decay (NMD). 
Interestingly, expression of alternative, NMD-inducing exons in other splice factors has been 
shown to regulate the protein expression level of the own gene or of other splice factors and 
thus to control indirectly the splicing process. Furthermore, tissue-specific differences of 
NMD activity have been associated with disease pathogenesis. Together, this suggests that 
the novel exon in PRPF3 may have regulatory function involved in the pathogenesis of RP.  
A novel silent point mutation in RHO has been identified to change the last nucleotide of an 
exon and was predicted to impair accurate donor splice site usage. Comprehensive analysis 
in cell culture showed that the mutation severely disturbed exon recognition and induces the 
production of two aberrant transcripts. Manipulation of the spliceosome by modified U1 small 
nuclear ribonucleoproteins and inhibition of a competitive cryptic splice site could re-direct 
accurate splice site selection. Furthermore, this combinatory strategy has been shown to 
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restore almost the same splice isoform ratio than observed in non mutated conditions. Our 
results indicate that this novel method provides a promising strategy for future therapeutic 
treatments. Since our approach is mutation-dependent, but disease-independent, it also 
represents a strategy to develop similar treatments in other disorders. 
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6. Zusammenfassung  
Derzeit nutzen schätzungsweise 70% aller menschlichen Gene alternatives Spleissen, um 
mehrere, teilweise auch gewebespezifische, Proteinvarianten zu erzeugen. Ausserdem ist 
bekannt, dass die Pathogenese vieler Krankheiten von Mutationen ausgelöst wird, die drei 
Hauptursachen haben: entweder beeinflussen sie das Spleißen direkt negativ, oder betreffen 
Spleissfaktoren, oder kommen in gewebespezifisch gespleißten Sequenzen vor. Die erbliche 
Augenkrankheit Retinitis pigmentosa (RP), von der weltweit über 1.5 Millionen Patienten 
betroffen sind, führt von schweren visuellen Einschränkungen bis hin zu absoluter Blindheit. 
Im Gegensatz zu den meisten Krankheiten sind in RP alle drei Einflüsse des Spleissens auf 
die Pathogenese erwiesen. Trotzdem sind die Pathogenesemechanismen nicht vollständig 
aufgeklärt und noch keine Therapie erhältlich. In den letzten Jahren wurden viele neue 
Therapiemöglichkeiten entwickelt. Doch solange die krankheitsauslösende Mutation nicht 
identifiziert, die Proteinfunktion nicht bekannt oder die Pathogenese nicht verstanden ist, ist 
es schwierig neue und effiziente Therapieansätze zu entwickeln. Deshalb hat diese Studie 
versucht den Einfluss des Spleissens auf die Pathogenese von RP über die Bestimmung der 
Genstruktur, die Mutationssuche und über die Erforschung der Mutationskonsequenzen 
sowie der Proteinfunktion zu ergründen. Die Entwicklung einer viel versprechenden, 
therapeutischen Strategie zur Wiederherstellung einer mutierten Spleissstelle in Rhodopsin 
(RHO) vervollständigte diese Arbeit. 
Mittels einer bioinformatischen EST Datenbankanalyse wurden Varianten von RP 
assoziierten Genen vorausgesagt und für fast alle von ihnen konnten mehrere Isoformen 
gefunden werden. Das zeigt, dass diese Gene häufiger alternativem Spleissen zu 
unterliegen scheinen als andere Gene. Die Expression eines neuen Exons in dem 
Spleissfaktor PRPF3 konnte in der Retina vom Menschen und von Mäusen bestätigt werden. 
Da sich bei ubiquitär exprimierten Spleissfaktoren die Frage stellt, wie die Mutationen zu den 
retinaspezifischen Symptomen von RP führen können, wurde die Funktion des neuen Exons 
analysiert. Tatsächlich konnte bewiesen werden, dass die Expression des Exons zum Abbau 
des alternativen Transkripts führt. Interessanterweise kann die Expression von alternativen, 
Transkriptabbau vermittelnden Exonen in anderen Spleissfaktoren die eigene 
Proteinexpression und die anderer Spleissfaktoren kontrollieren, um damit den 
Spleissprozess zu regulieren. Zudem wurden gewebespezifische Unterschiede der 
Abbauaktivität mit Krankheiten assoziiert. Das lässt vermuten, dass das neue Exon des 
PRPF3s regulatorische Funktion in der Pathogenese von RP haben könnte.  
Eine neue Punktmutation in der letzten Base eines Exons von RHO könnte die Erkennung 
der Spleissstlelle negativ beeinflussen. Umfassende Charakterisierung zeigte tatsächlich, 
dass die Mutation die Exonerkennung erheblich stört, was zur Entstehung zweier Transkripte 
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führt, die nicht funktionelle Proteine erzeugen würden. Die Manipulation des Spleisseosoms 
durch veränderte U1 Ribonukleinproteine und Hemmung einer konkurrierenden, kryptischen 
Spleissstelle konnte die korrekte Exonerkennung verbessern und annährend das gleiche 
Verhältnis der Spleissvarianten wie im nicht mutierten Zustand wiederherstellen. Unsere 
Resultate zeigen, dass diese Methode eine viel versprechende Strategie für zukünftige 
therapeutische Ansätze darstellt. Da unsere Methode von der Mutation, aber nicht von der zu 
behandelnden Krankheit abhängt, kann diese Strategie auch die Basis für die Entwicklung 
von Therapien für andere Krankheiten bilden. 
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7. Appendix 
7.1. Abbreviations 
1 
11-cis RDH 
11-cis retinol dehydrogenase 15 
A 
A 
adenosine 23 
AAV 
adeno-associated virus 115 
ABCA4 
ATP-binding cassette transporter A4 33 
adRP 
autosomal dominant RP 17 
AL 
retinal 15 
all-trans RDH 
all-trans retinol dehydrogenase 14 
Alu repeat 
form of SINE 76 
AOs 
antisense oligonucleotides 143 
arRP 
autosomal recessive RP 19 
ARPE-19 
 retinal pigment epithelial cells ............... 73 
AS 
acceptor splice site 23 
ASF/SF2 
alternative splice factor/ splice factor 2 82 
ATM 
ataxia telangiectasia 29 
ATP 
adenosine-tri-phosphate 12 
B 
BBS 
Bardet-Biedl syndrome 16 
BMD 
Becker’s muscular dystrophy 31 
bp 
base pairs 22 
BRCA1 
breast cancer 1 81 
BS 
branch site 23 
Bt 
ox  90 
C 
C3H 
mouse strain 31 
C57BL/6J 
mouse strain 31 
Ca2+ 
calcium 13 
CA4 
carbonic anhydrase IV 54 
CaMK 
Ca2+/calmodulin-dependent kinase 148 
CBF1 
centromere binding factor 1 35 
CC 
connecting cilium 12 
cdc2 
cell division cycle 2 genes 147 
cDNA 
complementary DNA 72 
CELF 
CUG binding and ETR binding factors 26 
CERKL 
ceramide kinase like protein 31 
Cf 
dog 91 
cGMP 
cyclic GMP 13 
CIR 
CBF1-interacting transcription corepressor
 35 
CKII 
casein kinase II 81 
CNGB1 
rod cGMP gated channel subunit B 31 
COL2A1 
procollagen II 29 
COS 7 
monkey kidney cells 74 
COX 
cytochrome c oxidase 134 
CRALBP 
cellular retinaldehyde binding protein 15 
CRB1 
crumbs homologue 1 31 
CRBP 
cellular retinol binding protein 14 
CRX 
cone-rod homeobox gene 32 
CS 
cryptic splice site 26 
CSNB 
congenitial stationary night blindness 16 
CUG-BP1 
CUG-binding protein 1 30 
D 
DM 
myotonic dystrophy 30 
DMD 
Duchenne muscular dystrophy 31 
DMEM 
Dulbecco's modified Earle's medium 73 
DMPK 
myotonic dystrophy protein kinase 30 
DNA 
deoxyribonucleic acid 22 
DS 
donor splice site 23 
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E 
E 
retinyl ester 15 
EBV 
Eppstein-Bar-virus 73 
EJC 
exon junction complex 27 
ER 
endoplasmatic reticulum 17 
ERG 
electroretinogram 18 
ESE 
exonic splicing enhancer 26 
ESS 
exonic splicing silencer 26 
ESTs 
expressed sequence tags 48 
ETR 
elav-type RNA binding protein 26 
exon 
protein coding region 22 
EYS 
eyes shut homologue 31 
F 
FMR1 
fragile-X mental retardation 1 31 
FSCN2 
fascin 2 52 
FXTAS 
fragile-X-associated tremor/ataxia syndrome
 31 
G 
G 
guanosine 24 
GAPDH 
glyceraldehyde 3-phosphate dehydrogenase
 78 
GCL 
ganglion cell layer 10 
gDNA 
genomic DNA 73 
GDP 
guanosine di-phosphate 13 
Gg 
chicken 91 
GMP 
guanosine mono-phosphate 13 
GTP 
guanosine tri-phosphate 13 
GUCA1B 
guanylate cyclase activating protein 1 54 
H 
HEK 293T 
human kidney cells 73 
hnRNPs 
heterogeneous nuclear ribonucleoproteins
 26 
Hs 
human 89 
I 
ILM 
inner limiting membrane 11 
IMPDH1 
inisitol monophosphate dehydrogenase 1 31 
INL 
inner nuclear layer 10 
intron 
noncoding intervening sequence 22 
IPL 
inner plexiform layer 10 
IRBP 
interphotoreceptor retinoid binding protein 14 
IS 
inner segments 10 
ISE 
intronic splicing enhancer 26 
ISS 
intronic splicing silencer 26 
K 
K+ 
potassium 14 
KH 
hnRNP K homology 26 
KSRP 
KH-type splicing regulatory protein 26 
L 
LCA 
leber congential amaurosis 16 
LRAT 
lecithin retinal acyl transferase 14 
Lsm 
small nuclear core-like RNPs 22 
M 
MAPK 
 mitogen-activated protein kinase ....... 148 
MBNL1 
muscleblind-like protein 1 30 
MERTK 
c-mer protooncogen receptor tyrosine kinase
 54 
mG7 
seven-methyl guanoside 22 
MGB probes 
minor groove binder probes 107 
mini-mut 
mutated RHO minigene construct  105 
mini-mut_c 
mini-mut including adaptation of the CS 105 
mini-wt 
RHO minigene construct  105 
mini-wt_c 
mini-wt including adaptation of the CS 105 
Mm 
mouse 89 
mRNA 
messenger ribonucleic acid 22 
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N 
 
Na+ 
Sodium 13 
NAS 
nonsense-associated altered splicing 27 
NF1 
neurofibromatosis type 1 29 
NLS 
nuclear localization signal 78 
nm 
nanometers 13 
NMD 
nonsense-mediated decay 27 
nPTB 
neuronal PTB 138 
NR2E3 
nuclear receptor subfamily 2 group E3 52 
NRL 
nuclear leucine zipper 32 
NSAID 
nonsteroidal anti-inflammatory drug 134 
O 
OH 
hydroxyl group 24 
OL 
retinol 15 
OLM 
outer limiting membrane 10 
ONL 
outer nuclear layer 10 
OPL 
outer plexiform layer 10 
OPA1 
optic atrophy 1 81 
ORF 
open reading frame 31 
OS 
outer segments 10 
P 
P 
phosphate 24 
PAP1 
PIM-1 associated protein 33 
pcDNA4/V5-HisC 
protein expression vector 73 
PCK 
rhodopsin kinase 14 
PCR 
polymerase chain reaction 72 
PDE 
phosphodiesterase 13 
PDE+ 
activated PDE 13 
PDE6A 
phosphodieserase 6A 21 
PDE6B 
phosphodiesterase 6B 21 
PEI 
polyethylenimine 74 
 
PIM-1 
proto-oncogene serine/threonine kinase 1 33 
PIP  
percent idently plot 72 
poly(A) 
polyadenylation site 22 
PR 
photoreceptor 10 
PRCD 
progressive rod-cone dystrophy 52 
pre-mRNA 
precursor messenger RNA 22 
PROM1 
prominin 1 52 
PRPF3 
pre-mRNA processing factor 3 33 
PRPF31 
pre-mRNA processing factor 31 21 
PRPF4 
pre-mRNA processing factor 4 34 
PRPF8 
pre-mRNA processing factor 8 33 
PRPH2 
peripherin 2 19 
Pt 
chimpanzee 91 
PTB 
polypyrimidine tract binding protein 79 
PTC 
premature termination codon 25 
PTM 
pre-mRNA trans-splicing molecule 145 
PWI domain 
Pro-Trp-Ile domain 69 
R 
RCC1 
regulator of chromosome condensation 1  32 
RD 
retinal dystrophies 16 
RDS 
retinal degeneration slow 19 
RGR 
retinal G-protein coupled receptor 31 
RHO 
rhodopsin 13 
RHO+ 
activated RHO 13 
RISC 
RNA-induced silencing complex 146 
Rn 
rat. 90 
RNA 
ribonucleic acid 22 
RNAi 
RNA interference 146 
ROM1 
rod outer segment membrane protein 1 19 
RP 
retinitis pigmentosa 16 
RP1 
retinitis pigmentosa 1 21 
RP2 
retinitis pigmentosa 2 21 
RP9 
retinitis pigmentosa 9 34 
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RPE 
retinal pigment epithelium 10 
RPE65 
RPE-specific 65kDa protein 14 
RPGR 
retinitis pigmentosa GTPase regulator 21 
RRM 
RNA recognition motif 26 
RT-PCR 
reverse transcription PCR 69 
S 
SAG 
arrestin 52 
SC35 
serine-arginine rich 2 protein 79 
SCA 
spinocerebellar ataxia 31 
Scn8a 
sodium channel Na 1.6 31 
Scnm1 
sodium channel modifier 1 31 
SEMA4A 
semaphorin B 53 
SF1 
splice factor 1 23 
SF2/ASF 
splice factor 2,  alternative splice factor 82 
SFRS5 
splice factor arginine/serine rich 5 148 
SINEs 
short interspersed nuclear elements 76 
siRNAs 
small interfering RNAs 146 
Sm proteins 
small nuclear core ribonucleoproteins 22 
SMA 
spinal muscular atrophy 30 
SMaRT 
spliceosome mediated RNA trans-splicing 145 
SMCD 
Schmid metaphyseal chondrodysplasia 83, 
140 
SMN 
survival of motor neurons 23 
SNPs 
single nucleotide polymorphisms 126 
snRNA 
small nuclear ribonucleic acid 22 
snRNPs 
small nuclear ribonucleoproteins 22 
SOS 
suppression of splicing 28 
SPF30 
splicing factor 30 71 
SR proteins 
serine/arginine rich proteins 26 
SRp40 
splice factor arginine/serine rich 5  148 
SRPK1 
serine/arginine rich protein kinase 1 26 
SS 
splice site 23 
 
T 
T 
transducin 13 
T+ 
activated T 13 
tau 
tubulin-associated unit 30 
TNF 
tumor necrosis factor 17 
TOPORS 
topoisomerase I binding arginine/serine rich 
protein 134 
Tra2-β1 
transformer2- β1, SR protein 79 
Tri-snRNP 
tri-snRNP subcompex 24 
TULP1 
tubby-like protein 1 52 
U 
U1 
snRNP unit 1 22 
U1-Mut 
U1 snRNA construct adapted to the RHO 
mutation 106 
U1-RHO-Mut 
U1 snRNA construct adapted to the RHO 
mutation and the CS 106 
U1-RHO-Wt 
U1 snRNA construct adapted to the CS 106 
U1-Wt 
U1 snRNA construct 106 
U11 
snRNP unit 11 23 
U12 
snRNP unit 12 23 
U2 
snRNP unit 2 22 
U2AF 
U2 auxiliary factor 23 
U4 
snRNP unit 4 22 
U4atac 
snRNP unit U4atac 23 
U5 
snRNP unit 5 22 
U6 
snRNP unit 6 22 
U6atac 
snRNP unit U6atac 23 
UCEs 
ultraconserved exons 79 
Upf protein 
up-frameshift binding protein 27 
UPR 
unfolded protein response 17 
USH2A 
usherin 21 
UTR 
untranslated region 30 
UV 
ultraviolet 13 
Gaby-Gerda Tanner  Appendix 
 167
V 
VEGF 
vascular endothelial growth factor 146 
X 
xlRP 
X-linked RP 19 
Z 
ZNF9 
zinc finger protein 9 30 
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